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vAbstract 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
characterized by preferential motor neuron death in the brain and spinal cord. The rapid 
disease progression results in death due to respiratory failure, typically within 3-5 years 
after disease onset. While ~90% of cases occur sporadically, remaining 10% of ALS 
cases show familial inheritance, and the number of genes linked to ALS has increased 
dramatically over the past decade.  
FUS/TLS (Fused in Sarcoma/ Translocated to liposarcoma) is a nucleic acid binding 
protein that may regulate several cellular functions, including RNA splicing, 
transcription, DNA damage repair and microRNA biogenesis. More than 50 mutations in 
the FUS gene are linked to 4% of familial ALS, and many of these may disrupt the 
nuclear localization signal, leading to variable amounts of FUS accumulation in the 
cytoplasm. However, the mechanism by which FUS mutants cause motor neuron death is 
still unknown.  
The studies presented in this dissertation focused on investigating the properties of 
FUS mutants in the absence and presence of stress conditions. We first examined how 
ALS-linked FUS mutants behaved in response to imposed stresses in both cell culture 
and zebrafish models of ALS. We found that FUS mutants were prone to accumulate in 
stress granules in proportion to their degree of cytoplasmic mislocalization under 
conditions of oxidative stress, ER stress, and heat shock.  
vi
However, many FUS missense mutants are retained predominantly in the nucleus, 
and this suggested the possibility that these mutants might also perturb one or more 
nuclear functions.  In a human cell line expressing FUS variants and in human fibroblasts 
from an ALS patient, mutant FUS expression was associated with enlarged promyelocytic 
leukemia nuclear bodies (PML-NBs) under basal condition. Upon oxidative insult with 
arsenic trioxide (ATO), PML-NBs in control cells increased acutely in size and were 
turned over within 12-24 h, as expected. However, PML-NBs in FUS mutant cells did not 
progress through the expected turnover but instead continued to enlarge over 24 h. We 
also observed a persistent accumulation of the transcriptional repressor Daxx and the 11S 
proteasome regulator in association with these enlarged PML-NBs. Furthermore, the 
peptidase activities of the 26S proteasome were decreased in FUS mutant cells without 
any changes in the expression of proteasome subunits. 
These results demonstrate that FUS mutant expression may alter cellular stress 
responses as manifested by (i) accumulation of mutant FUS into stress granules and (ii) 
inhibition of PML-NB dynamics. These findings suggest a novel nuclear pathology 
specific to mutant FUS expression that may perturb nuclear homeostasis and thereby 
contribute to ALS pathogenesis. 
vii
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1Chapter I 
Introduction to Amyotrophic Lateral Sclerosis 
2I.1 Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND) is a progressive 
neurodegenerative condition characterized by loss of motor neurons in the cerebral 
cortex, brainstem and spinal cord. The term ALS encompasses the pathological features 
of patients in that “amyotrophic” refers to the muscle atrophy caused by lower motor 
neuron degeneration and “lateral sclerosis” describes the fibrotic changes in the lateral 
columns of the spinal cord (Rowland and Shneider 2001). ALS was initially described by 
the French physician Jean-Marin Charcot in 1869, but we still do not understand the 
disease mechanisms underlying preferential degeneration of motor neurons. The mean 
age of onset is 55 years old but rare juvenile onset also occurs. ALS is classified as 
familial (fALS) and sporadic (sALS) forms. Ninety percent of ALS cases occur 
sporadically, and the remaining ten percent of ALS cases show familial inheritance that 
may be linked to specific gene mutations. Death occurs due to respiratory failure in most 
cases, typically within 3 to 5 years after symptom onset. At present, no treatment exists to 
significantly slow the course of this disease.  
I.1.1 Epidemiology 
ALS affects 2.16 individuals per 100,000 per year in the general European 
population (Logroscino, Traynor et al. 2010), and this rate is consistent with the study 
based on US population (McGuire, Longstreth et al. 1996). Males are affected more 
frequently than females (Logroscino, Traynor et al. 2010, Mehta, Antao et al. 2014). The 
3lifetime risk of ALS is 1:350 for men and 1:400 for women (Johnston, Stanton et al. 
2006). Incidence rate gradually increases with advanced age, but it decreases 
considerably after the age of 80 years (Logroscino, Traynor et al. 2010).  
The incidence rate in certain areas including Guam, Japan’s Kii Peninsula, and 
western New Guinea is much higher (Gajdusek and Salazar 1982, Kuzuhara and Kokubo 
2005). For instance, the incidence rate of Guam ALS was 7.5/100,000/year during the 
period of 1980-1989 (Okumura 2003). Several theories have been proposed to explain the 
high frequency of disease in this region. Khabazian et al. reported that this higher 
incidence rate is caused by exposure to neurotoxins such as sterol glucosides and β-
methylamino-L-alanine (BMAA) (Khabazian, Bains et al. 2002), suggesting 
environmental risk factors may contribute to disease pathogenesis (Al-Chalabi and 
Hardiman 2013). In addition to cyanotoxins, proposed potential risk factors include 
smoking, exercise, football play, heavy metal and pesticides exposure, and armed 
services (Al-Chalabi and Hardiman 2013). According to the gene-time-environment 
(GTE) model, accumulated exposure to environmental risk factors is able to approach the 
threshold for disease, and certain types of mutations in genes can shorten the duration to 
reach the threshold (Al-Chalabi and Hardiman 2013).  
I.1.2 Clinical phenotypes, diagnosis and treatment 
ALS is the most common motor neuron disease and affects both upper and lower 
motor neurons in the spinal cord, brain stem, and cortex. Some individuals exhibit 
4restricted phenotypes involving either lower motor neuron (LMN) signs or upper motor 
neuron (UMN) signs only, and they are diagnosed with progressive spinal muscular 
atrophy or primary lateral sclerosis, respectively. The symptoms for LMN loss include 
fasciculation, cramps, and muscle atrophy, and those in UMN degeneration show 
spasticity and hyperreflexia (Gordon 2013). The signs of ALS usually begin in a single 
limb in about two-thirds of patients (limb-onset ALS) (Kiernan, Vucic et al. 2011). 
Bulbar-onset ALS, affecting ~25% of patients, causes difficulties in speaking and 
swallowing, and limb features are developed later (Kiernan, Vucic et al. 2011). With 
disease progression, most patients develop problems in swallowing and eating food. 
There is no single biomarker for the diagnosis of ALS. Clinicians examine the 
combination of UMN and LMN signs developed in the same body region and identify 
subsequent evidence of disease progression to other regions (Kiernan, Vucic et al. 2011). 
The El Escorial diagnostic criteria were developed in 1994 for ALS diagnosis by the 
World Federation of Neurology for research and clinical trial purposes. This guideline 
line has been modified several times to improve sensitivity and diagnostic certainty 
(Miller, Munsat et al. 1999), but a 9-12 month delay usually occurs before clinicians are 
able to confirm diagnosis (Al-Chalabi and Hardiman 2013). As ALS progresses rapidly 
and the median survival of patients is about 2 to 3 years from symptom onset, it is critical 
to develop a marker to provide more rapid diagnosis so that appropriate therapies can be 
initiated earlier in the course.  
5No cure is yet available for ALS. Riluzole is the only drug shown to provide even a 
modest benefit of 2 to 3 months for survival (Miller, Mitchell et al. 2012). Riluzole 
exhibits anti-glutamatergic properties, which has been proposed to reduce excitotoxicity 
in ALS (Stevenson, Yates et al. 2009), but it may also affect other components such as 
sodium channels (Sierra Bello, Gonzalez et al. 2012). Its side effects can include diarrhea, 
fatigue, and dizziness. In the U.S, more than 50% of patients take this medicine (Gordon 
2013).  
I.2 Causative Genes and pathological Mechanisms 
While most cases of ALS are sporadic, about 5 to 10 percent of ALS patients are 
affected by autosomal dominant inheritance. To date, more than 20 genetic loci have been 
identified accounting for most fALS and a small portion of sALS cases (Renton, Chio et 
al. 2014) (Table 1-1). Important cellular processes influenced by these gene products 
include vesicle trafficking, RNA metabolism, cytoskeletal dynamics, and protein 
degradation (Renton, Chio et al. 2014). Mutations in four major ALS genes, including 
superoxide dismutase 1 (SOD1), TAR DNA-binding protein (TARDBP), fused in sarcoma 
(FUS) and chromosome 9 open reading frame 72 (C9ORF72) account for over 50% of 
fALS cases (Rosen, Siddique et al. 1993, Sreedharan, Blair et al. 2008, Kwiatkowski, 
Bosco et al. 2009, DeJesus-Hernandez, Mackenzie et al. 2011, Renton, Majounie et al. 
2011). Mutations in several other genes including ubiquilin2 (UBQLN2), profilin1 
(PFN1), optineurin (OPTN), and valosin-containing protein (VCP) are also identified in 
6           Table 1-1 Causative genes identified in ALS
Subtype Gene symbols Function
ALS1 SOD1
InheritanceChromosome
21q22.1 Dominant
Onset
Adult
ALS2
ALS3
ALS4
ALS5
ALS6
ALS7
ALS8
Alsin
unknown
Senataxin
Spatascin
FUS
unknown
VAPB
ALS9 Angionenin
ALS10 TARDBP
2q33 Recessive Juvenile
18q21 Dominant Adult
9q34 Dominant Juvenile
15q15-q21 Recessive Juvenile
16p11 Dominant Adult
20p13 Dominant Adult
20q13.3 Dominant Adult
14q11.2
1p36.22 Dominant Adult
Dominant Adult
GEF signaling
RNA metabolism
RNA metabolism
RNA metabolism
Vascularization
Vesicle Tracfficking
unknown
unknown
unknown
Gene name
Superoxide dismuatse 1
C9ORF72 9p21.2 Dominant AdultALS-FTD
ALS11
ALS12
FIG4
Optineurin
6q21
10p13 Adult
Dominant Adult
ALS13
ALS14
ALS15
ALS16
ALS18
ALS2
unknown
SETX
SPAST
Fused in sarcoma
unknown
VAMP (vesicle-associated 
membrane protein)-associated 
protein B and C
ANG
TAR DNA-binding protein
FIG4 homologue
OPTN
ATXN2 Ataxin 2 12q23-q24.1
VCP Valosin-contaning protein 9p13
UBQLN2 Ubiquilin 2 xp11.21
SIGMAR1 Sigma non-opioid intracelular 
receptor 1
9p13
PFN1 Profilin 1 17p13.3
Chromosome 9 open reading 
frame 72
Enzyme
Dominant 
Dominant 
Dominant 
Dominant 
Recessive
Protein degradation
Cytoskeletal 
movement
Calcium signalingJuvenile
Adult
Recessive
Both
unknown
Adult
Vesicle Tracfficking
Vesicle Tracfficking
Vesicle Tracfficking
RNA metabolism
Adult
ALS21 MATR3 Matrin 3 5q31.2 Adult RNA metabolism
ALS-FTD CHCHD10 Coiled-coil-helix-coiled-coil-helix  
domain containing 10
22q11.23 Adult Oxidative 
phosphorylation
Dominant 
Dominant 
TBK1 TANK-binding kinase 1 12q14.2ALS-FTD AdultDominant Protein degradation
7ALS but they are less prevalent (Johnson, Mandrioli et al. 2010, Maruyama, Morino et al. 
2010, Deng, Chen et al. 2011, Wu, Fallini et al. 2012). Recently, new ALS genes are 
identified including matrin 3 (MATR3), coiled-coil-helix-coiled-coil-helix domain 
containing 10 (CHCHD10), and TANK-binding kinase 1 (TBK1) (Bannwarth, Ait-El-
Mkadem et al. 2014, Johnson, Pioro et al. 2014, Cirulli, Lasseigne et al. 2015, 
Freischmidt, Wieland et al. 2015).  
The dominant missense mutations in SOD1 were the first reported in 1993 following 
genetic linkage to chromosome 21q22.1 in 1993 (Rosen, Siddique et al. 1993). Over one 
hundred mutations have been found in SOD1, and they account for ~20 percent of fALS 
and ~3 percent of sALS (Andersen 2006). The most frequent variant of SOD1 mutations 
in North America is the A4V mutation (Cudkowicz, McKenna-Yasek et al. 1997). 
Individuals harboring SOD1-A4V have an aggressive course, and death can occur within 
a year after symptom onset (Cudkowicz, McKenna-Yasek et al. 1997). Transgenic mouse 
models expressing mutant SOD1 have been developed that have contributed the most 
insights regarding possible pathogenic mechanisms in ALS (McGoldrick, Joyce et al. 
2013). Proposed mechanisms include misfolded mutant SOD1 aggregates, axonal 
transport defects, non-cell autonomous toxicity, impairment of the ubiquitin-proteasome 
system, and the disruption of mitochondria function.  
The mutations in gene TARDBP, which encodes TAR DNA binding protein 43 
(TDP-43) were identified in 2008 (Sreedharan, Blair et al. 2008). Initially, TDP-43 was 
identified as the major component of ubiquitin positive inclusions in frontotemporal lobar 
8degeneration (FTLD) (Neumann, Sampathu et al. 2006). The mutations in TDP-43 affect 
~4 % of fALS and ~1% of sALS (Chio, Calvo et al. 2012). TDP-43 is composed of two 
RNA recognition motifs, a nuclear localization signal, a nuclear export signal and a C-
terminal glycine-rich domain. While TDP-43 is expressed predominantly in the nucleus, 
it shuttles between the nucleus and cytoplasm (Ayala, Zago et al. 2008). More than 50 
mutations of TDP-43 are identified, and most of them are clustered at the C-terminal 
glycine-rich regions that may serve as a low complexity or prion-like domain (Cushman, 
Johnson et al. 2010, Robberecht and Philips 2013). The normal function of TDP-43 is 
thought to regulate RNA splicing, trafficking, transcription, and miRNA biogenesis (Lee, 
Lee et al. 2012). Several pathological properties of TDP-43 have been discovered, 
including abnormal hyper-phosphorylation and ubiquitination of TDP-43, sarkosyl-
insoluble TDP-43 inclusion, formation of the truncated 20-25 kDa TDP-43 C-terminal 
fragments (CTFs), translocation of TDP-43 into cytoplasm and lack of normal 
expressions in the nucleus (Lee, Lee et al. 2012). 
The locus of FUS/TLS (fused in sarcoma/translocated in liposarcoma) was mapped 
on chromosome 16p11 from three independent studies analyzing European and North 
American pedigrees affected with autosomal dominant ALS (Abalkhail, Mitchell et al. 
2003, Ruddy, Parton et al. 2003, Sapp, Hosler et al. 2003). Mutations in FUS were 
identified in 2009 by sequencing analysis of affected families (Kwiatkowski, Bosco et al. 
2009, Vance, Rogelj et al. 2009). In common with TDP-43, FUS contains nucleic acid 
binding motifs and an intrinsically disordered region, but the two proteins are organized 
9differently. The discovery of the mutations in TDP-43 and FUS provided a rationale for 
considering altered RNA metabolism as a major contributor to motor neuron 
degeneration (Ling, Polymenidou et al. 2013). The pathological features include 
abnormal FUS-positive cytoplasmic inclusions in motor neurons of patients 
(Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009). Interestingly, these 
inclusions are TDP-43-negative (Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 
2009). More than 50 mutations in FUS account for ~4% of fALS and ~1% of sALS 
(Deng, Gao et al. 2014). Most FUS mutations cluster within a nuclear localization signal 
(NLS) at the C-terminus, and these are thought be disrupt the NLS, which impairs 
transportin-1 mediated nuclear import of FUS (Dormann, Rodde et al. 2010). It is still 
unknown whether FUS causes motor neuron degeneration by a loss-of function 
mechanism, a toxic gain-of-function mechanism, or both.  
A hexanucleotide repeat expansion (GGGGCC)n in C9ORF72 indicated that a large 
intronic repeat expansion could contribute to ALS (DeJesus-Hernandez, Mackenzie et al. 
2011, Renton, Majounie et al. 2011). This expansion located in chromosome 9p21 may 
account for the majority of fALS (~40 percent) and ~25 percent of FTD, strongly 
supporting the concept of a pathological overlap between ALS and FTD (Majounie, 
Renton et al. 2012). The C9ORF72 repeat expansion may affect ~7 percent of sALS in 
people of European ancestry (Majounie, Renton et al. 2012). The normal function of this 
gene is unknown. The pathological length of the expanded repeats is still unclear, but 
several hundreds or thousands of repeats may contribute to disease (Robberecht and 
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Philips 2013). Pathological features include TDP-43-positive inclusions in the spinal 
cord, cortex, and hippocampus and TDP-43-negative but p62/SQSTM1-ubiquitin-
positive inclusions in the hippocampus and cerebellum (Al-Sarraj, King et al. 2011, 
DeJesus-Hernandez, Mackenzie et al. 2011). In addition, the neuronal cells from the 
frontal cortex and spinal cord in patients with C9ORF72 mutations contain abnormal 
RNA foci (DeJesus-Hernandez, Mackenzie et al. 2011). Interestingly, though this gene 
with abnormal expansion does not contain an AUG start codon, it can direct the 
production of insoluble dipeptides (poly GA, poly GP, and poly GR) by repeat-associated 
non-ATG (RAN) translation. Therefore, at least three hypotheses have been proposed to 
explain the pathogenesis associated with C9ORF72 repeats: (1) C9ORF72 
haploinsufficiency, (2) repeat-associated RNA toxicity, and (3) toxic RAN protein species 
(Ling, Polymenidou et al. 2013). 
Clearly, ALS pathology is very complex. Several molecular mechanisms based on 
the nature of causative genes have been proposed, including oxidative stress, 
mitochondria dysfunction, excitotoxicity, protein aggregation, dysregulated endosomal 
trafficking, impaired axonal transport, neuroinflammation, and altered RNA metabolism 
(Ferraiuolo, Kirby et al. 2011).  
I.3 ALS Links to Frontotemporal Dementia (FTD)  
Frontotemporal dementia (FTD) or frontotemporal lobar degeneration (FTLD) is a 
progressive neuronal degeneration in the frontal and temporal cortices. It is the second 
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most common dementia after Alzheimer’s disease and affected individuals change their 
personality and behavior with gradual defects in language skills (Van Langenhove, van 
der Zee et al. 2012). Mutations in genes encoding the microtubule-associated protein tau 
(MAPT) and progranulin (PGRN) account for 20% of FTD (Hutton, Lendon et al. 1998, 
Baker, Mackenzie et al. 2006). FTDs are classified pathologically based on the type of 
neuronal inclusions in the cortex (Lillo and Hodges 2009). TDP-43 has been found as the 
main component of the ubiquitin positive inclusions in the large portion of FTD patients 
and most ALS patients (Neumann, Sampathu et al. 2006). ~15% of FTD patients become 
affected with ALS and ~15% of ALS patients develop FTD with TDP-43 positive 
inclusions in cortical neurons (Ringholz, Appel et al. 2005, Lillo and Hodges 2009). 
These results suggest that ALS shares several clinical and pathological features with 
FTD. Supporting this notion, ALS-linked mutations in C9ORF72 genes are identified in 
FTD as well (DeJesus-Hernandez, Mackenzie et al. 2011).  
In addition to TDP-43 inclusions in FTD, FUS-positive inclusions are also identified 
and account for ~9% of FTD (Ling, Polymenidou et al. 2013). In contrast to ALS-FUS, 
which is caused by mutations in FUS, cytoplasmic FUS in FTD harbors rare or no genetic 
alternation (Neumann, Rademakers et al. 2009, Van Langenhove, van der Zee et al. 
2010). We still do not know how one protein contributes to the disease pathogenesis in 
both ALS and FTD.  
I.4 Molecular Mechanisms of FUS 
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I.4.1 The normal function of FUS 
FUS was initially identified as a component in human myxoid liposarcomas where 
the N-terminal portion of FUS fused with CCAAT enhancer-binding homologus protein 
(CHOP) as a consequence of a chromosome translocation t(12;16)(q13.3;p11.2) (Crozat, 
Aman et al. 1993). FUS is expressed ubiquitously in human tissues and cultured cell lines 
but is absent in cardiac muscle cells and melanocytes (Andersson, Stahlberg et al. 2008). 
FUS localizes predominately in the nucleus but also shuttles rapidly between nucleus and 
cytoplasm (Zinszner, Sok et al. 1997). FUS comprises several domains including a Q/G/
S/Y-rich domain, RGG-rich regions, an RNA recognition motif (RRM), a zinc finger 
motif and a PY-type nuclear localization signal (PY-NLS) recognized by the nuclear 
import receptor, Transportin 1 (Figure 1). Both the QGSY-rich domain and glycine rich 
region (amino acids 1-239) have a disordered prion-like property that may facilitate the 
self-aggregation of FUS (Cushman, Johnson et al. 2010). With TAF15 (TATA-binding 
protein associated factor 15) and EWS (Ewing sarcoma protein), FUS belongs to the FET 
family. TAF15 and EWS have domain structures similar to FUS, and they are also 
associated with FTD and ALS (Law, Cann et al. 2006, Tan and Manley 2009, Mackenzie 
and Neumann 2012). 
FUS binds RNA, single-stranded DNA with lower affinity, and double stranded DNA 
and regulates RNA biogenesis including splicing, transcription, and mRNA transport 
(reviewed in (Lagier-Tourenne, Polymenidou et al. 2010, Ling, Polymenidou et al. 
2013)).  
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Transcription FUS was found in a complex of RNA polymerase II and its general 
transcription factor TFIID (Bertolotti, Melot et al. 1998). Later, FUS binding to the C-
terminal domain of RNA polymerase II (RNAPII) is observed (Schwartz, Ebmeier et al. 
2012). This interaction can prevent premature hyperphosphorylation of Ser2 at the C-
terminal domain of RNAPII. Further analysis of this interaction demonstrated that FUS 
binding to RNA can serve as a seed that recruits RNA-free FUS to form a fibrous 
assembly, and RGG-Zn-RGG and prion-like domain of FUS can contribute to this 
assembly (Schwartz, Wang et al. 2013). While FUS promotes RNAPII transcription, FUS 
can inhibit RNAPIII transcription through direct interaction with the transcription factor 
TATA-binding protein (TBP) in HeLa cells (Tan and Manley 2010). In addition, FUS can 
regulate target gene transcription through binding on the specific single-stranded DNA 
sequences containing three copies of the TCCCCGT, AAAGTGTC, or AGGTTCTA 
located within their promotor regions (Tan, Riley et al. 2012).Transcriptions of cyclin D1 
and Manganese superoxide dismutase (MnSOD) may be regulated by FUS (Wang, Arai et 
al. 2008, Dhar, Zhang et al. 2014). In addition, Ishigaki et al. found that binding FUS to 
antisense RNA strands at the promotor regions decreased transcription of the coding 
strand, indicating that FUS regulates both transcription and alternative splicing (Ishigaki, 
Masuda et al. 2012). Consistent with this finding, a recent study reveals that FUS should 
be present during the transcription reaction to effect splicing events through an 
interaction between RNAP II and U1 snRNP (Yu and Reed 2015).  
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Splicing Previously, FUS was identified in H complex as heterogeneous nuclear 
ribonucleoparticles (hnRNP) P2 (Calvio, Neubauer et al. 1995), and FUS 
immunoprecipitation experiment reveals that FUS interacts with splicing factors such as 
polypyrimidine tract-binding protein (PTB or hnRNPI), SRm160 and SR proteins (SC35 
and SRp75) (Meissner, Lopato et al. 2003). This indicates that FUS plays a role in 
splicing and spliceosome assembly. More recently, FUS interaction with essential 
splicing factor U1 snRNP has been found in several studies (Sun, Ling et al. 2015, Yu, 
Chi et al. 2015, Yu and Reed 2015).  
The CLIP-seq approaches have identified that FUS targets more than 5,500 RNAs in 
human brains and more than 6,800 in various cell lines (Ishigaki, Masuda et al. 2012, 
Lagier-Tourenne, Polymenidou et al. 2012, Orozco, Tahirovic et al. 2012, Rogelj, Easton 
et al. 2012). These RNAs have exceptionally long introns and multiple binding sites. FUS 
binding across the pre-mRNA displays a sawtooth-like pattern in both mouse and human 
brains because FUS is clustered at the beginning of long introns (>100kb) and decreases 
gradually toward the 3’ end (Lagier-Tourenne, Polymenidou et al. 2012, Rogelj, Easton et 
al. 2012). This binding pattern also implicates the role of FUS in the stabilization of 
nascent RNA during transcriptional elongation. FUS binding occurs with preference for a 
GUGGU motif (Lagier-Tourenne, Polymenidou et al. 2012).  
The microtubule-associated protein Tau (MAPT) is reported as the first physiological 
splice target of FUS in neurons (Orozco, Tahirovic et al. 2012). In the mouse brain, FUS 
binds to Tau pre-mRNA directly, and the depletion of FUS in the rat hippocampal 
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neurons enhances the expression of Tau exons 3 and 10, which results in impaired 
cytoskeletal organization. Another study using high-throughput sequencing in mouse 
primary cortical neurons with FUS knockdown demonstrated that FUS mediated 
alternative splicing in genes such as Mapt, Camk2a and Fmr1 (Ishigaki, Masuda et al. 
2012). 
The splicing targets of FUS also include the gene coding for RNA-binding proteins 
(RBP) in human brains and mouse neurons, and FUS regulates the splicing of these genes 
through binding to their highly conserved introns (Nakaya, Alexiou et al. 2013). 
Interestingly, the authors found that FUS bound to the two conserved introns between 
exon 6 and exon 8 of human and mouse FUS itself. 
Previous studies showed that FUS prefers to bind to GGUG-containing RNA (Lerga, 
Hallier et al. 2001, Iko, Kodama et al. 2004) and the major RNA binding sites within FUS 
localize at the RGG2-ZnF-RGG3 domains (Iko, Kodama et al. 2004). Recent study 
revealed that FUS binding was targeted to the whole length of pre-mRNAs with limited 
sequence preference to GGU (Rogelj, Easton et al. 2012). Others found that FUS binds to 
RNA through AU-rich stem-loops (Hoell, Larsson et al. 2011). 
All together, these studies support the idea that FUS regulates splicing on nascent 
transcripts and target RNAs contain long introns. Moreover, proteins translated from 
these target RNAs play an important role in neuronal development and synaptic 
maintenance. However, these studies couldn’t reveal a defined FUS binding motif. 
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RNA transport Although FUS expresses predominantly in the nucleus (Andersson, 
Stahlberg et al. 2008), FUS is able to shuttle between nucleus and cytoplasm (Zinszner, 
Sok et al. 1997). This property of FUS may contribute to RNA transport and local 
translation. For instance, FUS is able to translocate to dendritic spines through 
microtubules and actin filaments concomitant with increased RNA content in the spine of 
cultured hippocampal neurons (Fujii, Okabe et al. 2005). FUS depletion in hippocampal 
pyramidal neurons showed abnormal spine morphology and attenuated spine density. 
Furthermore, FUS mediates the transport of mRNA encoding an actin-stabilizing protein 
Nd1-L for its local translation in dendritic spines of mouse hippocampal neurons through 
the stimuli with the glutamate receptor mGluR5 (Fujii and Takumi 2005).  
miRNA production FUS is found in the large Drosha complex with TDP-43 and can 
bind to Drosha and pri-miRNA such as pri-miR-9-2 and 15a (Gregory, Yan et al. 2004, 
Morlando, Dini Modigliani et al. 2012). While FUS mutants (R521C and P525L) do not 
alter Drosha binding, FUS depletion in neuronal cells alters the large class of miRNA 
expression including specific neuronal miRNA, which is critical for neuronal function, 
activity, and differentiation. This result suggests that insufficient FUS expression in 
nucleus by FUS mutants may participate in ALS pathogenies through the alternation of 
miRNA biogenies. 
DNA damage response FUS is initially identified as a target of ATM (ataxia-
telangiectasia mutated) which catalyses FUS phosphorylation at Ser42 when cells are 
exposed to ionizing radiation (IR) to cause DNA double-strand break (Gardiner, Toth et 
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al. 2008). The rapid recruitment of FUS to the sites of laser-induced DNA double-strand 
breaks is mediated by the poly (ADP-ribose) polymerase (PARP), and the prion-like 
domain of FUS promotes accumulation at sites of DNA damage (Mastrocola, Kim et al. 
2013, Rulten, Rotheray et al. 2014). In addition, the interaction between FUS and histone 
deacetylase 1 (HDAC1) in response to DNA damage is discovered, and this complex 
could work for DNA repair in neurons (Wang, Pan et al. 2013). The authors found that 
cultured motor neurons expressing ALS-linked FUS mutants R244C, R514S, H1517Q, 
and R521C fail to recruit FUS at the site of DNA damage as well as diminish FUS 
interaction with HDAC1. Moreover, motor cortex tissues from ALS patients expressing 
FUS-R521C or P525L exhibit increased γH2AX positive staining that indicates increased 
DNA damage, suggesting ALS with FUS mutants has deficits in DNA repair (Wang, Pan 
et al. 2013).  
I.4.2 FUS animal models of ALS 
I.4.2.1 Rodent model  
Before the discovery of ALS-linked mutations in FUS, two FUS knockout mouse 
lines were generated. FUS null mice having inbred C57BL/6 background died within 16 
hours after birth because of chromosome instability and abnormal lymphocyte 
development suggesting FUS may play a critical role in genome maintenance (Hicks, 
Singh et al. 2000). Another FUS knockout mouse model was generated from an outbred 
background (CD1 with 129/SvEv) and showed male sterility and enhanced sensitivity to 
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irradiation (Kuroda, Sok et al. 2000). However, these mouse models were not examined 
for defects in motor function. Recently, FUS knockout outbred homozygous mice were 
generated using a mixed background of B6 and ICR strains to analyze motor phenotypes 
(Kino, Washizu et al. 2015). Surprisingly, FUS knockout did not develop ALS-like 
symptoms. Instead of motor neuron degeneration, FUS knockout mice developed 
vacuolation in the hippocampus and exhibited hyperactivity and reduced anxiety-related 
behaviors, suggesting that the phenotype of FUS knockout is more like FTLD. 
To investigate the toxic gain of FUS function, several transgenic rodent lines 
expressing FUS variants have been developed. So far, two rat and six mouse models 
expressing either FUS-WT, mutants (R521C, R521G, or R495X), or truncated forms 
(1-359 or 1-478) have been generated (Table 1-2). The detailed information about these 
transgenic models will be discussed below. 
The first transgenic rat models expressing human FUS-WT and FUS-R521C were 
generated in 2011 (Huang, Tong et al. 2012). Overexpression of FUS-R521C in rats 
resulted in progressive paralysis with loss of neurons in cortex and hippocampus. These 
affected neurons contained ubiquitin aggregates. However, these rats did not develop 
obvious motor phenotypes. Over expression of FUS-WT also induced neuron death at 
one year of age and showed a deficit in learning and memory more indicative of an 
FTLD-like phenotype. 
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The first transgenic mouse lines expressing HA-tagged human FUS-WT were 
generated by the Shaw group, and both hemizygous and homozygous mouse lines were 
examined (Mitchell, McGoldrick et al. 2013). While hemizygous mice (expression level 
1.6x control) showed no motor pathology, homozygous transgenic mice (expression level 
1.9x control) developed motor neuron degeneration with globular and skein-like-FUS and 
ubiquitin-negative inclusions in motor neurons. Somatic brain transgenic (SBT) mice 
were generated by bilateral intracerebroventricular injection of recombinant adeno-
associated virus (rAAV) expressing V5-tagged human FUS-wild type, R521C, or 
p.G466VfsX14 (FUS14) (Verbeeck, Deng et al. 2012). Mice expressing the FUS14 
mutant exhibit neuronal cytoplasmic inclusions recognized by antibodies to ubiquitin, 
p62, α-internexin, and the poly-adenylate(A)-binding protein 1 (PABP-1) at 3 months of 
age. Despite FUS14 mice harboring ubiquitin positive FUS inclusions, this mouse line 
did not develop a motor phenotype or degeneration. In 2013, FUS transgenic mice 
expressing a truncated human FUS construct, which contains only the region of 1-359 
amino acid, lacking nuclear localization signals and major RNA binding motifs, were 
generated and displayed severe motor phenotypes with FUS cytoplasmic aggregation 
(Shelkovnikova, Peters et al. 2013). These mice developed motor neuron degeneration at 
the age of 2.5 to 4.5 months, and death occurred within several days after onset, 
indicating that FUS aggregation in neurons may be sufficient to cause ALS-like 
phenotypes. The other transgenic mouse model expressing FUS-R521C exhibited 
evidence of DNA damage in cortical and spinal motor neurons as well as dendritic and 
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synaptic defects in the spinal motor neurons (Qiu, Lee et al. 2014). The authors observed 
that an interaction between HDAC1 and endogenous FUS was diminished in the FUS-
R521C mice. Furthermore, FUS-521C mice displayed splicing defects in 5’ noncoding 
exons of the brain-derived neurotrophic factor (Bdnf) gene and impaired transportation of 
Bdnf mRNA into distal dendrites. Recently, transgenic mouse models expressing either 
FUS-WT or FUS-R521G showed severe motor defects with neuroinflammation, 
denervated neuromuscular junctions, and premature death (Sephton, Tang et al. 2014). 
However, the disease onset in these mouse models was 10 to 14 days old, and there was 
no control for global EGFP over expression in these models. Interestingly, the R521G 
mouse that escaped from early lethality exhibits defects in motor function and social 
interactions. Although these mouse models do not show the pathological features 
including FUS mislocalization, aggregation and motor neuron loss, the FUS-R521G 
mouse exhibits a reduction of dendritic branches and mature spines suggesting that the 
FUS mutant might disrupt synaptic homeostasis through a toxic gain of function 
(Sephton, Tang et al. 2014).  
I.4.2.2 Other animal models 
In addition to rodent models, zebrafish (Danio reio), Caenorhabditis elegans, and 
Drosophila melanogaster have been used to investigate the pathological role of FUS in 
ALS. The zebrafish (Danio rerio) has several advantages for the study of human disease 
because of its genetic homology to mammals, external fertilization, large egg production, 
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rapid development, and transparency of embryo. It has been used widely in biomedical 
research, including ALS (Patten, Armstrong et al. 2014). The knockdown of endogenous 
FUS or over expression of mutant FUS (R521H) showed abnormal motor phenotypes 
including swimming defects, axon shortening, and abnormal branchings (Kabashi, 
Bercier et al. 2011, Armstrong and Drapeau 2013). These results suggest that both gain 
and loss of FUS function are involved in motor neuron degeneration. Consistent with this 
finding, the overexpression or loss of the Drosophila homologue Cabeza (Caz) exhibits 
motor neuron degeneration, neuromuscular junction disruption, reduced viability, and 
shortened lifespan (Sasayama, Shimamura et al. 2012, Xia, Liu et al. 2012). Furthermore, 
FUS mutant expressions in C. elegant causes progressive motor dysfunction and reduced 
lifespan by a dominant gain-of-function (Murakami, Yang et al. 2012). Taken together, 
these animal models suggest loss of FUS function and gain-of-toxicity may act together 
to participate in FUS mediated pathology. 
I.4.3 The pathological role of FUS in ALS 
All FUS mutations reported to date are dominant except for one recessive mutation, 
H517Q, found in the index Cape Verdian family (Kwiatkowski, Bosco et al. 2009). Most 
FUS mutations localize within the PY-NLS region and may affect translocation into the 
cytoplasm upon disruption of the interaction with Transportin 1 (Bosco, Lemay et al. 
2010, Dormann, Rodde et al. 2010, Ito, Seki et al. 2011, Kino, Washizu et al. 2011). The 
most aggressive FUS mutations, such as P525L and R495X, contain disrupted nuclear 
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localization signals, localize mostly to the cytoplasm, and cause juvenile onset with short 
survival of 1 to 2 years (Baumer, Hilton et al. 2010, Huang, Zhang et al. 2010). Motor 
neurons from these patients contain basophilic inclusions, whereas individuals harboring 
FUS-R521C mutations show tangle-like cytoplasmic inclusions in both neurons and glial 
cells (Baumer, Hilton et al. 2010, Huang, Zhang et al. 2010, Mackenzie, Ansorge et al. 
2011). While several roles of FUS in altered stress responses, protein aggregate 
formation, and altered RNA metabolism have been proposed, we still do not fully 
understand which molecular mechanisms are most relevant to motor neuron toxicity in 
mutant FUS mediated ALS. 
I.4.3.1 Stress granules 
Upon stress exposure, eukaryotic cells stall translation and form cytoplasmic RNA-
protein complexes, referred to as ribonucleoprotein (RNP) granules, including processing 
bodies (P-bodies) and stress granules (Anderson and Kedersha 2008, Buchan and Parker 
2009). Stress granules are dynamic structures and may protect cells from insults with 
oxidative stress, heat shock, or glucose deprivation by conserving energy and producing 
the essential proteins for survival and recovery (Kedersha, Ivanov et al. 2013).  
Initial findings showed that oxidative stress induced localization of endogeneous or 
GFP-tagged FUS to stress granules in HeLa cells (Andersson, Stahlberg et al. 2008). 
Later, mutant TDP-43 associated with ALS is accumulated into stress granules following 
oxidative stress (Colombrita, Zennaro et al. 2009). This result suggests that impaired 
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stress responses may contribute to ALS pathogenesis. Therefore, we investigated cellular 
localizations of FUS variants under stress conditions in a cell culture and zebrafish model 
of ALS (in chapter II). Further discussion related to stress granules in ALS pathogenesis 
appears in chapter IV. 
I.4.3.2 Altered RNA metabolism and Gem loss 
CLIP/exon array with depletion of FUS expression revealed that FUS deficiency 
altered the levels or splicing of target mRNAs, suggesting that insufficient expression of 
FUS in the nucleus by ALS-linked FUS mutants may participate in pathological effects 
through alteration on RNA metabolism (Lagier-Tourenne, Polymenidou et al. 2012, 
Rogelj, Easton et al. 2012, Ling, Polymenidou et al. 2013). For instance, the depletion of 
FUS expression in human neurons derived from stem cells or mouse brain decreases the 
expression of Csma1, Nrxn3, Nlgnl, Smyd3 and Kenip4, which are essential for 
axonogenesis, cytoskeleton organization, and synaptic formation and function (Lagier-
Tourenne, Polymenidou et al. 2012).  
FUS mutants are found to accumulate the essential components for splicing in 
cytoplasmic aggregates and reduce their activity (Gerbino, Carri et al. 2013, Sun, Ling et 
al. 2015, Yu, Chi et al. 2015). Patient fibroblasts harboring FUS mutant R514G or R521C 
show the mislocalization of U1 snRNP, such as SmB and U1 snRNA in cytoplasm (Yu, 
Chi et al. 2015). Moreover, SmB showed co-localization with cytosolic FUS mutants. 
Knockdown of U1 snRNP such as U1-70K or U1 in zebrafish showed motor neuron 
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defect, indicating that U1 snRNP is important to motor neuron homeostasis. In addition, 
Sun et al. found that snRNA levels are changed in ALS patient fibroblasts harboring FUS 
mutants, and reduced interaction with U1-70K and Sm-B/D are also observed in HeLa 
cells expressing GFP tagged FUS-R495X or P525L (Sun, Ling et al. 2015). There results 
indicate that FUS play an important role for splicing regulation in HeLa cells and patient 
fibroblasts. The RNA-mediated oligonucleotide annealing, selection, and ligation with 
next-generation sequencing (RASL-seq) analysis in ALS patient fibroblasts with R521G, 
H517Q, and M511Nfs*6 (NLS) mutations in FUS revealed altered splicing events 
compared to fibroblasts from three control individuals. FUS mutant fibroblasts showed 
57 splicing events had an increased long isoform and 53 splicing events had an enhanced 
short isoform. These changes in snRNPs result in loss of Gems, one of subnuclear 
organelles, supporting the notion that defects in RNA metabolism and Gem assembly 
may contribute to motor neuron death in ALS.  
In addition to Gems, expression of FUS mutants has been reported to alter the 
assembly of other nuclear bodies including speckles and paraspeckles (Nishimoto, 
Nakagawa et al. 2013, Shelkovnikova, Robinson et al. 2014, Takanashi and Yamaguchi 
2014). Therefore, the roles of nuclear bodies and possible toxic effects of FUS mutants 
on nuclear body assembly will be discussed in the following section. 
I.5 Possible toxic effects of FUS on nuclear bodies 
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Mammalian cell nuclei contain several subnuclear organelles including nucleoli, 
nuclear speckles and paraspeckles, Cajal bodies, nuclear Gems, histone locus bodies, and 
promyelocytic leukemia bodies (PML-NBs) (Mao, Zhang et al. 2011). These nuclear 
bodies are membrane-less and highly dynamic. Dysfunction of these assemblies has been 
linked to conditions including neurodegenerative diseases and cancers (Zimber, Nguyen 
et al. 2004, Woulfe 2008, de The, Le Bras et al. 2012) (Table 1-3).  
Nucleolus The Nucleolus is assembled around the cluster of tandemly repeated 
ribosomal DNA genes and plays a role in ribosomal RNA synthesis and nascent ribosome 
assembly (Pederson 2011). These events occur in three distinct subnucleolar 
compartments termed the fibrillar center (FC), dense fibrillar component (DFC) and 
granular component (GC) (Boulon, Westman et al. 2010). The FCs contain rDNA and 
transcription factor UBF. The transcription by RNA Pol I machinery produces pre-rRNA, 
45S rRNA. This event occurs either in the FCs or at the border between the FC and the 
DFC. The DFC contains pre-rRNA processing factors including the small nucleolar 
ribonucleoproteins (snoRNP), and fibrillarin. The GC encloses the FC and the DFC and 
works for pre-ribosome subunit assembly. In addition to the role in rRNA biogenesis, the 
nucleolus also regulates cellular stress responses. Under stress conditions including 
transcription inhibition, viral infection, or DNA damage, nucleolus re-organizes its 
structure and protein composition (Boulon, Westman et al. 2010). A recent proteome 
database for human nucleolus reveals that more than 4,500 proteins can accumulate in 
nucleolus transiently or persistently (Ahmad, Boisvert et al. 2009).  
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 Table 1-3 Nuclear bodies
Name Number per cell Size (µm) Components Proposed Functions Findings in ALS research
Nucleolus 1-4 0.5-8.0 Fibrillarin,Nucleolin, B23/NPM rRNA biogenesis
Toxic dipeptides (GR and PR) 
accumulation in ALS-C9ORF72 
Speckles 20-50 0.8-1.8 SC35, Malat1 storage/assembly/modification of pre-mRNA splicing factors
Decreased the number of poly 
(A) foci in ALS-FUS
Paraspeckles 5-20 0.5 PSP1, PSF, p54nrb/NONO
nuclear retention of adenosine 
to inosine hyperedited mRNAs
FUS interacts with p54nrb      
Cytoplasmic p54nrb inclusions in 
ALS-FUS 
Cajal bodies/Gems 0-10 0.1-2.0 p80 coilin/SMN assembly and trafficking of snRNP and snoRNP
Gem loss in ALS-FUS and ALS-
TDP43
PML-NB 1-30 0.3-1.0 PML, Daxx, Sp100 cellular stress response, nuclear protein quality control
PML-positive intranuclear 
inclusion 
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Nucleolar dysfunction is found in ALS (Hetman and Pietrzak 2012). The polymers of 
arginine-rich dipeptides (GR and PR) translated from the ALS associated gene C9ORF72 
repeat expansion, translocate to the nucleus, and accumulate in the nucleolus causing 
deficits in rRNA biogenesis, concomitant with cell death (Kwon, Xiang et al. 2014). 
Speckles Nuclear speckles or SC35 domains are enriched with components for pre-
mRNA splicing and locate in the inter chromatin regions of the nucleoplasm (Spector and 
Lamond 2011). Pre-mRNA splicing factors include small nuclear ribonucleoproteins 
(snRNPs) and serine-arginine rich (SR) proteins. SR proteins contain the arginine/serine-
rich dipeptide domain (RS domain) and the RNA-recognition motif. In addition to pre-
mRNA splicing factors, several RNAs including metastasis-associated lung 
adenocarcinoma transport 1 (MALAT1) long non-conding RNA, and a population of 
poly(A)+ RNAs also accumulate in nuclear speckles. Transcription inhibition either by 
the drug treatment or as the result of heat shock exposure increases the size of speckles 
concomitant with accumulation of splicing factors indicating that nuclear speckles may 
regulate storage, assembly, and modification of splicing factors (Spector and Lamond 
2011). In SH-SY5Y cells expressing FUS mutants poly (A) mRNA and SMN1 are 
sequestered in the cytoplasm and decreased the number of nuclear speckles (Takanashi 
and Yamaguchi 2014).  
Paraspeckles Paraspeckles were recently discovered in 2002 and are distinct from 
nuclear speckles, although they are located adjacent to speckles in the inter chromatin 
space (Fox, Lam et al. 2002). Only mammalian cells contain typically 10 to 20 
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paraspeckles that are formed by the complex of the RNA-protein structure. The 
paraspeckle proteins include PSF/SFPQ, P54NRB/NONO, and PSPC1 (paraspeckle 
protein 1), which are the members of the DBHS (Drosophila melanogaster Behavior, 
Human Splicing) family. These proteins along with a long nuclear non-coding RNA 
(lncRNA) NEAT1 (also known as Men ε/β), can form paraspeckles (Fox and Lamond 
2010). Paraspeckles may control gene expression through the nuclear retention of 
adenosine to inosine hyperedited mRNAs harboring double stranded RNA regions. HeLa 
cells treated with Actinomycin D (1 µg/ml) to inhibit RNA Pol transcription show that 
paraspeckles move to the perinucleolar cap region with other RNA Pol factors suggesting 
paraspeckles are involved in the cellular stress response (Fox and Lamond 2010).  
While the level of NEAT1 is low in the nervous tissues and paraspeckles are absent 
in neurons under basal condition, NEAT1_2 lncRNA levels in the patient spinal motor 
neurons are up-regulated abnormally during the early stage of ALS (Nishimoto, 
Nakagawa et al. 2013). Moreover, FUS is identified as an essential component of 
paraspeckles through binding to either NEAT1_2 long non-coding RNA or p54nrb/
NONO (Nishimoto, Nakagawa et al. 2013, Shelkovnikova, Robinson et al. 2014). FUS is 
also able to regulate NEAT1 levels and participate in paraspeckle formation 
(Shelkovnikova, Robinson et al. 2014). Cytoplasmic FUS inclusion accumulates other 
paraspeckle proteins such as p54nrb/NONO, PSP1, and PSF in cultured cells. Consistent 
with cell culture results, p54nrb/NONO positive inclusions are found in motor neurons of 
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ALS patient harboring FUS mutations, suggesting that a disruption of paraspeckle 
assembly may contribute to ALS pathogenesis.  
Cajal Bodies Cajal bodies (CBs) were first described by the Spanish neurobiologist 
Santiago Ramon y Cajal in 1903 (Lafarga, Casafont et al. 2009). While coilin/p80 is the 
common CB component, the uridine-rich small nuclear RNA (U1, U2, U4, U5 and U6) 
and associated proteins are also found in CBs (Nizami, Deryusheva et al. 2010). The role 
of CBs has been proposed as the site for the assembly and modification of small nuclear 
ribonucleoprotein (snRNPs) and snoRNPs. The newly assembled snRNPs in cytoplasm 
are imported back to the nucleus and concentrated first in CBs. Later maturated snRNPs 
are translocated to nuclear speckles prior to the localization into the active genes for 
participating in pre-mRNA splicing. In addition, CBs may regulate telomerase RNP 
assembly and telomere length homeostasis (Mao, Zhang et al. 2011). 
GEMs Gemini of coiled bodies (GEMs) concentrated with survival of motor neuron 
(SMN) is similar in size to CBs and often localize near CBs (Liu and Dreyfuss 1996). In 
primary neurons and in Drosophila, SMN is colocalized with coilin. Gems normally 
contain survival motor neuron (SMN) protein and serve functions related to snRNP 
assembly and RNA splicing (Liu and Dreyfuss 1996, Pellizzoni, Kataoka et al. 1998). 
The disruption of GEM formation is the pathological hallmark of spinal muscular atrophy 
(SMA), the childhood onset of motor neuron degenerative disease (Pellizzoni, Kataoka et 
al. 1998). The reduced expression levels of SMN can causes Gem depletion. The change 
in GEM numbers and the reduction of SMN expression are also observed in ALS cases, 
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suggesting the link between SMA and ALS. For instance, reduced GEM numbers is 
found in both HeLa cells with TDP-43 knockdown and spinal motor neurons in ALS 
patients harboring TDP-43 mutation (Ishihara, Ariizumi et al. 2013). Moreover, FUS 
mutant expression in cellular models and human fibroblasts mediated a reduction in Gem 
formation (Yamazaki, Chen et al. 2012). Gem loss is also associated with a decrease in 
the number of Cajal bodies and a concomitant increase in PML body number in SMA 
motor neurons (Tapia, Bengoechea et al. 2012), further supporting a role for nuclear 
bodies in motor neuron homeostasis and survival. 
PML-NBs Promyelocytic leukemia bodies (PML-NBs) were first described in the 
early 1960s as the presence of dense spherical objects in the nucleus by electron 
microscopy (Lallemand-Breitenbach and de The 2010). Later, in 1991, the 
characterization of these nuclear bodies is initially observed and named nuclear dot 
protein 55 (NDP-55) (Ascoli and Maul 1991). PML-NBs form discrete nuclear foci 
0.2-1.0 µm wide and present in most mammalian cells (Bernardi and Pandolfi 2007). The 
main component of PML-NB is PML protein. PML (also called RNF71 or TRIM19) is a 
member of the tripartite motif (TRIM) protein family characterized by structural elements 
including a RING (Really Interacting New Gene) finger, two B box zinc fingers, and a 
coiled-coil domain (RBCC motif). This RBCC motif contributes to self-dimerization to 
form PML-NBs and mediates the binding of PML to the SUMO E2 ligase UBC9 (de The, 
Le Bras et al. 2012). The proposed role of PML-NBs includes DNA damage response 
(Dellaire, Ching et al. 2006), apoptosis (Takahashi, Lallemand-Breitenbach et al. 2004, 
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Bernardi, Papa et al. 2008), cellular senescence (Vernier, Bourdeau et al. 2011), gene 
transcription (Block, Eskiw et al. 2006), and anti-viral response (Everett and Chelbi-Alix 
2007). Recently, PML-NBs are reported to regulate nuclear protein quality control and 
oxidative stress response (Guo, Giasson et al. 2014, Sahin, de The et al. 2014, Sahin, 
Ferhi et al. 2014).  
PML-NBs have been shown in the nervous system to influence neurodevelopment 
and synaptic plasticity under normal conditions (Regad, Bellodi et al. 2009, Butler, 
Martinez et al. 2013, Korb and Finkbeiner 2013). In several neurodegenerative 
conditions, PML is found in neuronal intranuclear inclusions in affected brain tissues 
(Woulfe 2008). Interestingly, intranuclear inclusions in some ALS patient tissues show 
immunoreactivity to PML that could be associated with ALS pathogenesis (Seilhean, 
Takahashi et al. 2004).  
Mutant FUS expressions are reported to perturb the assembly of nuclear bodies 
including nuclear Gems (Yamazaki, Chen et al. 2012, Groen, Fumoto et al. 2013, Sun, 
Ling et al. 2015). The loss of nuclear Gems is the pathological hallmark in spinal 
muscular atrophy, a childhood-onset motor neuron disease (Pellizzoni, Kataoka et al. 
1998). Interestingly, Gem loss may also be associated with a decrease in the number of 
Cajal bodies and accompanying increase in PML body number in SMA motor neurons 
(Tapia, Bengoechea et al. 2012). Collectively, these observations provide evidence that 
PML-NBs may play a role in motor neuron survival and homeostasis. However, the 
dynamic of PML-NBs has not been addressed in the condition of ALS. 
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In this thesis, I investigated the role of FUS mutants under stress conditions in cell 
culture and zebrafish models of ALS. Mutant FUS with a disrupted nuclear localization 
signal mislocalized to the cytoplasm and accumulated into stress granules in a proportion 
to FUS expressions in the cytoplasm under the condition of oxidative stress and heat 
shock. However, many FUS mutants are retained predominantly in the nucleus. This 
observation guided us to investigate nuclear perturbation of subnuclear bodies caused by 
FUS mutants, which had not previously been explored. PML-NBs play a role in nuclear 
protein quality control and nuclear stress responses. A human cell line (HEK293) 
expressing FUS mutants (R495X, R521G or P525L) and human fibroblasts from an ALS 
patient harboring FUS-R521G mutation showed impaired PML-NB dynamics under 
oxidative stress conditions, providing novel evidence that mutant FUS may contribute to 
ALS pathogenesis by gain-of-toxicity in the nucleus. 
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Chapter II:  
Mutant FUS proteins that cause amyotrophic lateral sclerosis  
incorporate into stress granules 
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II.1 Preface 
This work is published as: 
Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate  
into stress granules 
Daryl A. Bosco, Nathan Lemay, Hae Kyung Ko, Hongru Zhou, Chris Burke, Thomas J. 
Kwiatkowski Jr, Peter Sapp, Diane McKenna-Yasek, Robert H. Brown Jr, and  
Lawrence J. Hayward  
(2010) Human Molecular Genetics 19(21): 4160-4175. 
I performed all of the described zebrafish work including microinjection, 
immunostaining, confocal image acquisition. 
All figures including supplemental figures were subsequently renumbered to  
incorporated to this chapter. 
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II.2 Abstract 
Mutations in the RNA-binding protein FUS (fused in sarcoma) are linked to 
amyotrophic lateral sclerosis (ALS), but the mechanism by which these mutants cause 
motor neuron degeneration is not known. We report a novel ALS truncation mutant 
(R495X) that leads to a relatively severe ALS clinical phenotype compared with FUS 
missense mutations. Expression of R495X FUS, which abrogates a putative nuclear 
localization signal at the C-terminus of FUS, in HEK-293 cells and in the zebrafish spinal 
cord caused a striking cytoplasmic accumulation of the protein to a greater extent than 
that observed for recessive (H517Q) and dominant (R521G) missense mutants. 
Furthermore, in response to oxidative stress or heat shock conditions in cultures and in 
vivo, the ALS-linked FUS mutants, but not wild-type FUS, assembled into perinuclear 
stress granules in proportion to their cytoplasmic expression levels. These findings 
demonstrate a potential link between FUS mutations and cellular pathways involved in 
stress responses that may be relevant to altered motor neuron homeostasis in ALS. 
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II.3 Introduction 
 Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative condition 
that kills motor neurons in the brain and spinal cord, causing progressive weakness and 
death within 3-5 years. Although 90% of cases occur sporadically, mechanistic insights 
relating specific gene defects to motor neuron death have been obtained by identifying 
familial ALS genes and observing the consequences of their expression in cellular and 
animal models (Dion, Daoud et al. 2009). The critical sequence of events leading to ALS 
is not known, but recurring themes in its pathogenesis include: (i) excitotoxicity, (ii) 
impaired intracellular transport, (iii) mitochondrial dysfunction and (iv) protein 
misfolding and aggregation. Since 2006, altered RNA-binding proteins or their 
mislocalization have been implicated in the pathogenesis of both familial ALS (fALS) 
and sporadic ALS (sALS) (Lemmens, Moore et al. 2010, van Blitterswijk and Landers 
2010). The initial discovery of the RNA-binding protein TDP-43 (TAR DNA binding 
protein-43) as a major constituent of neuronal inclusions in sALS (Neumann, Sampathu 
et al. 2006, Wang, Wu et al. 2008) was followed by the identification of mutations in the 
TARDBP gene that encodes TDP-43 in a subset of both fALS and sALS cases (Kabashi, 
Valdmanis et al. 2008, Sreedharan, Blair et al. 2008). Since 2009, specific mutations in 
the gene that encodes the RNA-binding protein FUS were linked to fALS (Belzil, 
Valdmanis et al. 2009, Chio, Restagno et al. 2009, Kwiatkowski, Bosco et al. 2009, 
Ticozzi, Silani et al. 2009, Vance, Rogelj et al. 2009, Blair, Williams et al. 2010, Corrado, 
Del Bo et al. 2010, Damme, Goris et al. 2010) and also implicated in sALS (Belzil, 
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Valdmanis et al. 2009, Corrado, Del Bo et al. 2010, DeJesus-Hernandez, Kocerha et al. 
2010, Lai, Abramzon et al. 2011). Both FUS and TDP-43 share related structural 
elements, suggesting that they function in roles linked to RNA processing or regulation 
(Lagier-Tourenne and Cleveland 2009, Lemmens, Moore et al. 2010). TDP-43 and FUS 
mutations each are associated with ~5% of fALS cases, which indicates that 
abnormalities in these two genes collectively approach the 10-20% prevalence of variants 
in Cu/Zn superoxide dismutase (SOD1) among individuals with fALS (Lemmens, Moore 
et al. 2010). 
FUS (fused in sarcoma) was originally named TLS (translocated in liposarcoma) 
upon the discovery of a chromosomal translocation event in myxoid liposarcoma that 
produced a potent oncoprotein comprising amino acid residues 1-266 of FUS/TLS 
(encoded by exons 1-7) fused at its C-terminus to the transcription factor CHOP (Crozat, 
Aman et al. 1993, Rabbitts, Forster et al. 1993). The 526-residue full-length FUS/TLS 
(Crozat, Aman et al. 1993) was subsequently identified as the heterogeneous nuclear 
ribonucleoprotein (hnRNP) P2 (Calvio, Neubauer et al. 1995) and found to be expressed 
in both neuronal and non-neuronal tissues with a predominantly nuclear localization 
(Morohoshi, Arai et al. 1996, Andersson, Stahlberg et al. 2008). However, a redistribution 
of FUS into the cytoplasm has been observed in response to transcriptional inhibition 
(Zinszner, Albalat et al. 1994), and FUS also shuttles rapidly between the nucleus and 
cytoplasm for the transport of mRNA (Zinszner, Sok et al. 1997). 
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FUS is a member of the TET family of proteins (Law, Cann et al. 2006, Tan and 
Manley 2009), which, in addition to TLS/FUS, also includes EWS (Ewing’s sarcoma) 
and TAF15 (TATA-binding protein-associated factor 15), which are thought to have 
originated from a common ancestral gene (Morohoshi, Ootsuka et al. 1998). These three 
proteins all share an amino terminus enriched in Ser, Tyr, Gln, and Gly residues, a 
conserved RNA-recognition domain, a zinc finger motif, and RGG-rich regions that may 
be important for RNA binding. The domain structure of FUS (Figure 2-1A) includes an 
N-terminal domain with transcriptional activating properties and a C-terminal domain 
capable of binding DNA, RNA, and splicing factors (Law, Cann et al. 2006), consistent 
with putative functions of FUS in DNA damage-repair, transcription, and splicing 
(Kuroda, Sok et al. 2000, Meissner, Lopato et al. 2003, Wang, Arai et al. 2008). The 
highly conserved C-terminus also harbors most of the reported fALS-linked FUS 
mutations (Belzil, Valdmanis et al. 2009, Chio, Restagno et al. 2009, Kwiatkowski, 
Bosco et al. 2009, Ticozzi, Silani et al. 2009, Vance, Rogelj et al. 2009, Blair, Williams et 
al. 2010, Corrado, Del Bo et al. 2010, Damme, Goris et al. 2010), which cluster within 
residues 514-525 (Figure 2-1A). One identified consequence of FUS mutations is an 
aberrant accumulation of FUS in the cytoplasm of motor neurons and glia in human post-
mortem tissues (Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009), which has 
been recapitulated following acute expression of FUS mutants in mammalian cells 
(Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009, DeJesus-Hernandez, Kocerha 
et al. 2010). FUS immunoreactivity has been detected in the cytoplasmic and nuclear 
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aggregates that are a pathological hallmark in subtypes of frontotemporal lobar 
degeneration (Neumann, Rademakers et al. 2009, Neumann, Roeber et al. 2009), 
including conditions with overlapping motor neuron disease pathology (Munoz, 
Neumann et al. 2009). Nuclear aggregates characteristic of polyglutamine diseases also 
contain FUS (Neumann, Roeber et al. 2009, Doi, Koyano et al. 2010). Taken together, 
these initial clues suggest that altered FUS properties or its cytoplasmic mislocalization 
may play a causative role in neurodegeneration, but the cellular mechanism(s) most 
relevant to FUS aggregation and fALS pathogenesis have not been elucidated. 
TDP-43 was recently shown to accumulate in cytoplasmic stress granules following 
oxidative stress (Colombrita, Zennaro et al. 2009). Stress granules are one type of 
intracellular aggregate that contains non-translating polyadenylated mRNAs, translation 
initiation factors, small ribosome subunits, and RNA-binding proteins (Buchan and 
Parker 2009). The dynamic formation of stress granules in response to insults such as 
oxidative stress, heat shock, or ischemia is thought to protect cells by allowing them to 
shift energy expenditure from translation towards repair and recovery (Anderson and 
Kedersha 2008). That TDP-43 associates with stress granules raises the possibility that 
motor neuron vulnerability in ALS could be related in part to impaired adaptation to 
certain cellular stresses. 
Here, we investigated the effect of ALS-causing mutations in the C-terminus of FUS 
on the subcellular mislocalization of the protein, and also investigated whether specific 
stresses relevant to ALS may trigger the formation of cytoplamsic FUS inclusions. Upon 
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expressing FUS variants in both stable cell lines and zebrafish embryos, we observed a 
striking cytoplasmic accumulation of FUS for a novel C-terminal truncation mutation, 
R495X, that exhibits a relatively severe fALS clinical phenotype. Furthermore, we found 
that mutant FUS, but not the wild type protein, assembles into stress granules in response 
to translational arrest induced by either oxidative stress or heat shock. 
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II.4 Results 
II.4.1 Cytoplasmic accumulation of FUS variants   
The coding sequence of FUS (Figure 2-1A) contains a putative nuclear localization 
signal (NLS) spanning residues Pro508-Tyr526 at the C-terminus (Lee, Cansizoglu et al. 
2006, Zakaryan and Gehring 2006), which differs from other known ‘classical’ NLS 
sequences (Sorokin, Kim et al. 2007). This region of FUS overlaps with the clustering of 
11 fALS-linked missense mutations (Belzil, Valdmanis et al. 2009, Chio, Restagno et al. 
2009, Kwiatkowski, Bosco et al. 2009, Ticozzi, Silani et al. 2009, Vance, Rogelj et al. 
2009, Blair, Williams et al. 2010, Corrado, Del Bo et al. 2010, Damme, Goris et al. 
2010), some of which lead to increased cytoplasmic localization of FUS in human central 
nervous system tissue or upon overexpression in mammalian cell cultures (Kwiatkowski, 
Bosco et al. 2009, Vance, Rogelj et al. 2009, DeJesus-Hernandez, Kocerha et al. 2010).   
Here, we identified a family (FALS521) with early-onset ALS caused by a novel 
mutation (R495X) that segregated with ALS. The R495X mutation causes the truncation 
of the final 32 amino acids from the C-terminus of FUS (Figure 2-1A). Disease onset 
varied widely within FALS521, although in this pedigree the onset occurred earlier in 
later generations (16 and 18 years in generation V). The mean age of onset for affected 
individuals in this pedigree was 35 ± 16 years, with an average survival of 16.4 ± 10 
months from disease onset. This disease course was relatively more severe than that 
described for the index F577 (autosomal recessive H517Q mutation) and F55 (autosomal 
dominant R521G mutation) pedigrees, which are associated, respectively, with onset ages 
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of 45 ± 4 and 40 ± 13 years, and disease durations of 168 and 27 ± 17 months 
(Kwiatkowski, Bosco et al. 2009). The R495X truncation mutant shares a common 
feature with the recently reported de novo FUS splice-acceptor site mutation 
(G466VfsX14), namely, removal of the C-terminal NLS. The G466VfsX14 mutation 
skips the inclusion of exon 14, produces a frameshift of exon 15 and thereby adds an 
aberrant tail of 13 amino acids at the C-terminus in place of the normal residues encoded 
by exons 14 and 15 in WT FUS. This mutation is also associated with an early onset age 
(20 years) and a short disease course (death within 2 years) for the single individual 
reported to date (DeJesus-Hernandez, Kocerha et al. 2010).  
To establish whether an altered C-terminus perturbs FUS localization when 
expressed at near-endogenous levels, we engineered stable HEK-293 cell lines that 
express doxycycline-inducible GFP-tagged FUS constructs, including wild type (WT) 
FUS, mutants associated with autosomal recessive (H517Q) and dominant (R521G) 
fALS, and two truncation constructs (R495X and G515X). FUS R495X represents the 
aforementioned early-onset fALS mutant, while G515X is an experimental mutant that 
was engineered to remove only the C-terminal 12 amino acids encoded by exon 15, 
which includes the main cluster of ALS mutants (Figure 2-1A) . 
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Figure 2-1 Domain structure of FUS and expression of normal and mutant FUS in 
HEK-293 cell lines. 
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Figure 2-1 Domain structure of FUS and expression of normal and mutant FUS in 
HEK-293 cell lines.  
(A) The functional domains of FUS (www.uniprot.org) include a Gln-Gly-Ser-Tyr (QGSY)-rich region 
(blue), a Gly-rich domain (red), an RNA recognition motif (RRM; green), an Arg-Gly (RG)-rich region 
(yellow), which contains a RanBP2-type zinc finger domain (ZF; orange) and a putative NLS (light 
green). Labeled are fALS-linked mutants within exons 14 and 15, with those investigated here (R495X, 
H517Q and R521G) highlighted in red. Truncated FUS constructs of this study included an ALS-linked 
mutant (R495X) and an experimental mutant (G515X, blue), which removed the sequence encoded by 
exon 15. These residues are underlined in the primary sequence. (B) GFP-FUS stable lines and naïve 
HEK-293 cells were cultured with (+) or without (−) doxycycline for 40 h, and lysates containing 3 µg 
total protein/lane were analyzed by western blot using anti-GFP, anti-FUS and anti-GAPDH (loading 
control) antibodies. (C) Confocal microscopy of HEK-293 cell lines following induction with 
doxycycline for 40 h and staining with the nuclear dye DAPI (blue) and an anti-GFP antibody. A strong 
cytoplasmic GFP-FUS signal was observed for the R495X and G515X mutants with a truncated NLS, 
whereas GFP-FUS(WT, R521G and H517Q) exhibited a predominately nuclear localization. Scale bar, 
10 µm. (D) Quantitative analysis of GFP fluorescence from live cells (see Materials and Methods) 
showed that the ratio of cytoplasmic:nuclear GFP fluorescence intensity was significantly higher for 
GFP-FUS(R521) compared with GFP-FUS(WT), and for the truncation mutants GFP-FUS(R495X and 
G515X) compared with the other GFP-FUS proteins (WT, R521G and H517Q). Asterisks indicate 
statistically significant differences between cell lines (n = 11–28 cells analyzed per line) as determined by 
the Kruskal–Wallis ANOVA followed by a Dunn's multiple comparison test (*P < 0.05, **P < 0.01).
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Western blot analysis using an antibody to GFP confirmed that all GFP-FUS proteins 
were expressed in these cells lines at similar levels to each other upon induction with 
doxycycline for 40 h, although GFP-FUS proteins were not detected in the absence of 
doxycycline (Figure 2-1B). An anti-FUS antibody (see Materials and Methods) also 
showed that induced GFP-FUS proteins were expressed at near-endogenous levels 
(within 1–2-fold), and that the expression of these exogenous proteins did not greatly 
alter endogenous FUS expression levels (Figure 2-1B). Although this anti-FUS antibody 
recognized all GFP-FUS constructs, we observed in earlier experiments that an anti-FUS 
antibody targeted to the N-terminus (residues 1–50) unexpectedly did not efficiently 
detect the two C-terminal truncation mutants. Although the explanation for this 
differential antibody reactivity among the FUS constructs is unclear, it suggests that an 
absence of the normal C-terminus can influence the N-terminal epitope recognized by 
certain anti-FUS antibodies. 
 Confocal microscopy of these HEK-293 cells immunostained for GFP revealed an 
intense nuclear expression for WT, H517Q and R521G GFP-FUS, with additional weak 
cytoplasmic expression of the R521G mutant (Figure 2-1C). In contrast, the R495X and 
G515X truncation mutants exhibited a dramatic shift in the expression from the nucleus 
to the cytoplasm. The abnormal partitioning of GFP-FUS mutants remained stable during 
the period of 24–72 h after induction, and GFP-FUS expression at these levels through a 
continuous exposure to doxycycline was not associated with any overt change in cellular 
morphology, proliferation or viability for up to 6 days, the latter being measured by 
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trypan blue staining [P > 0.05 for the comparison of GFP-FUS (WT, R521G and R495X) 
and host HEK-293 cells by ANOVA; data not shown]. Furthermore, live-cell imaging 
indicated a similar pattern of GFP-FUS fluorescence and also revealed numerous highly 
mobile cytoplasmic granules upon the expression of the G515X and R495X truncation 
mutants. Quantitative measurements of GFP fluorescence intensity in live cells showed 
that the cytoplasmic:nuclear expression ratio per unit volume was significantly increased 
by 2-fold for GFP-R521G, by 29-fold for GFP-R495X and by 48-fold for GFP-G515X in 
comparison with that for GFP-WT FUS (Figure 2-1D). We hypothesized that a higher 
expression level following acute transfection may be an important determinant of the 
subcellular localization and aggregation propensity for FUS mutants. Indeed, transient 
transfection of GFP-FUS constructs into host HEK-293 cells yielded ~5-fold higher 
expression for all five GFP-FUS proteins compared to doxycycline-induced levels in the 
stable HEK-293 cell lines. In contrast to the faint, diffuse cytoplasmic expression pattern 
of GFP-FUS(R521G) in the inducible HEK-293 cells (Figure 2-1C), a 40 h transient 
transfection of this same construct into HEK-293 cells resulted in prominent cytoplasmic 
aggregates (Figure 2-2). Furthermore, the size of cytoplasmic inclusions containing GFP-
FUS (R495X or G515X) was larger in the acutely transfected cells compared to the stable 
lines. However, transient transfection of GFP-FUS (WT or H517Q) constructs maintained 
a predominately nuclear localization (Figure 2-2), despite their elevated expression 
levels.  These results are consistent with the previous reports of aggregate formation upon 
expression of Arg521 FUS mutants by acute transfection in both neuronal and non-
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neuronal cell lines (Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009). These 
results show that i) the C-terminus of FUS plays a functional role in its nuclear 
localization and ii) an increase in the absolute level of FUS cytoplasmic expression likely 
contributes to its aggregation.  
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We hypothesized that a higher expression level following acute transfection may be 
an important determinant of the subcellular localization and aggregation propensity for 
FUS mutants. Indeed, transient transfection of GFP-FUS constructs into host HEK-293 
cells yielded ∼5-fold higher expression for all five GFP-FUS proteins compared with 
doxycycline-induced levels in the stable HEK-293 cell lines (Figure 2-3). In contrast to 
the faint, diffuse cytoplasmic expression pattern of GFP-FUS(R521G) in the inducible 
HEK-293 cells (Figure 2-1C), a 40 h transient transfection of this same construct into 
HEK-293 cells resulted in prominent cytoplasmic aggregates (Figure 2-3). Furthermore, 
the size of cytoplasmic aggregates containing GFP-FUS(R495X or G515X) was larger in 
the acutely transfected cells compared with the stable lines. However, transient 
transfection of GFP-FUS(WT or H517Q) constructs maintained a predominately nuclear 
localization (Figure 2-3), despite their elevated expression levels. These results are 
consistent with the previous reports of aggregate formation upon expression of Arg521 
FUS mutants by acute transfection in both neuronal and non-neuronal cell lines 
(Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009). Thus, our results here show 
that (i) the C-terminus of FUS plays a functional role in its nuclear localization, and (ii) 
an increase in the absolute level of FUS cytoplasmic expression likely contributes to its 
aggregation. 
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Figure 2-3 Transient transfection of GFP-FUS constructs into HEK-293 cells yields 
increased expression levels compared to indued cell lines. 
(A) GFP-FUS constructs were acutely transfected into naive HEK-293 cells for 40 h, and stable 
HEK-293 cells were induced to express the GFP-FUS proteins with doxycycline for 40 h, after which cell 
lysates were prepared (Methods). Immnoblotting of these lysates (3 µg total protein/ lane) with anti-GFP 
and anti-GAPDH (loading standard) antibodies followed by a densitometry analysis revealed that 
transiently transfected cells express GFP-FUS at ~5 fold higher levels compared to the stable lines. (B) 
Fluorescence microscopy of the transiently transfected GFP-FUS HEK-293 cells described in (A) 
revealed prominent GFP-FUS cytoplasmic aggregates (green) for GFP-FUS(R521G, R495X, and 
G515X), whereas GFP-FUS(WT and H517Q) exhibited a relatively diffuse expression pattern in the 
nucleus (DAPI; blue). Scale bar, 10 µm. 
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II.4.2 Cytoplasmic FUS mutants incorporate reversibly into stress granules in vitro  
Given that the ALS-linked mutants affect the subcellular localization and aggregation 
propensity of FUS, we hypothesized that mutant FUS proteins may also exhibit an altered 
response to conditions of cellular stress compared to WT FUS. Markers of increased 
oxidative stress are a consistent finding in brain and spinal cord tissues from individuals 
with ALS (Ferrante, Browne et al. 1997, Barber, Mead et al. 2006). To investigate the 
response of FUS to oxidative stress, we exposed HEK-293 cells expressing GFP-FUS 
variants to 0.5 mM sodium arsenite for 1 h, which increases intracellular ROS (Lii, Lin et 
al. 2011) and is known to induce the formation of stress granules (Thomas, Martinez 
Tosar et al. 2009). Immunofluorescence with the anti-TIAR stress granule marker 
revealed that >95% of cells for each of the HEK-293 lines produced stress granules upon 
exposure to arsenite (Figure 2-4). This was consistent with observations under this 
condition in other cell types (Kedersha and Anderson 2007) and showed that the acute 
formation of stress granules was not compromised by the expression of fALS-linked FUS 
mutants. Moreover, the cytoplasmic versus nuclear partitioning of GFP-FUS proteins 
observed in untreated HEK-293 cells was not altered by arsenite exposure (compare 
Figures 2-1 and 2-4).   
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Figure 2-4 Incorporation of mutant FUS into stress granules in HEK-293 cells.  
Each GFP-FUS HEK-293 stable cell line was induced with doxycycline for 40 h, treated with 0.5 mM 
sodium arsenite for 1 h, and then probed with anti-GFP (green) and anti-TIAR (red) antibodies, and the 
nuclear dye DAPI (blue). Cytoplasmic aggregates containing GFP-FUS were detected with anti-GFP for 
the R521G, R495X and G5151X lines, but not for the WT and H517Q lines. Composite images indicate 
that the accumulated GFP-FUS(R521G, R495X and G515X) co-localized with the TIAR stress granule 
marker. Scale bar, 10 µm.
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A striking effect of arsenite treatment was that GFP-FUS mutants (R521G, R495X 
and G515X) were incorporated into the stress granules, as visualized by the co-
localization of GFP with the TIAR (Figure 2-4) and G3BP (Figure 2-5A) stress granule 
markers. The majority (~70-80%) of TIAR-positive stress granules co-localized with the 
R495X and G515X mutants, while ~30% of stress granules co-localized with R521G. In 
contrast, <10% of stress granules co-localized with H517Q and WT FUS proteins under 
these conditions. We observed similar patterns of mutany FUS incorporation into stress 
granules when cells were treated with 10 mM thapsigargin for 2 h (Figure 2-5B), which 
also induces stress granules (Loschi, Leishman et al. 2009). Thapsigargin is a selective 
inhibitor of the endoplasmic reticulum (ER) Ca2+-ATPase that induces ER stress, possibly 
related to depletion of intracellular Ca2+ stores (Yoshida, Monji et al. 2006). There were 
no overt signs of toxicity associated with the incorporation of mutant FUS into stress 
granules. Moreover, the viability as measured by the MTT cell proliferation assay 
following arsenite treatment for up to 4 h did not differ (P > 0.05 by ANOVA) among 
naïve cells or those expressing GFP-FUS(WT, R521G and R495X) (Figure 2-5C). These 
FUS cell lines also exhibited a similar capability to recover from sodium arsenite 
exposure (P > 0.05; Figure 2-5D). 
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Figure 2-5 Stress granule formation was induced in HEK-293 cells upon both 
sodium arsenite and thapsigargin treatment.  
(A) Immunofluorescence of stable GFP-FUS HEK-293 cells treated with sodium arsenite was performed 
as described in Fig. 2, except that the G3BP (red) stress granule marker was employed here.  Confocal 
microscopy revealed similar results as in Fig. 2, in that GFP-FUS(R521G, R495X, and G515X) co-
localize to stress granules that are formed upon sodium arsenite treatment, whereas GFP-FUS(WT and 
H517Q) exhibited a predominately nuclear (DAPI, blue) expression pattern. (B) GFP-FUS(R521G, 
R495X, and G515X) also co-localized to TIAR-positive (red) stress granules as in (A) upon treatment 
with 10 µM thapsigargin for 2 h, whereas GFP-FUS(WT and H517Q) did not. (C) Transiently transfected 
(40 h) untagged-GFP did not co-localize to TIAR-positive (red) stress granules upon treatment with the 
sodium arsenite (described in Fig. 2), but rather exhibited a relatively diffuse nuclear and cytoplasmic 
expression pattern under these conditions.  Scale bar, 10 µm.
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The GFP tag itself does not mediate the recruitment of GFP-FUS(R521G, R495X 
and G515X) into stress granules because free GFP maintained a diffuse nuclear and 
cytoplasmic expression pattern upon oxidative insult with arsenite (Figure 2-6). In 
addition, transient transfection of untagged FUS constructs followed by sodium arsenite 
treatment produced the same results as those described above for the GFP-FUS stable 
lines; FUS(R521G and R495X) proteins incorporated into stress granules, whereas 
transfected FUS WT and endogenous FUS proteins were not detected in stress granules 
(Figure 2-6). 
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Figure 2-6 Incorporation of FUS into stress granules is not mediated by the GFP 
tag.  
(A) Transiently transfected (40 h) untagged-GFP did not co-localized to TIAR-positive (red) stress 
granules upon treatment with sodium arsenate (described in Figure 2-4) within HEK-293 cells, but rather 
exhibited a relatively diffuse nuclear and cytoplasmic expression pattern under these conditions. (B) 
Untagged FUS (R521G and R495X) proteins, but not WT, were incorporated into stress granules upon 
transient transfection (16 h here, compared to 40 h in Figure 2-3) of the respective construct into 
HEK-293 cells followed by arsenate treatment. Endogenous FUS did not incorporate into stress granules, 
as illustrated by the image of non-transfected (NT) HEK-293 cells after arsenate treatment. FUS 
expression was detected by immunofluoresencec (Methods) with the anti-FUS antibody (Behtyl Labs, 
#A300-293A; 1:400). Scale bar, 10 µm (A and B). (C) Western analysis (Method) of cell lysates prepared 
from the experiment described in (B). Duplicate experiments are shown for each cell line, and the ratio of 
FUS/GAPDH reflects the average of the densitometry measurement for these experiments. 
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To explore the dynamics of GFP-FUS (R521G, R495X, and G515X) recruitment into 
stress granules, we first exposed HEK-293 lines to arsenite and performed live cell 
confocal imaging at 37°C (Figure 2-7). We observed that only a minority of cells 
expressing the R495X or G515X mutants contained GFP-FUS aggregates prior to the 
addition of arsenite (Figure 2-7, t=0 min). Within 4-7 min of exposure to arsenite, cells 
expressing the G515X mutant began to accumulate larger perinuclear aggregates (Figure 
2-7). Similarly, cells expressing the R495X mutant formed prominent aggregates by 7-10 
min (Figure 2-7). Cells expressing GFP-FUS(R521G), which exhibited a much lower 
cytoplasmic expression level, eventually formed perinuclear foci with a significant delay 
and weaker intensity compared to the other mutants (Figure 2-7). In agreement with our 
analysis of fixed HEK-293 cells (Figure 2-4), live cells expressing GFP-FUS(WT) 
(Figure 2-7) or GFP-FUS(H517Q) (not shown) maintained the nuclear localization of 
GFP without forming detectable cytoplasmic aggregates. These results suggested that the 
abundance of FUS variants in the cytoplasm contributes both to the extent and to the 
speed of their recruitment into stress granules following an oxidative insult. 
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Figure 2-7 Recruitment of GFP-FUS into perinuclear stress granules was more 
rapid and extensive for truncation mutants.  
GFP-FUS(R521G, R495X or G515X) was induced for 4 days in HEK-293 cells, and a time series of GFP 
intensities was acquired in live cells at 37°C over 30 min following the addition of 0.5 mM sodium 
arsenite. Differential interference contrast (DIC) images (left) indicate cell positions, and confocal 
fluorescence images (right) show maximum-intensity z-projections obtained from serial 0.2 µm slices 
using a 60× objective. GFP fluorescence revealed a rapid (within 4–7 min) formation of FUS(R495X and 
G5151X) aggregates, whereas FUS(R521G) formed smaller, less intense aggregates with a slower time 
course. Scale bar, 10 µm.
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To determine whether the accumulation of FUS variants into stress granules was 
reversible, we measured the response of GFP-FUS-expressing cell lines to heat shock, 
another stress granule inducer (Buchan and Parker 2009). Live cell confocal imaging was 
performed on HEK-293 cells at 37°C to observe the distribution of GFP-FUS at baseline, 
and the microscope stage and objective were then heated to 42.5°C within an enclosed 
chamber. We observed the assembly of intense perinuclear GFP-FUS aggregates within 
7-10 min for the R495X and G515X mutants, while smaller and less intense aggregates 
of the H517Q and R521G mutants required ~15 min to form and continued to evolve 
over 30 min (Figure 2-8). Upon return of the microscope stage to 37°C, we observed that 
aggregates containing GFP-FUS disassembled within minutes (Figure 2-8), consistent 
with the reversible nature of these structures (Buchan and Parker 2009). Overall, these 
results showed that the fALS-linked FUS mutants (R495X > R521G, H517Q) and the 
engineered truncation (G515X), but not WT FUS, were dynamically and reversibly 
incorporated into stress granules in response to conditions that impair cellular translation 
initiation. 
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Figure 2-8 Formation of cytoplasmic GFP-FUS aggregates was reversible after 
heat shock.  
GFP-FUS(WT, H517Q, R521G, R495X or G515X) was induced for 3 days in HEK-293 cells, and a time 
series of GFP intensities (acquired as in Fig. 3) was detected in live cells over the indicated time course 
(hh:mm) upon shifting from 37–42.5°C. Cytoplasmic FUS inclusions assembled most rapidly (by 7–12 
min) in cells expressing GFP-FUS(R495X and G5151X) and to a lesser extent in cells expressing GFP-
FUS(R521G and H517Q). Aggregate formation was reversible within minutes of a temperature shift back 
to 37°C, as shown for GFP-FUS(R521G, R495X and G5151X). Scale bar, 10 µm.
 65
II.4.3 FUS variants do not localize to processing bodies under conditions of  
oxidative Stress   
Whereas stress granules form transiently in response to stress, processing bodies (P-
bodies) are distinct cytoplasmic silencing foci that are present constitutively and can be 
augmented by stress (Moore 2005). Since stress granules are physically and functionally 
associated with P-bodies, which play a role in mRNA degradation, we probed for the co-
localization of GFP-FUS with GE-1/hedls, a constituent of P-bodies but not stress 
granules (Kedersha and Anderson 2007). We observed P-bodies under baseline conditions 
in HEK-293 cells expressing GFP-FUS (WT and mutants) but saw no evidence of co-
localization with GFP (data not shown).  Furthermore, no co-localization of P-bodies and 
GFP-FUS was observed upon treatment of cells with 1 mM sodium arsenite for 2 h, 
despite the close contact of P-bodies with stress granules containing GFP-FUS (Figure 
2-9). Thus, although GFP-FUS variants are recruited into stress granules under conditions 
of acute stress, these variants i) do not incorporate acutely into associated P-bodies, and 
ii) do not prevent the normal docking of P-bodies to stress granules. 
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Figure 2-9 Cytoplasmic GFP-FUS in stress granules did not co-localize with 
adjacent P-bodies.  
HEK-293 cell lines stably expressing GFP-FUS proteins were treated as described in Figure 2, except 
that 1 mM sodium arsenite was administered for 2 h and cells were probed with anti-Hedls/GE-1, a 
marker of P-bodies (red). Scale bar, 10 µm. None of the GFP-FUS proteins co-localized with the P-body 
marker. However, P-bodies localized in close proximity to stress granules containing the GFP-
FUS(R521G, R495X and G515X) variants, and in some cases P-bodies appeared docked to these stress 
granules (see inset for G515X; scale bar, 1 µm).
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II.4.4 GFP-FUS variants localize to the cytoplasm and accumulate into  
stress granules in zebrafish embryos   
To determine whether the mislocalization of human FUS mutants to the cytoplasm in 
HEK-293 cells also occurs in spinal neurons or other cell types relevant to ALS, we 
injected zebrafish embryos at the 1-2 cell stage with mRNAs encoding GFP-FUS(WT, 
H517Q, R521G, R495X, or G515X). Under these conditions, the GFP-FUS gene product 
can be expressed in a mosaic pattern throughout the embryo for several days. At 25 h 
post-fertilization (hpf), we observed the distribution of expressed GFP-FUS proteins in 
the spinal cord and somatic musculature near the region of the yolk sac extension (Figure 
2-10 and Figure 2-11). Similar to the expression in HEK-293 cells, human FUS WT and 
the H517Q and R521G mutants each exhibited a predominantly nuclear pattern in the 
spinal cord, whereas the R495X and G515X truncation mutants accumulated in the 
cytoplasm. 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Figure 2-10 Expression of GFP-FUS variants in spinal cord and body wall muscle 
of zebrafish embryos.  
Zebrafish eggs were injected at the 1–2 cell stage with mRNAs encoding GFP-FUS variants. Embryos 
were fixed at 25 hpf, and the intact body wall region was immunostained with anti-GFP (green) and a 
nuclear marker (Draq5, blue). Confocal image stacks (40× objective, Δz = 1.0 µm) were acquired in a 
longitudinal orientation (red box) from the lateral body muscle (m) extending medially through the spinal 
cord (sc) and notochord (n). Shown are representative medial and lateral slices. For embryos expressing 
GFP-FUS(WT, H517Q and R521G), the GFP signal was predominantly nuclear, whereas for embryos 
expressing the R495X truncation mutant, the GFP localized mostly to the cytoplasm. Scale bar, 50 µm.
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Figure 2-11 Expression of GFP-FUS variants in spinal cord of zebrafish embryos.  
Zebrafish eggs were injected with mRNAs encoding GFP-FUS variants, and embryos were processed for 
confocal microscopy (100×) as described in Figure 6. Shown are representative 0.9 µm slices (left panels) 
and 0.4 µm slices acquired using a 3.44× optical zoom (right panel). The higher magnification clearly 
showed the nuclear expression of GFP-FUS(WT, H517Q and R521G) variants and cytoplasmic 
accumulation of the R495X or G515X truncation mutants in the spinal cord. Scale bars, 10 µm.
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To investigate the behavior of FUS-mutants in response to a physiological stress in 
vivo, we next applied a heat shock to zebra fish embryos expressing FUS variants.  After 
heat shock to 42.5°C for 45 min, we observed TIAR-containing foci indicative of stress 
granule formation (Figure 2-12). Moreover, the R521G, R495X, and G515X mutants 
formed perinuclear aggregates that co-localized with anti-TIAR immunofluorescence 
(Figure 2-12), demonstrating their incorporation into stress granules in vivo. 
Surprisingly, the recessive H517Q mutant exhibited a granular cytoplasmic expression 
pattern in some regions upon heat shock to 42.5°C, representing the only insult employed 
in the present study that could shift the expression of this mutant from the nucleus to the 
cytoplasm (Figure 2-12). Under this condition, cells expressing GFP-FUS(WT) 
occasionally showed cytoplasmic expression, but to a lesser extent than H517Q (Figure 
2-12). Overall, our experiments suggest that multiple factors influence the subcellular 
localization of GFP-FUS in vivo, including the presence of mutant residues near the C-
terminus and the nature and extent of imposed stresses. 
In additional experiments, we injected zebrafish eggs from a transgenic line 
expressing GFP in motor neurons (Flanagan-Steet, Fox et al. 2005) with mRNAs 
encoding untagged FUS mRNA variants (human WT, H517Q and R521G). The gross 
morphology of embryos injected with the mutant constructs was similar to controls for up 
to at least 3 days of development (data not shown). We occasionally observed shorter 
ventrally projecting GFP-positive motor axons in the region of the yolk sac extension for 
those injected with R521G versus WT or H517Q mRNAs (data not shown), but this was 
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not a consistent finding, and we were unable to document any convincing defects in 
motor axon outgrowth or arborization pattern compared with controls. 
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Figure 2-12 Heat shock increased the cytoplasmic localization of the H517Q 
mutant and triggered accumulation of R521G, R495X and G515X into stress 
granules in vivo.  
Confocal slices of zebrafish spinal cord from 25 hpf embryos incubated at 42.5°C for 45 min followed by 
immediate fixation and double immunostaining with anti-GFP (green) and anti-TIAR (red). For a group 
of spinal cord cells from embryos expressing the H517Q mutant, the GFP redistributed to the cytoplasm 
in a granular pattern without incorporating prominently into stress granules, whereas this occurred only 
rarely for cells expressing GFP-WT FUS. For embryos expressing the R521G, R495X and G515X 
mutants, the GFP assembled into aggregates that co-localized with anti-TIAR staining. Nuclei were 
stained with Draq5. Left panel obtained at 100×, right panels obtained using 3.44× optical zoom. Scale 
bars, 10 µm.
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II.5 Discussion 
 This study has identified a critical role of the C-terminus of FUS in nuclear 
localization and its perturbation by a subset of FUS mutants that cause fALS. 
Furthermore, our results revealed a mutant-specific response to cellular stress that leads 
to the incorporation of cytoplasmic fALS-linked FUS protein into stress granules. 
Although the C-terminus of FUS differs from classical nuclear localization signals 
that are recognized by karyopherin α (importin α) (Sorokin, Kim et al. 2007), an analysis 
of the evolutionarily related EWS protein (Zakaryan and Gehring 2006) suggested that 
the C-terminus of FUS may nonetheless function to mediate nuclear localization. 
Moreover, the C-terminal sequence of FUS is consistent with a ‘PY-NLS’ type of nuclear 
targeting signal that binds to the human karyopherin β2/transportin (Kapβ2) receptor 
(Lee, Cansizoglu et al. 2006, Lange, Mills et al. 2008). Our results showed that truncation 
of this putative FUS NLS in the R495X and G515X mutants (Figure 2-1A) caused a 
dramatic increase in cytoplasmic accumulation of FUS compared to the missense 
(H517Q and R521G) mutants, which have only a single amino acid substitution within 
the NLS (Figure 2-1C and 1D). Thus, these studies provide compelling evidence that the 
C-terminus of FUS is required for normal nuclear–cytoplasmic partitioning of the protein 
and that fALS-linked mutations disrupt this equilibrium. 
 Although cytoplasmic FUS accumulation was observed previously for some 
overexpressed fALS-linked missense mutants (Kwiatkowski, Bosco et al. 2009, Vance, 
Rogelj et al. 2009, DeJesus-Hernandez, Kocerha et al. 2010), the downstream 
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consequence(s) of this mislocalization on cellular pathways, including those involved 
with stress responses, remains largely unknown. Here, we showed that GFP-FUS mutants 
retained in the cytoplasm assemble into stress granules in response to acute insults, 
including oxidative stress (Figure 2-4, Figure 2-5A and Figure 2-7), ER stress (Figure 
2-5B) and heat shock (Figure 2-8 and figure 2-12). Although inhibition of transcription 
causes a redistribution of WT FUS from the nucleus to the cytoplasm (Zinszner, Albalat 
et al. 1994), we found here that inhibition of translation induced by other cellular stresses 
does not prominently alter the subcellular localization of WT-FUS. However, an 
enhanced cytoplasmic accumulation of the autosomal recessive mutant (H517Q) was 
detected upon heat shock in vivo (Figure 2-12), which may have implications for ALS 
(discussed below). 
Why does cytoplasmically localized mutant FUS assemble into stress granules?  One 
possibility is that FUS associates directly with specific mRNAs or other proteins that 
mediate the integration of FUS into stress granules. FUS has been shown to bind mRNAs 
encoding actin-related proteins, such as actin-stabilizing protein Nd1-L, which may be 
important for the transport of this mRNA to dendrites for local translation and 
maintenance of spine morphology (Fujii, Okabe et al. 2005, Fujii and Takumi 2005); 
however, comprehensive data regarding mRNAs bound by FUS are lacking. The fALS-
linked R521G mutant retains the ability to complex with GGUG-containing RNAs 
(Lerga, Hallier et al. 2001, Kwiatkowski, Bosco et al. 2009), indicating that FUS 
mutations do not abrogate RNA binding. Moreover, our data demonstrate that the C-
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terminal NLS does not directly mediate interactions with other RNPs or RNAs required 
for targeting of FUS to stress granules, as evidenced by the significant incorporation of 
the truncation mutants (R495X and G515X) into these structures.  
The association of FUS and other RNA-binding proteins with stress granules appears 
to be specific, as cytoplasmic free GFP does not localize to stress granules (Figure 2-6) 
(Andersson, Stahlberg et al. 2008). Although some RNA-binding proteins such as Nova1 
do not incorporate into stress granules (Colombrita, Zennaro et al. 2009), others such as 
TDP-43 show this property under conditions of translational arrest induced by oxidative 
stress (Colombrita, Zennaro et al. 2009) or upon expression of a pathogenic, fragmented 
form of this protein (Nishimoto, Ito et al. 2010). One study reported the co-localization of 
transfected GFP-FUS (WT) into stress granules in HT-1080 cells  (Andersson, Stahlberg 
et al. 2008); however, the association of GFP-FUS (WT) with stress granules was not 
observed in acutely transfected HEK-293 cells (Gal, Zhang et al. 2011). In addition, we 
did not observe stress granules in the absence of an applied stress for our stable HEK-293 
cell line expressing the GFP-FUS (R521G) mutant or in HEK-293 cells acutely 
transfected (16 h) with FUS(R521G) (Figure 2-6), although stress granules have been 
detected for this mutant under acute transfection conditions in other laboratories (Gal, 
Zhang et al. 2011). These apparent discrepancies may result from a difference in cell 
lines, transfection procedures, or exogenous FUS expression levels. Consistent with this 
hypothesis was our observation of increased cytoplasmic aggregation for FUS mutants 
when expressed at higher levels in transiently transfected (40 h) cells compared with 
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stable cell lines (Figure 2-3). These data indicate that the aggregation propensity of FUS, 
as well as its cellular localization and binding interactions, may be sensitive to the 
expression level of FUS, the translational state of individual cells and factors related to 
cell type; this sensitivity to altered cellular homeostasis may be expected based on the 
regulatory functions of proteins within the hnRNP family (Dreyfuss, Matunis et al. 1993). 
Although mutant FUS incorporates into stress granules, it does not significantly associate 
with P-bodies (Figure 2-9). A specific association with stress granules over P-bodies has 
also been reported for the ALS-associated TDP-43 protein (Colombrita, Zennaro et al. 
2009).  
The observation that both FUS and TDP-43 can associate with stress granules raises 
the possibility that ALS-related mutants might perturb the normal response to stress in 
maladaptive ways. Although we cannot exclude the possibility that under some 
conditions FUS WT may also associate with stress granules, the fALS-linked mutations 
significantly shift the subcellular equilibrium of FUS towards the cytoplasm and enhance 
its association with stress granules. In fact, the R495X mutation that truncates the NLS 
results in the highest levels of cytoplasmic FUS compared with the other fALS-linked 
mutants studied here (Figure 2-1). Furthermore, cytoplasmic expression of R495X 
correlated with its incorporation into stress granules. That this mutation is also associated 
with a severe, early-onset clinical phenotype, which is similar to the de novo FUS 
G466VfsX14 mutation (DeJesus-Hernandez, Kocerha et al. 2010), raises the possibility 
that the vulnerability of motor neurons to mutant FUS is proportional to FUS expression 
77
in the cytoplasm. In contrast to FUS R495X, the autosomal recessive FUS H517Q mutant 
exhibits weak cytoplasmic expression under homeostatic cellular conditions (Figure 2-4 
and Figure 2-10). That this mutant protein could more readily translocate to the 
cytoplasm upon induction of heat shock in vivo (Figure 2-12) suggests an enhanced 
susceptibility to thermal stress compared with FUS WT. Although it is not clear whether 
motor neuron vulnerability stems from a loss of normal FUS nuclear function or an 
altered cytoplasmic function, or both, the notion that cytoplasmic expression levels of 
RNA-binding proteins may correlate with ALS pathogenesis has also been supported for 
TDP-43 based on cell culture and animal model studies with mutant forms of that protein 
(Wegorzewska, Bell et al. 2009, Barmada, Skibinski et al. 2010). 
We observed that mutant FUS recruitment to stress granules is reversible following 
an acute insult (Figure 2-8). In addition, we found no evidence of acute toxicity 
associated with the incorporation of mutant FUS into stress granules, as measured by the 
MTT cell proliferation assay (Figure 2-5). In light of these observations, how might this 
mutant-specific property, i.e. incorporation of mutant FUS into stress granules, play a role 
in ALS pathogenesis? It is plausible that more chronic changes in cellular homeostasis as 
a consequence of mutant FUS expression could produce a maladaptive outcome. For 
example, the inappropriate sequestration of mutant FUS and its biological binding 
partners into stress granules may impair the cellular response to chronic oxidative stress, 
protein misfolding, heat shock or other insults that cause translational arrest. Further, 
chronic stress may culminate in the conversion of stress granules into larger pathological 
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aggregates, a possibility that is supported by the detection of mRNA-associated proteins 
within the inclusions of adult onset motor neuron disease (Fujita, Ito et al. 2008). A 
similar mechanism has been proposed for the accumulation of aggresomes into end-stage 
Lewy bodies, the pathological hallmark of Parkinson's disease and other 
synucleinopathies (Olanow, Perl et al. 2004). However, the detection of mRNA and its 
associated proteins in ALS aggregates is not a consistent finding in all reports 
(Colombrita, Zennaro et al. 2009). Thus, it remains to be determined whether FUS-
associated stress granules are linked to the formation of end-stage ALS aggregates, and 
whether FUS-containing aggregates detected in post-mortem CNS tissues of affected 
individuals are neurotoxic themselves or simply markers of altered cellular homeostasis. 
Although we did not observe acute toxicity as a consequence of mutant FUS 
expression at near-endogenous levels in either the HEK-293 cells or the zebrafish 
embryos, further studies using model systems that more closely recapitulate the relevant 
neuronal environment, such as primary motor neurons and/or transgenic models, may 
reveal mutant-specific phenotypes related to FUS toxicity. We note that, to date, there has 
been no evidence published that directly links mutant FUS expression or its localization 
to cellular dysfunction. Nevertheless, our findings suggest that candidate pathways 
related to the regulation of stress defenses in motor neurons may be appropriate for 
further investigation of the pathogenic role of FUS in ALS. Dysregulation of specific 
stress responses may also contribute to the preferential motor neuron vulnerability 
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observed in other forms of ALS caused by mutant SOD1, mutant TDP-43 and, perhaps, 
in sALS. 
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II.6 Materials and Methods 
Human subjects 
The clinical information and biological samples (blood and/or autopsy tissues) were 
collected from fALS cases and control individuals after informed consent was obtained. 
All protocols were approved by the Institutional Review Board at the institutions 
involved. 
Identification of the FUS-R495X mutation in human fALS 
DNA was available from two of the eight affected individuals in family F521. The 
coding region of exon 14 of the FUS gene was amplified by polymerase chain reaction 
from the DNA of a fALS patient using flanking primers with 19 and 21 base pair tails 
added to the 5′-end to standardize sample sequencing. Samples were sequenced by the 
method described previously (Kwiatkowski, Bosco et al. 2009), and the FUS c.1566C>T 
mutation that truncates FUS translation at Arg495 was confirmed using bidirectional 
Sanger methods. Sequencing data were aligned and analyzed for heterozygous 
polymorphisms using Consed (Gordon, Abajian et al. 1998): FUS_ex14F: 
t a g t a a a a c g a c g g c c a g t A G G C T C G G G G A A C ATA G G ; F U S _ e x 1 4 R : 
taggaaacagctatgaccatgAGCCCTCAAAATGAAACCAC. 
Stable inducible HEK-293 cell lines 
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Isogenic cell lines expressing GFP-FUS variants under doxycyline-inducible control 
were established using the Flp-In T-REx system (Invitrogen). The Flp-In T-REx 293 line 
(Invitrogen, R780-07) contained a single stably integrated FRT site that allowed targeted 
integration of each GFP-FUS expression cassette into the same transcriptionally active 
genomic locus. Flp-In T-REx 293 cells were co-transfected with the expression vector 
(pcDNA5/FRT/TO-TOPO containing GFP-FUS) and the Flp recombinase vector 
(pOG44) using the Effectene transfection reagent (Qiagen). Selection for stable 
integration was performed beginning 48 h after transfection using medium that contained 
150 µg/ml Hygromycin B (Invitrogen, 10687-010). This yielded isogenic cell populations 
that could induce GFP-FUS at approximately one to two times that of endogenous FUS 
(Fig. 1B) upon incubation with 1 µg/ml doxycycline for 40 h. 
Cell culture and drug treatments 
HEK-293 cells with stably integrated GFP-FUS constructs (described above) were 
maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% 
TET-tested fetal bovine serum (Atlanta Biologicals, s10350H), 2 mM L-glutamine 
(Gibco, 25030), 15 µg/ml blasticidin (Invitrogen, R210-01), 150 µg/ml hygromycin B 
(Invitrogen, 10687-010) and 1% penicillin and streptomycin solution (Gibco, 15140). For 
drug treatments, the following stocks were prepared and stored at freezing temperatures: 
50 mg/ml doxycycline (Sigma, D9891) in water (−80°C), 100 mM sodium arsenite 
(Sigma, 71287) in water (−20°C) and 1 mM thapsigargin (Sigma, T9033) in DMSO 
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(−20°C). Prior to treatment with drugs, cells were plated at 1 × 105 cells/ml into 24-well 
dishes containing 12 mm coverslips (Fisher, NC9708845) that were pre-treated with 
poly-L-lysine (Sigma, P8920) according to the manufacturer's instructions. Cells were 
allowed to adhere to the coverslips overnight, and FUS expression was induced upon 
addition of 1 µg/ml doxycycline (Sigma, D9891) for 40 h. Cells were then exposed to 
either 0.5 or 1 mM sodium arsenite for 1–2 h (as noted) or 10 µM thapsigargin for 2 h. 
Immunofluorescence of HEK-293 cells 
Cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 1% 
Triton X-100 for 10 min, or with cold 100% methanol for 10 min on ice. Cells were then 
blocked with 2% goat serum (Jackson ImmunoResearch Labs, 005-000-121), 0.1% Triton 
X-100, 50 mM NH4Cl and 10 mg/ml bovine serum albumin (BSA) in Dulbecco's 
phosphate-buffered saline (PBS) for 1 h at 37°C. Antibodies were diluted in 0.15% goat 
serum, 0.1% Triton X-100 and PBS. Primary antibody incubation conditions were as 
follows: 1:250 mouse anti-TIAR (BD Transduction Labs, 610352) for 30 min at 37°C; 
1:500 mouse anti-G3BP (BD Transduction Labs, 611126) for 30 min at 37°C; and 1:250 
mouse anti-GE-1/hedls/p70 S6 kinase (Santa Cruz Biotechnology, sc-8418) for 12 h at 
4°C. Secondary anti-mouse IgG antibody conjugated to Dylight 549 (Jackson 
ImmunoResearch Labs, 715-505-151) was used at 1:1500–1:3500. The GFP signal was 
enhanced by 1:1000 Alexa Fluor 488-conjugated rabbit anti-GFP (Invitrogen, A21311). 
Coverslips were mounted with Vectashield hard-set mounting medium containing DAPI 
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(Vector Laboratories, H-1500). Confocal microscopy was performed using a Solamere 
Technology Group CSU10B spinning disk confocal system equipped with a Yokogawa 
CSU10 spinning disk confocal scan head, a laser assembly consisting of an argon ion 
laser (50 mW at 488 and 514 nm and 13 mW at 457 nm), and three solid-state lasers (25 
mW at 561 nm, 30 mW at 636 nm and 45 mW at 405 nm). Image stacks were acquired 
using a 100× oil objective, a Roper Coolsnap HQ2 camera and MetaMorph V7.6.3 
software, using a slice thickness, Δz, of 2 µm. Images were analyzed using NIH ImageJ 
software (http://rsb.info.nih.gov/ij), optimized for contrast using linear scaling only, and 
compiled using CorelDraw software. 
Live-cell imaging and fluorescence quantitation 
Cells were cultured on 35 mm glass-bottom dishes coated with poly-D-lysine 
(P35GC-1.5-14-C; MatTek, Ashland, MA, USA) and washed with PBS containing 0.9 
mM CaCl2 and 0.5 mM MgCl2 (Ca/Mg/PBS) immediately before imaging. Confocal 
microscopy was performed on a Solamere Technology Group (Salt Lake City, UT, USA) 
CSU10B spinning disk confocal system attached to a Nikon TE2000-E2 motorized 
inverted fluorescence microscope equipped with a Nikon Perfect Focus System (Nikon 
Instruments, Melville, NY, USA). This system included a custom laser assembly with an 
AOTF for rapid wavelength change via fiber optics coupled to a Yokogawa CSU10 
spinning disk confocal scan head with high efficiency dichroic mirrors and laser-blocking 
filters. For GFP confocal imaging, cells were illuminated with an argon ion laser 
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operating in standby mode (20 mW at 488 nm at the laser) using a Nikon VC Plan Apo 
60× oil objective (NA: 1.4), and the fluorescence emission passed through a 525/50 nm 
GFP bandpass filter before entering a Rolera MGi EMCCD 14-bit camera (Qimaging, 
Surrey, BC, Canada). MetaMorph V7.6.3 (Molecular Devices) software was used for 
equipment control and image acquisition. Images were analyzed using NIH ImageJ 
software and plug-ins from the McMaster University Biophotonics Facility (http://
www.macbiophotonics.ca/imagej/). 
For quantitative GFP imaging of live cells (Figure 2-1D and Figure 2-2), a stack of 
60–100 thin slices (Δz = 0.2 µm, t = 1500 ms, EM gain = 3800 for each slice) was 
acquired at room temperature. The dark-current image (acquired for t = 1500 ms with the 
laser off) was subtracted from each raw image, and variations in illumination and 
detection efficiencies at each pixel were corrected by dividing the dark-adjusted 
intensities by a normalized flat-field image of a uniformly green fluorescent slide 
(Chroma Technology, Rockingham, VT, USA) acquired using the same 525/50 nm 
bandpass filter. For the quantitation of cytoplasmic versus nuclear signal per unit volume 
for each cell, the average intensity of 10 × 10 pixel (1.83 µm × 1.83 µm) regions of 
cytoplasm (c), nucleus (n) and background (b) were obtained for each of 6–10 
representative and contiguous 0.2 µm slices. The cytoplasmic/nuclear ratio for each 
representative slice was calculated as (c−b)/(n−b), and the ratios obtained from the 
contiguous slices were averaged for each cell. 
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For live-cell movies, cells were washed in Ca/Mg/PBS as above and then maintained 
in either Ca/Mg/PBS or DMEM without vitamins to minimize oxidative photobleaching 
of GFP (Bogdanov, Bogdanova et al. 2009) at 37°C in a humidified chamber exposed to 
5% CO2. For some experiments, heat shock to 42.5°C and cooling back to 37°C was 
performed using stage and objective heaters (20/20 Technology, Inc., Wilmington, NC, 
USA). Focus was maintained between time points with the Perfect Focus System, which 
was turned off during z-series acquisition. Maximum intensity z-projections of the 
fluorescent signal from stacks assembled from slices (each 0.2 µm thick) at each time 
point were constructed using ImageJ. Images were optimized for contrast using linear 
scaling only, and movies of sequential time points were assembled using ImageJ. 
GFP-FUS expression in zebrafish embryos 
The maintenance of zebrafish and associated experimental procedures were 
conducted according to an approved Institutional Animal Care and Use Committee 
(IACUC) protocol. Tricaine stock solution (pH 7.0) was made using 0.4 g ethyl 3-
aminobenzoate methanesulfonate salt (Sigma, A5040) plus 2.1 ml 1 M Tris (pH 9.0) in 
100 ml of water and stored at −20°C. mRNAs encoding GFP-FUS constructs (WT or 
mutant) were synthesized using mMessage mMachine SP6 or T7 Ultra kits (Ambion) and 
stored in 1 mM Na citrate (pH 6.4). mRNAs were diluted with nuclease-free water to 500 
ng/µl, and 2–3 nl of the diluted solution was injected into the yolk sac at the 1–2 cell 
stage of zebrafish eggs from strain crawfish. Embryos were maintained in egg water (60 
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mg of instant ocean sea salt in 1 l of water containing 0.05% methylene blue) in an 
incubator at 28.5°C. GFP-FUS fusion proteins were detected at 24–30 hpf either by live 
embryo GFP imaging or by immunofluorescence. For immunostaining, embryos were 
dechorionized and fixed for 2 h at room temperature in PBS containing 4% 
paraformaldehyde, permeabilized with ice-cold acetone for 9 min at −20°C and then 
washed for 5 min with PBS containing 0.1% Tween-20 (PBS-T) four times at room 
temperature. Embryos were equilibrated in blocking solution (1% DMSO, 1% BSA, 2% 
goat serum and 0.05% Triton X-100 in PBS) for 1 h at room temperature and then 
incubated with mouse anti-TIAR antibody (above, 1:1000 in blocking solution) overnight 
at 4°C. A rabbit anti-mouse secondary antibody conjugated to Alexa Fluor 568 
(Invitrogen A11061, 1:2000) and rabbit anti-GFP antibody conjugated to Alexa Fluor 488 
(above, 1:400) were applied for 1 h in blocking buffer at room temperature. Embryos 
were then rinsed four times in PBS-T for 15 min, and nuclei were stained with Draq5 
(DR50200, Biostatus) for 10 min. After wash in PBS-T for 15 min, the whole-body wall 
region excluding head and yolk sac was isolated and mounted in Prolong Gold Anti-Fade 
reagent (Invitrogen P36934). Image stacks were acquired in longitudinal orientation from 
the skin epithelial layer through the somatic muscles to the spinal cord and notochord 
using a Leica SP1 laser-scanning confocal microscope with a 40× oil objective (NA: 
1.25), 100× oil objective (NA: 1.40), 3.44× zoom capability and Leica LCS acquisition 
software (Version 2.61). For 100× image stacks, each slice was 0.9 µm thick, whereas for 
344× image stacks, each slice was 0.4 µm thick. For heat shock experiments, 
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dechorionized embryos at 25 hpf were incubated at 42.5°C for 45 min in egg water+4% 
Tricaine stock solution and then immediately fixed in pre-heated PBS containing 4% 
paraformaldehyde for 10 min at 42.5°C followed by 2 h at room temperature. At least 
five embryos for each condition were examined, and all experiments were performed at 
least three times. 
Western blots 
HEK-293 cells stably or transiently transfected with GFP-FUS constructs were 
allowed to express FUS for 40 h. Cells were then lysed in 50 mM Tris–HCl (pH 7.5) 
supplemented with 0.5 M NaCl, 1% NP-40, 1% deoxycholic acid, 0.1% SDS, 2 mM 
EDTA and complete protease inhibitor (Roche) for 30 min on a rocker at 4°C. A 
bicinchoninic acid (BCA) assay (ThermoScientific, 23227) was used to quantify the total 
protein concentration in each lysate, and the indicated amount of total protein in 
NuPAGE LDS sample buffer (Invitrogen, NP0007) was separated by SDS–PAGE using 
NuPAGE 4–12% Bis-Tris 1.0 mM precast gels and electrotransferred to PVDF 
membranes (Millipore, IPFL00010) using the XCell SureLock Mini-Cell system 
according to the manufacturer's instructions (Invitrogen). Blots were blocked and 
antibodies diluted with Odyssey Blocking Buffer (LiCor, 927–40000) according to the 
manufacturer's instructions. Primary antibody incubation conditions were as follows: 
1:10 000 dilution of rabbit anti-FUS (Bethyl Laboratories, A300-293A, epitope maps to 
the region of FUS comprised residues 400–450; we note that the A300-302A antibody, 
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which maps to FUS residues 1–50, is less reactive for the FUS truncation mutants 
described herein) and 1:1000 rabbit anti-GAPDH (Sigma, G9545) or a 1:5000 dilution of 
mouse Living Colors (anti-GFP; Clontech, 632380) and 1:1000 rabbit anti-GAPDH 
(Sigma, G9545) for 1 h at 25°C. Secondary antibody conditions were as follows: 1:10 
000 anti-rabbit IRDye 800 (LiCor, 926-32211) and 1:10 000 anti-rabbit IRDye 680 
(LiCor, 926-32220) when probed with anti-FUS/anti-GAPDH or 1:10 000 anti-mouse 
IRDye 800 (LiCor, 926-32210), and 1:10 000 anti-rabbit IRDye 680 (LiCor, 926-32220) 
when probed with Living Colors/anti-GAPDH for 1 h at 25°C. Bands were visualized 
with an Odyssey Infrared Imager (LiCor, Model 9120), and densitometry performed with 
the Odyssey Software (LiCor, V3.0). 
89
Chapter III 
Expression of ALS-linked FUS/TLS mutants inhibits PML nuclear body turnover 
90
III.1 Preface 
The following work is the final manuscript in preparation: 
Hae Kyung Ko, Sudarsanareddy Lokireddy, Hongru Zhou, Alfred L. Goldberg, and 
Lawrence J. Hayward 
I performed all experiments present here except the experiments for proteasome 
composition and activity. I performed the cell culture experiments, immunostaining, 
confocal image acquisition and quantitation, and Western blotting and EdU assays.   
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III.2 Abstract 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
characterized by preferential motor neuron death in the brain and spinal cord. Mutations 
in FUS/TLS (FUsed in Sarcoma/ Translocated in LipoSarcoma) cause ~4% of familial 
ALS cases, and the most consistently identified mutations cluster within a nuclear 
localization signal (NLS) sequence at the FUS C-terminus. While some FUS mutants that 
perturb the NLS mislocalize to the cytoplasm, others remain predominantly nuclear and 
may impair motor neuron homeostasis by a gain of toxicity within the nucleus.  
We observed that HEK293 cells expressing human FUS mutants (R495X, R521G, or 
P525L) exhibited enlarged promyelocytic leukemia nuclear bodies (PML-NBs) compared 
to control cells expressing endogenous FUS or a human WT FUS cDNA. Furthermore, 
following oxidative insult with arsenic trioxide (ATO) for 24 h, the turnover of PML-NBs 
was greatly impaired for mutant cells, concomitant with accumulation of the 
transcriptional repressor Daxx in enlarged PML-NBs. Although the expression of 
proteasome subunits was not altered, the peptidase activities of 26S proteasomes purified 
from mutant cells were significantly reduced. Cells expressing FUS mutants also 
contained larger PML-NBs than controls upon proteasome inhibition with 1 µM MG132. 
The polyubiquitin-binding protein p62/SQSTM1 colocalized with a fraction of large 
PML-NBs in FUS mutant cells. Furthermore, we observed that primary fibroblasts from 
an ALS patient harboring the FUS mutant R521G exhibited enlarged PML-NBs under 
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baseline conditions and a striking impairment of PML-NB turnover following ATO 
exposure.  
These findings indicate that mutant FUS expression in human cellular models of 
ALS (i) impairs the turnover of PML-NBs, a vulnerability that can be unmasked further 
upon ATO exposure, and (ii) leads to an inhibition of proteasome function. Our results 
reveal a robust yet previously unrecognized nuclear pathology specific to mutant FUS 
expression at endogenous levels that may contribute to ALS pathogenesis. 
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III.3 Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
characterized by preferential motor neuron death in the brain and spinal cord (Rowland 
and Shneider 2001). Affected individuals succumb to complications of weakness that 
include respiratory failure, typically within 3-5 years after disease onset. While ~10% of 
ALS cases show familial inheritance (fALS) that may be linked to specific gene 
mutations, 90% of cases occur sporadically in the context of genetic, epigenetic, or other 
environmental susceptibilities. The number of genes linked to ALS has increased 
dramatically over the past decade, and these include nucleic acid binding proteins such as 
TDP-43 and FUS/TLS, potentially implicating disruption of RNA metabolism in ALS 
pathogenesis (Sreedharan, Blair et al. 2008, Kwiatkowski, Bosco et al. 2009, Vance, 
Rogelj et al. 2009). 
FUS/TLS (Fused in Sarcoma/ Translocated to liposarcoma) also known as 
heterogeneous nuclear ribonucleoprotein P2 (hnRNP P2) (Calvio, Neubauer et al. 1995), 
is a nucleic acid binding protein localized predominantly to the nucleus. FUS comprises 
several domains including a Q/G/S/Y-rich domain, RGG-rich regions, an RNA 
recognition motif (RRM), a zinc finger motif and a PY-type nuclear localization signal 
(PY-NLS) recognized by the nuclear import receptor, Transportin 1 (Dormann, Rodde et 
al. 2010). More than 50 mutations in the FUS gene are linked to ~4% of fALS (Deng, 
Gao et al. 2014), and many of these may perturb the PY-NLS to cause cytoplasmic FUS 
accumulation (Ito, Seki et al. 2011, Kino, Washizu et al. 2011). Cytoplasmic mutant FUS 
94
can be recruited into stress granules upon exposure to thermal, oxidative, or ER stress 
(Bosco, Lemay et al. 2010, Dormann, Rodde et al. 2010, Ito, Seki et al. 2011, Bentmann, 
Neumann et al. 2012, Baron, Kaushansky et al. 2013, Daigle, Lanson et al. 2013, Vance, 
Scotter et al. 2013). Proposed roles of FUS include regulation of RNA splicing (Orozco, 
Tahirovic et al. 2012), transcription (Tan, Riley et al. 2012), DNA damage repair (Wang, 
Pan et al. 2013, Rulten, Rotheray et al. 2014), and microRNA processing  (Morlando, 
Dini Modigliani et al. 2012).  
Mammalian cell nuclei contain a variety of self-assembled membrane-less nuclear 
bodies including nucleoli, nuclear speckles and paraspeckles, Cajal bodies, nuclear Gems, 
histone locus bodies and promyelocytic leukemia nuclear bodies (PML-NBs) (Mao, 
Zhang et al. 2011). While our understanding of the organization and functions of these 
nuclear bodies remains incomplete, dysregulation of these bodies has been linked to 
conditions including neurodegenerative disease and cancer (Zimber, Nguyen et al. 2004, 
Woulfe 2008, de The, Le Bras et al. 2012). For example, FUS mutant expression in 
cellular models and human fibroblasts has been reported to be associated with decreased 
Gem formation (Yamazaki, Chen et al. 2012). Gems normally contain survival motor 
neuron (SMN) protein and serve functions related to snRNP assembly and RNA splicing 
(Liu and Dreyfuss 1996, Pellizzoni, Kataoka et al. 1998). Furthermore, acute 
overexpression of FUS mutants cause axonal defects in cultured cortical neurons 
associated with mislocalization of SMN into cytoplasmic complexes containing FUS, 
thereby decreasing axonal SMN (Groen, Fumoto et al. 2013). The RGG motifs of FUS 
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can interact with the Tudor domain of SMN, and ALS mutants can increase this 
interaction, potentially dysregulating SMN functions (Sun, Ling et al. 2015). Deficiency 
of SMN is a hallmark of spinal muscular atrophy (SMA), a childhood-onset motor neuron 
disease. Gem loss is also associated with a decrease in the number of Cajal bodies and 
concomitant increase in PML body number in SMA motor neurons (Tapia, Bengoechea et 
al. 2012), further supporting a role for nuclear bodies in motor neuron homeostasis and 
survival. 
PML protein forms the structural scaffold of PML-NBs, which  have been implicated 
in diverse cellular processes, including  in DNA damage response (Dellaire, Ching et al. 
2006), apoptosis (Takahashi, Lallemand-Breitenbach et al. 2004, Bernardi, Papa et al. 
2008), cellular senescence (Vernier, Bourdeau et al. 2011), gene transcription (Block, 
Eskiw et al. 2006), and anti-viral response (Everett and Chelbi-Alix 2007). PML is a 
member of the tripartite motif (TRIM) protein family characterized by structural elements 
including a RING finger, two B box zinc fingers, and a coiled-coil domains (RBCC 
motif). This RBCC motif contributes to self-dimerization to form PML-NBs and 
mediates the binding of PML to the SUMO E2 ligase UBC9 (de The, Le Bras et al. 
2012). The PML gene can specify several isoforms by alternative splicing in its carboxyl 
terminus, and so far seven isoforms have been characterized (Condemine, Takahashi et al. 
2006, Bernardi and Pandolfi 2007). A (15;17) chromosomal translocation involving the 
genes encoding PML and the retinoic acid receptor alpha (RARα) produces a PML-
RARα fusion protein that disrupts PML-NB function and triggers the pathogenesis of 
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acute promyelocytic leukemia (APL). Exposure to low concentrations of arsenic trioxide 
(As2O3, ATO) was found empirically to promote PML-RARα degradation and thereby 
improve PML-NB function, contributing to the cure of up to 70% of APL patients 
(Lallemand-Breitenbach, Zhu et al. 2012). In addition to leukemia, ATO-induced PML 
degradation is also observed in cultured cell lines (Lallemand-Breitenbach, Jeanne et al. 
2008, Geoffroy, Jaffray et al. 2010). Acute exposure in vitro to ATO (1 µM) potentiates 
PML crosslinking and sumoylation to strongly induce the formation of PML-NBs within 
1 h (Jeanne, Lallemand-Breitenbach et al. 2010). Upon prolonged exposure to ATO for 
>12 h, sumolyated PML and other sumoylated proteins recruited to PML-NBs normally 
are ubiquitinated by a key SUMO-dependent E3 ubiquitin ligase RNF4, which may target 
them for degradation via the ubiquitin-proteasome system (Lallemand-Breitenbach, Zhu 
et al. 2001, Geoffroy, Jaffray et al. 2010, Sahin, Ferhi et al. 2014). 
PML-NBs have been shown in the nervous system to influence neurodevelopment 
and synaptic plasticity (Regad, Bellodi et al. 2009, Butler, Martinez et al. 2013, Korb and 
Finkbeiner 2013). PML regulates neural progenitor cells in the developing CNS, and 
PML knockdown decreases cerebral cortex thickness observed at postnatal day 0 (Regad, 
Bellodi et al. 2009). PML-deficient adult mice also exhibit impaired learning and 
memory performance (Butler, Martinez et al. 2013). Moreover, neuronal intranuclear 
inclusions recognized by anti-ubiquitin antibody localize into PML-NBs in affected brain 
tissues for several neurodegenerative conditions (Woulfe 2008). Expression of 
polyglutamine expanded mutant ataxin-7 produces intranuclear inclusions of ataxin-7 that 
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disrupt PML-NBs (Janer, Werner et al. 2010), and induction of PML-NBs with interferon 
β increases the clearance of mutant ataxin-7 in a transgenic mouse model (Chort, Alves et 
al. 2013). Interestingly, intranuclear inclusions in some ALS patient tissues show 
immunoreactivity to PML that could be associated with ALS pathogenesis (Seilhean, 
Takahashi et al. 2004). While these observations collectively suggest that dysregulation 
of PML-NB functions may be relevant to neurodegenerative diseases, the potential role 
of  PML-NBs in ALS has not been specifically addressed. 
Accumulation of proteins linked to several neurodegenerative diseases may result 
from impaired activity of the cellular machinery for degradation of misfolded proteins 
(Goldbaum, Oppermann et al. 2003, Goldberg 2003, Broe, Shepherd et al. 2005, Amador-
Ortiz, Lin et al. 2007, Bennett, Shaler et al. 2007, Goldberg 2007, Kristiansen, Deriziotis 
et al. 2007, Blokhuis, Groen et al. 2013, Jucker and Walker 2013). High concentrations of 
mutated or misfolded proteins in cells can lead to their aggregation into oligomeric 
complexes or larger inclusions, which may frequently be ubiquitinated and have been 
proposed to be toxic to cells (Goldberg 2003, Liu, Wei et al. 2009). The major proteolytic 
system that blocks the buildup of misfolded proteins prior to aggregation, especially 
within the nucleus, is the ubiquitin proteasome system (UPS) (Goldberg 2003, Finley 
2009). Proteasomes are large ATP-dependent proteolytic complexes that are the primary 
sites for protein degradation in eukaryotic cells (Goldberg 2003, Finley 2009). The 26S 
proteasome degrades ubiquitinated proteins selectively through a multistep process that 
includes conjugate binding to its 19S regulatory complex, substrate deubiquitination, 
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unfolding and translocation into 20S core particles (Goldberg 2003, Finley 2009). 
Proteins then are hydrolyzed by three endopeptidase activities located within the 20S core 
particle (Goldberg 2003, Finley 2009). Impaired proteasome function has been associated 
with accumulation of misfolded proteins in several different cell models of 
neurodegenerative diseases (Goldbaum, Oppermann et al. 2003, Bennett, Shaler et al. 
2007, Kristiansen, Deriziotis et al. 2007). Furthermore, nuclear proteasomes, including 
both the 20S proteasome complex and 11S/PA28 regulatory factors, can localize to the 
vicinity of PML-NBs, suggesting that PML-NBs may serve an important role in nuclear 
protein quality control (Lallemand-Breitenbach, Zhu et al. 2001, Guo, Giasson et al. 
2014). 
In this study, we examined how FUS ALS mutants influence the dynamics of PML-
NBs in a human ALS cell model and in human ALS primary fibroblasts. We observed 
that FUS mutants expressed at near-endogenous levels affected the size of PML-NBs 
under baseline conditions and perturbed their normal turnover during exposure to 
prolonged oxidative stress. In addition, FUS mutants also inhibited proteasome activity 
with no apparent reduction in the amount of proteasomes.   
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III.4 Results 
III.4.1 Expression of FUS mutants expanded PML nuclear bodies 
To gain insights relevant to pathogenic mechanism caused by FUS mutant 
expression, we established inducible HEK293 cells expressing GFP-FUS variants from a 
single genetic locus (Bosco, Lemay et al. 2010). Human FUS variants included wild type 
(WT) and the ALS-linked mutants R495X, R521G, and P525L (Figure 3-1A). Treatment 
with doxycycline (2 µg/ml) for 48 h induced GFP-FUS expression at levels comparable 
to endogenous FUS (Figure 3-1B). Upon detection of GFP-FUS by direct visualization of 
GFP fluorescence, we observed that the WT and R521G FUS fusion proteins were 
localized primarily to the nucleus, while the R495X and P525L mutants were prominent 
both in the nucleus and the cytoplasm (Figure 3-1C), as has been reported previously 
(Dormann, Rodde et al. 2010, Baron, Kaushansky et al. 2013). We also observed the 
focal accumulation of intense nuclear GFP-FUS puncta in cells expressing either WT or 
mutant FUS (Figure 3-1C); similar foci have been reported in association with 
paraspeckle markers, including PSF, PSP1or p54nrb/NONO (Nishimoto, Nakagawa et al. 
2013, Shelkovnikova, Robinson et al. 2014) but not with SMN, coilin, or PML-NBs in 
cells expressing wild type FUS (Shelkovnikova, Robinson et al. 2014). While we also 
noted no evidence that GFP-FUS puncta colocalized with PML-NBs, we did observe a 
significant increase in the fluorescence signal of PML-NBs in FUS mutant cells 
compared to FUS WT or non-induced control cells (Figure 3-1C). We integrated the 
fluorescence intensity from confocal slices for voxels comprising individual PML-NBs 
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using Image J (see Methods) and plotted their cumulative frequency for mutant and 
control cells (Figure 3-1D). The population of PML-NBs in mutant cells showed 
significantly greater fluorescence compared to those in control cells (WT or non-
induced), with an increase in the median values by 38% and an increase in the values at 
the 75th percentile by 54% (Figure 3-1D, p < 0.001 by Kruskal-Wallis test followed by 
Dunn’s multiple comparison test, n= 77-174 cells per group). The largest PML-NBs, with 
intensities >20,000 in relative fluorescence units (RFU), were observed in >50% of cells 
expressing FUS mutants but were much less frequent in control cells (Figure 3-1E). The 
presence of enlarged PML-NBs upon FUS mutant expression was independent of 
whether FUS remained primarily nuclear (R521G) or mislocalized partially to the 
cytoplasm (R495X and P525L). However, the number of PML-NBs per cell did not 
change significantly (Figure 3-1F), which was consistent with a larger size rather than an 
increased number of PML-NBs. These results suggested an association between FUS 
mutant expression and expansion of the PML-NB compartment, which we decided to 
explore further.  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Figure 3-1 HEK293 cells expressing FUS mutants exhibited large PML-NBs. 
(A) FUS contains several domains including a Gln-Gly-Ser-Tyr (QGSY)-rich region, three Arg-Gly-Gly 
(RGG)-rich regions, an RNA recognition motif (RRM), a zinc-finger motif (ZnF) and a PY-type of 
nuclear localization signal (L). Human FUS (hFUS) -WT and ALS-linked mutant constructs (R495X, 
R521G and P525L) were fused to GFP and stably inserted into a single locus for inducible expression in 
HEK293 cells. (B) Western blots of cellular lysates (5 µg of protein loaded per lane) using anti-FUS 
detected endogenous FUS and induction of GFP-FUS with doxycycline (Dox) treatment. (C) PML-NBs 
were identified in maximum-intensity confocal z-projections from HEK293 cells immunostained with 
anti-PML antibody. Nuclei were outlined based on DAPI staining, and GFP-FUS was detected by GFP 
fluorescence. Scale bar, 5µm. (D) Cumulative frequency plot of PML-NB intensities (in relative 
fluorescence units, RFU) showed that the fluorescence of PML-NBs from mutant cells was larger 
compared to that from control cells (77-174 cells were analyzed from seven independent experiments, p < 
0.001). (E) Cells containing large PML-NBs (integrated intensity > 20,000 RFU) were more frequent for 
mutant compared to control cells (shown are mean ± S.D.; ***, p < 0.001 compared to controls).  (F) The 
number of PML-NBs per cell did not differ between mutant and control cells (shown are mean ± S.D.).
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III.4.2 FUS mutant expression inhibited the turnover of PML-NBs 
PML-NBs are highly dynamic structures implicated in the regulation of stress 
responses, DNA repair pathways, cellular senescence, and apoptosis (Sahin, Ferhi et al. 
2014). Under oxidative conditions in vivo, disulfide crosslinking of PML proteins 
organizes the physical scaffold for PML-NBs (Ishov, Sotnikov et al. 1999). We therefore 
examined how FUS mutants might affect the dynamic behavior of PML-NB formation 
and turnover upon exposure to mild oxidative stress.  
Cells were treated with a low concentration of ATO (1 µM) for 1 h to stimulate 
PML-NB assembly after 48 h induction of GFP-FUS variants (Figure 3-2). As shown in 
Figure 3-2, we observed a robust increase in PML incorporation into PML-NBs within 1 
h after ATO exposure for the WT and (-)Dox control cells. The extent of acute PML-NB 
formation in controls was similar to that observed for the mutant cells before treatment, 
while PML-NBs in the mutant cells only mildly increased further. This suggests that 
competency to respond acutely to the stress imposed by ATO seen in the control cells 
may be blunted in the mutant cells, possibly related to the increase in their constitutive 
PML-NB activation. Moreover, upon longer exposure to ATO (24 h), the PML signal 
within nuclear bodies decreased in FUS WT and (-)Dox control cells by 32% at the 
median and by 46% at the 75th percentile compared to 1 h ATO-treated control cells 
(p<0.001), as expected following the induction of ATO-triggered turnover. The 
fluorescence of PML-NBs in mutant cells after ATO for 24 h increased further by 50% at 
the median and 103% at the 75th percentile compared to 1 h ATO treated mutant cells 
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(Figure 3-2B, p < 0.001 by Kruskal-Wallis test followed by Dunn’s multiple comparison 
test). 
The fraction of control cells harboring one or more large PML-NBs increased from 
<20% at baseline to >80% after 1 h ATO exposure, returning to only ~30% after 24 h 
ATO (Figure 3-2C). In contrast, >50% of cells expressing ALS mutants exhibited large 
PML-NBs before ATO treatment, and this fraction increased further and was maintained 
following treatment (Figure 3-2C). For all cell lines, the number of PML-NBs per cell 
increased significantly after 1 h ATO compared to untreated cells, while the number of 
PML-NBs per cell returned to pre-treatment levels after 24 h ATO (Figure 3-2D). Soluble 
PML protein recruited to PML-NBs is thought to partition away from a diffuse nuclear 
fraction and associate with a highly insoluble nuclear matrix fraction (Lallemand-
Breitenbach, Zhu et al. 2001). Consistent with this, the accumulation of PML protein in 
the RIPA buffer insoluble pellet (P) fraction for FUS mutant cells compared to FUS WT 
cells was increased by 2.1 ± 0.4 fold after ATO treatment for 24 h (Figure 3-2E).  
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Figure 3-2 Expression of FUS mutants inhibited PML-NB turnover upon ATO 
treatment.  
(A) HEK293 cells treated with ATO (1 µM) showed enlargement of PML-NBs after 1 h and divergent 
properties for mutant compared to control cells after exposure for 24 h. Shown are maximum-intensity z-
stacks of GFP fluorescence and anti-PML antibody staining. Nuclei were outlined based on DAPI 
staining. Scale bar, 5µm. (B) Cumulative frequency plots show the intensities of individual PML-NBs on 
a log scale in untreated cells (left, n=43-64 cells) or those treated with ATO for 1 h (middle, n=44-69 
cells) or 24 h (right, n=70-100 cells). Guide lines indicate 75th percentile RFU values. (C) The fraction of 
mutant cells containing large PML-NBs (>20,000 RFU) was increased in the absence of ATO (two way 
ANOVA with Sidak’s multiple comparison test; *, p < 0.05 compared to controls). Acute treatment with 
ATO for 1 h increased the fraction of all cells expressing large PML-NBs, which was maintained for 
mutant cells after ATO treatment for 24 h (***, p < 0.001 compared to controls). Shown are mean ± S.D. 
(D) ATO treatment for 1 h increased the number of PML-NBs per cell (two way ANOVA followed by 
Tukey’s multiple comparison test; **, p < 0.01;, ***, p < 0.001 compared to untreated). (E) Cell lysates 
were separated into RIPA soluble (S) or pellet (P) fractions following no treatment or 1 µM ATO for 24 h. 
Western blot showed increased PML accumulation in the RIPA-insoluble pellet of mutant cells after ATO.
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A fraction of the PML protein in cells treated with ATO for 24 h redistributed into 
large cytoplasmic aggregates just outside the nuclear membrane both in control and 
mutant cells (Figure 3-2A and 3-3A). Such cytoplasmic assemblies of PML have been 
reported following mitosis in other cell lines, and these are stabilized in the presence of 
ATO, which inhibits the re-importation of PML during the cell cycle G1 phase (Lang, 
Grudic et al. 2012). To determine whether the rate of cell proliferation differed between 
our mutant and control cell lines in the absence or presence of ATO, we measured 5-
ethynyl-2’-deoxyuridine (EdU) incorporation over 1 h (Figure 3-3B). Under baseline 
growth conditions, a decrease in the fraction of cells incorporating EdU was observed for 
FUS mutant cells compared to controls. After treatment with ATO for 24 h, both mutant 
and control cells showed a similar decrease in EdU incorporation. Overall, these results 
suggested that FUS mutant expression may slow the cellular proliferation rate at baseline 
and that prolonged ATO exposure decreases the proliferation of control cells to a rate 
comparable to that of the mutant cells. This implies that mechanisms distinct from altered 
proliferation may contribute to the observed increase in PML-NB expansion in mutant 
cells following ATO treatment.    
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 III.4.3 Enlarged PML-NBs in FUS mutant cells recruited Daxx  
PML-NBs dynamically sequester a variety of partner proteins, including 
transcription factors, post-translational modifiers, DNA repair proteins, and viral 
components that may influence cellular homeostasis (Hofmann and Will 2003, Sahin, 
Ferhi et al. 2014). Since the PML-NB scaffold forms, proteins capable of undergoing 
sumoylation are attracted to the site via SUMO-interaction motif (SIM) domains on PML 
and related components. For example, the death domain-associated protein Daxx is a 
transcriptional repressor known to localize into PML-NBs (Li, Leo et al. 2000), and 
Daxx-PML interactions can induce apoptosis (Zhong, Salomoni et al. 2000, Bernardi and 
Pandolfi 2003, Bernardi, Papa et al. 2008). Also, an increased number of Daxx-
containing nuclear bodies was observed in spinal cord motor neuron sections from 
presymptomatic transgenic mice expressing ALS mutants of SOD1 (G93A or G85R), 
supporting a role for Daxx in a signaling pathway relevant to motor neuron death (Raoul, 
Buhler et al. 2006). 
We next examined whether PML-NBs induced by ATO treatment accumulated Daxx. 
While Daxx was expressed throughout the nucleoplasm and to a lesser degree in the 
cytoplasm in cells at baseline, Daxx became more concentrated in PML-NBs within 2 h 
upon ATO treatment (Figure 3-4A). Following exposure to ATO for 6-12 h in control 
cells, Daxx resumed a diffuse nuclear distribution (not shown), which was maintained 
even after 24 h of ATO (Figure 3-4A). In contrast, large PML-NBs in cells expressing 
FUS mutants maintained strong colocalization with Daxx after 24 h ATO (Figure 3-4A). 
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We quantified Daxx colocalization as a function of PML-NB intensity and found that the 
PML-NBs with the strongest fluorescence were most likely to maintain colocalization 
with Daxx (Figure 3-4B). The median intensity of PML-NBs colocalized with Daxx was 
greater for cells expressing FUS-R521G (by 3.9-fold) or FUS-R495X (by 4.2-fold) 
compared to FUS-WT (Figure 3-4C). Next, we analyzed whether Daxx accumulation 
affected cell viability after treatment with 1-5 µM ATO using a luciferase reporter assay 
to indicate ATP production in metabolically active cells. ATO exposure for 24 h did not 
differentially impair the viability of HEK293 cells expressing FUS mutants (Figure 
3-4D). This agrees with our previous study that indicated a lack of vulnerability to 
oxidative stress for these cells (Bosco, Lemay et al. 2010). 
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Figure 3-4 ATO induced localization of Daxx into large PML-NBs in FUS mutant 
cells.  
HEK293 cells were treated with 1 µM ATO for 24 h, and confocal z-stack images show localization of 
Daxx into large PML-NBs. Scale bar, 5µm. (B) Individual PML-NBs were sorted in 3D into those that 
colocalized with Daxx (solid symbols) and those that did not colocalize (open symbols). Shown are the 
PML-NB intensity distributions for each group. (C) The fluorescence intensity of PML-NBs that 
colocalized with Daxx (from n=29-61 cells) was greater for mutant compared to control cells. Shown are 
mean ± S.E.M. from three independent experiments. ***, p < 0.001. (D)Treatment with 1-5 µM ATO for 
24 h did not differentially affect the viability of FUS mutant compared to control cells. Shown are mean ± 
S.D. from three independent experiments. 
112
PML-NBs also facilitate the ubiquitination of sumoylated proteins by the SUMO-
dependent E3 ubiquitin ligase RNF4, which targets proteins to nuclear proteasomes for 
degradation (Lallemand-Breitenbach, Zhu et al. 2001, Lallemand-Breitenbach, Jeanne et 
al. 2008, Maroui, Kheddache-Atmane et al. 2012). One plausible mechanism to account 
for the observed increase in PML-NB size at baseline and the defect in PML-NB turnover 
after ATO could involve impaired recruitment of proteasomal subunits or regulators to 
PML-NBs in mutant-expressing cells. For instance, it has been shown that PML mutants 
(K160R or triple K65/160/490R) shows impaired degradation/turnover related to 
decreased accumulation to PML-NBs of the 11S proteasome regulator (comprising 
PA28αβ mixed heptamers), the 20S proteasome, or ubiquitin (Lallemand-Breitenbach, 
Zhu et al. 2001, Lallemand-Breitenbach, Jeanne et al. 2008). Therefore, we tested 
whether FUS mutant expression affected 11S proteasome regulator recruitment to PML-
NBs and observed strong colocalization between PML-NBs and the 11S regulator 
(detected with anti-PA28β antibody) in all of our cell lines (Figure 3-5). Even after ATO 
treatment for 24 h, the 11S regulator remained localized to large PML-NBs in cells 
expressing FUS mutants (Figure 3-5A). Cumulative frequency analysis confirmed that 
the 11S regulator colocalized persistently with the larger PML-NBs in cells after 
exposure to ATO for 24 h (Figure 3-5B). In addition, the median intensity of these PML-
NBs colocalized with the 11S regulator was greater for cells expressing FUS-R521G (by 
3.7-fold) or FUS-R495X (by 3.3-fold) compared to control cells (Figure 3-5C). 
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Figure 3-5 ATO triggered accumulation of 11S/PA28 into large PML-NBs in FUS 
mutant cells.  
(A) HEK293 cells were treated with 1 µM ATO for 24 h, and confocal z-stack images show localization 
of 11S/PA28 regulator into large PML-NBs. Scale bar, 5µm. (B) Individual PML-NBs were sorted in 3D 
into those that colocalized with 11S/PA28 (solid symbols) and those that did not colocalize (open 
symbols). Shown are the PML-NB intensity distributions for each group. (C) The fluorescence intensity 
of PML-NBs that colocalized with 11S/PA28 (from n=27-39 cells) was greater for mutant compared to 
control cells. Shown are mean ± S.E.M. from three independent experiments. **, p < 0.01; ***, p < 
0.001. 
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III.4.4 Mutant FUS expressions reduces 26S proteasome activities 
We considered the possibility that mutant FUS expression might impair proteasome 
activities, which could contribute to the defect in PML-NB turnover following ATO 
treatment as shown above. We did not observe any obvious difference in 26S proteasome 
subunit component levels including PA200, Rnp2, Rpt5, Rpn13 and MCP in both total 
lysate and affinity-purified 26S proteasomes from FUS mutant cells compared to (-)Dox 
and FUS-WT cells (Figure 3-6B). However, affinity-purified 26S proteasomes from cells 
expressing FUS mutants did show decreases in all three peptidase activities compared to 
cells with comparable WT FUS expression, including chymotrypsin-like activity (by 21 ± 
5%) assayed with suc-LLVY-amc, caspase-like activity (by 36 ± 18%) with suc-nLPnLD-
amc, and trypsin-like activity (by 19 ± 6%) with suc-VLR-amc (Figure 3-6A). These 
findings would suggest that protein breakdown by the ubiquitin-proteasome pathway is 
impaired in the cells expressing FUS mutants. To test this prediction, we transfected cells 
with the cDNA encoding Ub-G76V-GFP, a ubiquitin fused degradation (UFD) substrate 
that is rapidly degraded by this pathway (Dantuma, Lindsten et al. 2000). As shown in 
Figure 3-6C, overexpression of FUS mutants caused the accumulation of UFD substrate 
above levels in control cells. 
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Figure 3-6 FUS variant overexpression reduced 26S proteasome activities 
(A) 26S proteasomes were purified from HEK293 cells, and their peptidase activities including the 
chymotrypsin-like activity assayed with suc-LLVY-amc, caspase-like activity with suc-nLPnLD-amc, and 
trypsin-like with suc-VLR-amc were measured. Shown are means ± S.D. (B) No apparent difference was 
evident in the subunit composition of proteasomes purified by the UBL affinity method as shown by 
Western blot of total lysate analyzed against FUS, PA200/Blm10, Rnp2, Rpt5, Rpn13 and MCP. (C) 
Overexpression of FUS variants caused accumulation of a UPS pathway reporter substrate, UbG76V-GFP. 
HEK293 cells were transfected with UbG76V-GFP cDNA, and levels of GFP, FUS, Rpn2, Rpt5 and MCP 
were analyzed by immunoblotting. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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One additional possible consequence of impaired proteasome activities is the 
accumulation of ubiquitinated proteins in cells. However, we found no evidence for 
increased ubiquitinated proteins in either the Triton X-100 soluble (A) or insoluble (B) 
fractions (Figure 3-7). Interestingly, we observed a significant increase in the 
accumulation of sumolyated proteins detected by anti-SUMO2/3 antibody in Triton 
X-100 insoluble fractions after expression of FUS mutants (Figure 3-7B).  
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III.4.5 Inhibition of proteasome activity with MG-132 increased the size of  
PML-NBs in FUS mutant cells 
Impaired PML-NB turnover could be consistent with possible dysfunction of nuclear 
protein homeostasis. We next asked whether inhibition of the proteasome with MG132 (1 
µM) could also cause a similar enlargement of PML-NBs. HEK293 cells were exposed to 
MG132 for 24 h and stained with anti-PML antibody (Figure 3-8A). First, we examined 
if 1 µM of MG132 treatment induced the incorporation of FUS mutants into stress 
granules because others have shown that much stronger treatment with MG132 (10 µM) 
induces stress granule formation in HeLa cells (Mazroui, Di Marco et al. 2007). 
However, 1 µM MG132 for 24 h did not alter FUS localization (Figure 3-8A). Second, 
MG132 at 5-10 µM has been reported to increase the number of PML-NBs observed in 
cultured cells (Everett, Earnshaw et al. 1999, Kurki, Latonen et al. 2003). Notably, we 
also found that 1 µM MG132 treatment increased the number of PML-NBs per cell, but 
only for FUS-WT cells (Figure 3-8C). Interestingly, the integrated fluorescence 
intensities of PML foci in FUS mutant cells increased following MG132 treatment 
(Figure 3-8B) in a manner that resembled our observations in cells treated with ATO 
(Figure 3-2). MG132 treatment increased the average fluorescence intensity of PML-NB 
by >2-fold in FUS mutant cells compared to cells expressing WT FUS (Figure 3-8B). 
PML-NB fluorescence in mutant cells increased by 46% at the median and by 73% at the 
75th percentile compared to control cells (p < 0.001 by Kruskal-Wallis test followed by 
Dunn’s multiple comparison test). In contrast, 1 µM MG132 treatment did not change the 
120
integrated intensity distribution of PML foci in FUS-WT cells. Our results are consistent 
with chronic proteasome inhibition in FUS mutant cells as a possible contributing factor 
in the enlargement of PML-NBs.  
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Figure 3-8 FUS variant overexpression reduced 26S proteasome activities and 
enlarged PML-NBs after MG-132 treatment.  
(A) Confocal image z-stacks show HEK293 cells treated with 1 µM MG132 for 24 h and stained with 
anti-PML antibody. Scale bar, 5µm. (B) MG132 caused an increase in the average intensity of PML-NBs 
in FUS mutant cells. Shown are mean ± S.E.M. (C) The number of PML-NBs per cell increased after 
MG-132 treatment for FUS-WT cells. Shown are mean ± S.D. n= 53-69 cells from three independent 
experiments. *, p < 0.05; ***, p < 0.001. 
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III.4.6 FUS mutant cells increased abnormal nuclear p62 accumulation 
Protein aggregation is a hallmark in several neurodegenerative diseases, including 
ALS (Ross and Poirier 2004, Blokhuis, Groen et al. 2013, Jucker and Walker 2013). 
Proteasome subunits, chaperones, ubiquitin and p62/SQSTM1 can be major components 
in these inclusions, which may form when the production of misfolded proteins exceeds 
their rate of clearance. While we did not detect increased polyubiquitinated protein 
accumulation in Triton X-100 insoluble fractions (Figure 3-7B), we examined whether 
HEK293 cells expressing mutant FUS might show an increase in p62/SQSTM1 foci. We 
induced FUS variants with Dox for 48 h in HEK293 cells and stained with anti-p62 
antibody (Figure 3-9A). In addition to cytoplasmic p62, we observed both diffuse and 
focal immunoreactivity to p62 within the nucleus. Increased nuclear foci containing p62 
were present in FUS mutant cells compared to controls (Figure 3-9B). Next, we analyzed 
the expression levels of p62 by Western blotting of nuclear and cytoplasmic fractions as a 
function of RIPA solubility (Figure 3-9D and Figure 3-9E). These results showed that the 
more prominent p62 foci in the nucleus of FUS mutant cells were not related to any 
increase in total expression of p62. Previously, p62 nuclear foci in HeLa cells were 
reported to co-localize with PML-NBs (Pankiv, Lamark et al. 2010). In that system, 
siRNA-mediated knockdown of p62 inhibited the accumulation of polyubuquitinated 
proteins into PML-NBs upon treatment with the CRM1 inhibitor leptomycin B, which 
suggested that p62 may be a critical factor to recruit polyubiquitinated proteins into 
PML-NBs (Pankiv, Lamark et al. 2010). We asked whether PML-NBs in HEK293 cells 
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expressing FUS variants colocalized with p62 and found this to be true, especially for 
large PML-NBs in FUS mutant cells (Figure 3-9C). 
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Figure 3-9 Expression of FUS mutants increased the accumulation of nuclear p62/
SQSTM1 foci near large PML-NBs.  
(A) Confocal image z-stacks showed partial overlap of PML and p62 immunofluorescence staining. Scale 
bar, 5µm. (B) FUS mutant cells showed an increase in nuclear p62 foci per cell compared to controls (n= 
34-87 cells from >3 independent experiments). (C) More than 40% of large PML-NBs (integrated 
intensity > 20,000 RFU) colocalized with p62 in FUS mutant cells. (D) Western blotting of subcellular 
protein fractions showed no obvious change in nuclear or cytoplasmic p62 expression levels for mutant 
cells. (E) p62 levels did not change in RIPA-soluble or RIPA-insoluble fractions. Shown in (B) and (C) 
are mean ± S.D.; *, p < 0.05, **, p < 0.01. 
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III.4.7 ALS patient fibroblasts exhibited impaired PML-NB degradation upon  
ATO exposure 
We next analyzed PML-NB properties in human fibroblasts harboring the FUS-
R521G mutation. While control cells expressed FUS almost exclusively in the nucleus, 
FUS-R521G fibroblasts exhibited only subtle cytoplasmic mislocalization of FUS (Figure 
3-10A). The integrated fluorescence intensity of PML-NBs in fibroblasts was analyzed 
using the same method as for HEK293 cells. The intensity of PML-NBs in FUS mutant 
fibroblasts under basal conditions increased by 62% at the median and by 67% at the 75th 
percentile compared to control cells (Figure 3-10B). Consistent with the results observed 
in HEK293 cells, PML-NB turnover was strikingly impaired in FUS-R521G fibroblasts 
compared to controls (Figure 3-10A and Figure 3-10B). While the intensity of PML-NBs 
decreased in control cells, PML-NB fluorescence in fibroblast-R521G cells increased by 
4.8-fold at the median and by 7.7-fold at the 75th percentile compared to control cells 
(Figure 6B, p< 0.001 by Kruskal-Wallis test followed by Dunn’s multiple comparison 
test). While ~50% of cells expressing the R521G mutant exhibited large PML-NBs at 
baseline, only ~2.5% of control cells expressed large PML-NBs (Figure 3-10C). This 
fraction in FUS mutant cells increased further following ATO treatment, but only ~10% 
of control cells harbored large PML-NBs after ATO for 24 h (Figure 3-10C). The number 
of PML-NBs per cell in FUS-R521G fibroblasts was only modestly increased compared 
to control cells under baseline conditions (Figure 3-10D). ATO treatment for 24 h 
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decreased the average number of PML-NBs significantly in both control and FUS mutant 
cells (Figure 3-10D). 
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 3.5 Discussion 
In this study, we examined the dynamics of PML-NBs in a cellular ALS model 
expressing GFP-FUS variants and in primary human fibroblasts expressing endogenous 
mutant FUS. Our main observations upon FUS mutant expression include an enlargement 
of PML-NBs in the absence of imposed stress, failure to disassemble or degrade PML-
NBs following sustained ATO exposure, recruitment of Daxx and the 11S proteasome 
regulator to enlarged PML-NBs, decreased activity of isolated proteasomes without 
changes in 26S proteasome component levels, an increase in nuclear foci containing p62/
SQSTM1 that colocalized with large PML-NBs and impaired ATO-induced PML-NB 
degradation in ALS patient fibroblasts harboring the FUS-R521G mutant.  
PML-NB dynamics following oxidative stress is thought to require several steps, 
including PML sumolyation, RNF4 localization, ubiquitination of sumolyated PML-NB 
components, and recruitment and activity of proteasomes (Sahin, Ferhi et al. 2014). 
Impairment of one or more of these processes would be expected to perturb PML-NB 
turnover following prolonged exposure to ATO. For instance, the knockdown of RNF4 
expression or insufficient sumolyation of PML mutants (K160R or triple K65/160/490R) 
blocked ATO-induced PML-NB degradation (Lallemand-Breitenbach, Zhu et al. 2001, 
Lallemand-Breitenbach, Jeanne et al. 2008). The expression of FUS mutants in HEK293 
cells may perturb one of these critical events related to PML-NB degradation. We 
observed that acute treatment of HEK293 cells with ATO for 1 h induced enlargement of 
PML-NBs and the accumulation of both Daxx and the 11S proteasome regulator in all 
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cell lines; however, only in the cells expressing FUS mutants was PML-NB turnover 
blocked.  
To investigate mechanisms contributing to the impairment of PML-NB turnover, we 
measured the activities of isolated 26S proteasomes, which we found to be significantly 
decreased in FUS mutant cells compared to controls. Consistent with this result, global 
inhibition of proteasome activity with MG132 treatment was previously reported to 
inhibit ATO induced PML-NB degradation (Mattsson, Pokrovskaja et al. 2001, Tatham, 
Geoffroy et al. 2008, Sahin, Ferhi et al. 2014). Impaired proteasome activity has also 
been implicated as a pathogenic factor in ALS (Kabashi and Durham 2006). In a case of 
sporadic ALS and in a transgenic mouse model expressing SOD1-G93A, spinal cord 
tissues showed decreased proteasome activity measured with fluorogenic substrates, 
concomitant with a decrease in the level of 20S β5 catalytic subunits (Kabashi, Agar et al. 
2008, Kabashi, Agar et al. 2012). In addition, a mouse model with altered proteasome 
function exhibited motor neuron degeneration, further suggesting that decreased 
proteasome activity may contribute to ALS pathogenesis. Impaired proteasome activity 
may also explain our observation that nuclear p62/SQSTM1foci were increased 
abnormally in FUS mutant cells. Large PML-NBs co-localized with p62, which may help 
to sequester ubiquitinated protein into PML-NBs. Given that PML-NBs can localize with 
nuclear proteasomes, PML-NBs may play an important role in the degradation of 
ubiquitinated nuclear proteins under stressful conditions (Pankiv, Lamark et al. 2010). It 
is also possible that dysfunction of proteasomes impairs PML-NB function in FUS 
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mutant cells even in the absence of  ATO treatment, which is further supported by our 
observation of PML-NB enlargement in FUS mutant cells following proteasomal 
inhibition by MG132.  
Our observation of abnormal Daxx accumulation associated with impairment of 
PML-NB turnover may also be relevant to ALS pathophysiology. Daxx is known to 
accumulate acutely in PML-NBs and has previously been identified as a Fas-interacting 
protein participating in Fas-mediated cell death (Yang, Khosravi-Far et al. 1997). Daxx 
accumulation into PML-NBs was reported to promote pro-apoptotic gene expression in 
HT1080 cells exposed to anti-Fas antibody (10 ng/ml-1 µg/ml) (Torii, Egan et al. 1999). 
Furthermore, increased Daxx accumulation within PML-NBs in the spinal cord of ALS-
SOD1 transgenic mice was associated with motor neuron death (Raoul, Buhler et al. 
2006). This event occurred weeks before disease onset, suggesting that Daxx 
accumulation with Fas ligand up-regulation may contribute to motor neuron death in 
ALS-SOD1 mouse models (Raoul, Buhler et al. 2006). Although we observed abnormal 
Daxx accumulation into PML-NBs with ATO treatment, cell death in our FUS mutant cell 
lines was not induced (Figure 3-4). As Daxx is sumoylated when it is localized into PML-
NBs, it is likely that FUS mutant cells accumulate sumolyated proteins. Consistent with 
this, we observed that HEK293 cells expressing FUS-R495X increased the accumulation 
of SUMO2/3-modified proteins in Triton X-100 insoluble fractions (Figure 3-7). 
Evidence for abnormal SUMO accumulation is emerging as one component of ALS 
pathogenesis (Dangoumau, Veyrat-Durebex et al. 2013). For example, ALS mice 
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expressing mutant SOD1 down-regulate astroglial glutamate transporter EAAT2 
expression and activity, and the C-terminal fragment of EAAT2 conjugated with 
SUMO-1 (CTE-SUMO1) localizes to PML-NBs in the mutant SOD1 spinal cord (Gibb, 
Boston-Howes et al. 2007, Foran, Bogush et al. 2011).  
Fibroblasts obtained from ALS patient skin biopsies provide a useful tool for 
understanding the phenotypic effects of ALS mutant gene expression at endogenous 
levels. For example, fibroblasts from three sALS patients and individuals harboring either 
TDP-43-M337V mutant or UBQLN2-T487I recapitulated specific pathological features 
of ALS, including aggregate formation upon exposure to oxidative stress or proteasome 
inhibition (Yang, Zhang et al. 2015). We observed here that fibroblasts expressing the 
FUS-R521G mutant exhibited enlargement of PML-NBs under normal growth conditions 
and showed strikingly altered PML-NB turnover under stress conditions, both of which 
were consistent with our results using HEK293 cells. Going forward, it is exciting to 
consider the possibility that a readily observable PML-NB phenotype in accessible cells 
such as fibroblasts from ALS patients may be informative as a biomarker for 
susceptibility to FUS-mediated or even more general causes of ALS. 
HEK293 cells expressing ALS-linked FUS mutants showed impaired stress-
responsive PML-NB turnover and decreased proteasome activity. Furthermore, 
fibroblasts from an ALS patient harboring mutant FUS-R521G exhibited similarly 
enlarged PML-NBs and impaired PML-NB turnover. Overall, our results suggest that a 
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previously unappreciated gain of nuclear toxicity by mutant FUS could contribute to the 
pathogenesis of ALS by perturbing nuclear homeostasis.  
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3.7 Materials and Methods 
Cell culture  
Doxycycline-inducible FlpIn HEK293 (human embryonic kidney 293) cells 
expressing GFP-hFUS-WT, R521G or R495X were previously generated and cultured in 
DMEM media (Gibco) with 10% FBS (Sigma), 2mM L- glutamine (Gibco), 1% 
penicillin-streptomycin solution (Gibco), blasticidin and hygromycin B (Bosco, Lemay et 
al. 2010). The GFP-hFUS-P525L construct was a gift from Catherine L. Ward and Daryl 
A. Bosco (Univ. of Massachusetts Medical School) and was transfected with Flp 
recombinase vector (pOG44) into FlpIn T-Rex 293 cells to generate this additional cell 
line. Human fibroblasts from an individual with ALS harboring the FUS-R521G mutation 
and control fibroblasts were obtained from Dr. Robert H. Baloh (Washington University 
in St. Louis) and cultured in DMEM media (Gibco) with 10% FBS (Sigma), 1% 
penicillin-streptomycin solution (Gibco) and 1% MEM non-essential amino acid solution 
(Gibco). For ATO experiments, ATO (Sigma) was dissolved in 1 M NaOH to make a 0.25 
M stock solution, and a 1 mM working solution was freshly prepared in Tris-buffered 
saline at pH 7.4 (Lallemand-Breitenbach, Zhu et al. 2001). ATO (1 µM) was added for 1 - 
24 h to HEK293 cultures induced for 48 h to express FUS variants or to human 
fibroblasts.  
Western blots 
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HEK293 cells were treated with 2 µg/ml doxycycline (Dox) to induce GFP-FUS 
expression for 48 h, and cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 5 mM EDTA) with 
complete protease inhibitor for 40 min on ice. Protein concentrations were measured 
using a BCA assay (ThermoScientific, 23227). 10-20 µg of protein was separated by 10% 
Tris-HCl precast gels, transferred to nitrocellulose membranes and blocked in Odyssey 
blocking buffer for 1 h at room temperature. Anti-FUS (Santa Cruz Biotech, sc-47711, 
1:1000), p62 (BD Biosciences, 610832, 1:1000), GAPDH (Sigma, G9525, 1:10,000) or 
PML (Bethyl Laboratories, Montgomery, TX, A301-168A, 1:1000) antibodies were 
diluted in Odyssey blocking buffer with 0.1% Triton X-100  and incubated for overnight 
at 4 °C. IRDye 800 or 680 (LiCor) secondary antibody in Odyssey blocking buffer was 
incubated for 1 h at room temperature. Signals were detected using an Odyssey Infrared 
Imager (Licor), and the intensities were analyzed with the Licor Image Studio Lite Ver 
3.1. 
Immunofluorescence 
HEK293 cells were grown on glass coverslips coated with 10% poly L-lysine in 24-
well plates, and GFP-FUS expression was induced with Dox for 48 h. Cells were fixed in 
4% paraformaldehyde in phosphate buffered saline (PBS) for 15 min at room temperature 
(RT) and permeabilized in 0.2% Triton X-100 in PBS for 5 min. Cells were incubated 
with blocking solution containing 2% goat serum (Invitrogen), 0.1% Triton X-100 and 
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1% bovine serum albumin (BSA) in PBS for 1h at RT and primary antibodies in PBS 
with 0.15% goat serum and 0.1% Triton X-100 were applied for overnight at 4 °C. The 
rabbit anti-p62 (Santa Cruz Biotech, sc-255575), mouse monoclonal anti-PML (Santa 
Cruz Biotech, sc-966), rabbit anti-Daxx (Santa Cruz Biotech, sc-sc-7152) or rabbit 
anti-11S/PA28β proteasome regulator (Enzo, BML-PW8240) antibodies were diluted as 
1:200, 1:200, 1:500 and 1:500, respectively. Secondary antibodies, Alexa fluor 568 
conjugated goat-anti-rabbit (Invitrogen, A11011) or Alexa fluor 633 conjugated goat anti-
mouse (Invitrogen, A21050) were incubated in PBS with 0.15% goat serum and 0.1 % 
Triton X-100 for 1 h at RT. Coverslips were mounted with Prolong Gold mounting 
medium containing DAPI (Invitrogen, P36941), and images were acquired using a Leica 
TCS SP5 II laser scanning confocal microscope with 60X oil objective and 5X zoom. All 
images were acquired by sequential scanning with 0.42 µm thick slices and analyzed with 
Leica LAS AF Lite software or Fiji Image J (Schindelin, Arganda-Carreras et al. 2012).  
Human fibroblast cells were plated on glass coverslips coated with 10% poly L-
lysine in 24-well plates. Following ATO treatment for 24 h, cells are fixed in 4% PFA for 
15 min at RT and stained cells with anti-FUS (Bethyl Laboratories, Montgomery, TX, 
A301-168A, 1:500) and anti-PML (Santa Cruz Biotech, sc-966, 1:200) antibodies. All 
procedures are the same as for HEK293 cells.  
Quantification of confocal images 
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We wrote a macro program for Image J Fiji that incorporates the 3D ROI Manager of 
Thomas Boudier  (Ollion 2013) to define individual PML-NBs as 3D objects and to 
quantitate the integrated intensity of voxels within each PML-NB. DAPI images were 
used to segment the nuclear regions in 3D.  Distinct PML-NBs were segmented in 3D 
using radial Gaussian local thresholding from background-subtracted and filtered images, 
and the raw intensities within each 3D object were then integrated to obtain the total 
signal attributed to each PML-NB. The integrated intensities were then plotted either as a 
cumulative distribution or as a function of distance from the nuclear center. The 
integrated intensities of Daxx, 11S/PA28, and p62 foci were also analyzed with the same 
method using different thresholding parameters. 
Cell proliferation assay 
HEK293 cells were plated on poly-L lysine coated glass coverslips at a density of 
1000 cells per well and the next day treated with 2 µg/ml doxycycline to induce GFP-
FUS expression. After 48 h of induction, ATO (1 µM) was added for 24 h and cells were 
treated with 10 µM of EdU (Click-iT EdU Alexa Fluor 594 Imaging Kit, Invitrogen, 
C10339) for 1 h to incorporate labeled EdU into newly synthesized DNA. The procedure 
for EdU staining was performed according to manufacturer’s instructions and 
immunofluorescence images were obtained using a Nikon fluorescence microscope 
equipped with a 100x oil (1.3 N.A) objective. The number of DAPI positive and EdU 
incorporated cells was counted manually using Cell Counter software in Image J.  
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Cell viability assay 
HEK293 cells were plated on 96-well plates at a density of 800 cells per well. After 
48 h of doxycycline induction (2 µg/ml), cells were treated with different concentrations 
of ATO (0, 1, 2.5, or 5 µM) for 24 h. Cell viability was measured using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega, G7571) according to the manufacturer’s 
instructions. The luminescent signal generated by recombinant luciferase reports upon the 
amount of ATP present in metabolically active cells. 
Affinity purification of 26S proteasomes by UBL-method 
Purification of intact 26S proteasomes using the ubiquitin-like domain (UBL) was 
described previously (Besche, Haas et al. 2009, Besche and Goldberg 2012). Briefly, cells 
were harvested by scraping in cold PBS and centrifuged at 1000xg, 4°C for 5 min. The 
cell pellet was resuspended in buffer containing 25 mM HEPES, 5 mM MgCl2, 1 mM 
DTT, 1 mM ATP, 150 mM NaCl and Phosphatase inhibitor cocktail (#88667, Thermo 
Scientific, USA) and lysed by sonication (5 bursts of 10 sec each with 50 sec rest on ice). 
The crude lysate was centrifuged at 3,000×g, 4°C, for 5 min. The supernatant was 
centrifuged for 1 h at 100,000×g, 4°C. The resulting clarified lysates (100,000×g) were 
incubated for 2 h at 4°C with 2 mg purified GST-Ubl protein (Besche, Haas et al. 2009, 
Besche and Goldberg 2012) and a corresponding amount of glutathione-sepharose. After 
2 h of incubation, the slurry containing 26S proteasomes bound to GST-Sepharose was 
poured into an empty disposable column and washed with buffer. Proteasomes were 
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eluted by incubating the resin with excess purified His-UIM (2 mg/ml) at 4°C for 15 min 
(Besche, Haas et al. 2009, Besche and Goldberg 2012). His-UIM was removed from the 
eluate by incubating with Ni2+-NTA-agarose for 20 min at 4°C. Concentration of 26S 
proteasomes was calculated based on total protein content and assuming a molecular 
weight of 2.5 MDa. 
Measuring peptidase activity of affinity purified 26S proteasomes  
Proteasome peptidase activities have been measured using a protocol described 
elsewhere (Besche, Haas et al. 2009, Besche and Goldberg 2012). Briefly, the activity of 
proteasomes after affinity purification of 26S (~1 nM) or in extract (1-2 µg) was 
measured with 20 µM of fluorogenic substrates (suc-LLVY-amc, suc-nLPnLD-amc and 
suc-VLR-amc) in a buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 1 mM 
ATP, and 1 mM DTT. Fluorogenic hydrolysis was monitored at λex=380 nm and λem=460 
nm at 37°C for 60 min. Rate of hydrolysis was calculated based on the slope of 
fluorescence increase over time between 30-60 min (linear phase of the reaction). 
Cellular fractionation 
Cell fractionation was performed by lysing in 1% Triton-X buffer containing 50 mM 
Tris-Cl (pH 7.4), 150 mM NaCl, 1% [v/v] Triton X-100, 1 mM EDTA, 1 mM 
dithiothreitol (DTT), 1 mM Na3VO4, 0.1 mM NaF, and a cocktail of protease inhibitors 
by mixing for 20 min at 4 °C. Total lysate was centrifuged at 12,500xg for 30 min. The 
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supernatant were used as Triton-X-soluble fraction. The pellet was resuspended in a 
buffer containing 50 mM Tris-HCl (pH 7.4) plus 2% SDS, sonicated briefly (10 sec, 
Twice), and used as Triton-X-insoluble fractions. 
Statistics 
Data are presented as mean ± S.D. with significance indicated by *, p < 0.05; **, p < 
0.01; ***, p < 0.001, unless otherwise indicated. Significance was accepted for p < 0.05. 
Cumulative frequency was analyzed by the Kruskal-Wallis test followed by Dunn’s 
multiple comparison test. Other comparison data were analyzed by one-way ANOVA 
followed by Tukey’s multiple comparison test or two-way ANOVA followed by Sidak’s 
multiple comparison test. 
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Chapter IV 
Discussion and Conclusion 
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ALS is a progressive neurodegenerative disease characterized by loss of motor 
neurons in the brain and spinal cord. About 10% of ALS cases are caused by specific 
gene mutations and the number of genes linked to ALS has increased dramatically over 
the past decade (Renton, Chio et al. 2014). Mutations in FUS were identified in 2009, and 
many of these may perturb the nuclear localization signal sequence to cause cytoplasmic 
FUS accumulation (Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009). Although 
FUS has been proposed to regulate several events, including RNA splicing, transcription 
and DNA damage response (Deng, Gao et al. 2014), the mechanism by which FUS 
mutants cause motor neuron loss is not established. Several molecular mechanisms have 
been proposed, including oxidative stress, mitochondria dysfunction, protein aggregation, 
axonal transport defects and neuroinflammation (Ferraiuolo, Kirby et al. 2011). It is 
plausible that impaired cellular stress responses may serve as the initial step in disease 
pathogenesis. For example, oxidative stress is able to induce protein oxidation, which 
leads to the formation of protein aggregates (Mirzaei and Regnier 2008). Furthermore, 
these aggregates may sequester essential proteins including RNA binding proteins to 
cause axon defects (Groen, Fumoto et al. 2013). Therefore, we aimed to investigate the 
properties of FUS mutants in the absence and presence of stress conditions.  
In chapter II, we found that oxidative stress, ER stress, and heat shock induced 
incorporation of FUS mutants into stress granules in proportion to their degree of 
cytoplasmic mislocalization in both cell culture and zebrafish models of ALS. Our study 
142
suggests that the incorporation of FUS mutants into stress granules may perturb cellular 
stress responses. 
Although cytoplasmic FUS inclusions are the pathological features in postmortem 
tissues from ALS patients, FUS mutants in the nucleus may also contribute to motor 
neuron degeneration by perturbing one or more nuclear functions. Mammalian cell nuclei 
contain several nuclear bodies including nucleoli, nuclear speckles and paraspeckles, 
Cajal bodies and nuclear Gems, and PML-NBs (Mao, Zhang et al. 2011). Dysfunction of 
these assemblies has been linked to several diseases (Woulfe 2007, Woulfe 2008). PML-
NBs are reported to regulate nuclear protein quality control and oxidative stress response, 
which are essential for nuclear homeostasis (Guo, Giasson et al. 2014, Sahin, Ferhi et al. 
2014). Therefore, we aimed to examine how FUS mutant expression alters the dynamics 
of PML-NBs in the absence and presence of oxidative stress. 
In chapter III, we first observed that mutant FUS expression was associated with 
enlarged PML-NBs under baseline culture conditions in HEK293 cells. Later, HEK293 
cells expressing FUS variants were exposed to arsenic trioxide (ATO), which is known to 
produce reactive oxygen species. We found that PML-NBs responded differently to the 
insult of oxidative stress in FUS mutant cells. Control cells progressed through normal 
PML-NB enlargement followed by turnover, whereas in FUS mutant cells, ATO-triggered 
PML-NB degradation was inhibited such that enlarged PML-NBs accumulated, 
concomitant with accumulation of the transcriptional repressor Daxx (Figure 4).  
143
Next, we tried to find a possible mechanism involved in impaired PML-NB turnover. 
For normal turnover mechanism, SUMO-modified PML-NBs are ubiquitinylated by 
RNF4 and undergo degradation through the nuclear proteasome machinery (Sahin, Ferhi 
et al. 2014). One plausible mechanism to account for the observed increase in PML-NB 
size at baseline and the defect in PML-NB turnover after ATO could involve impaired 
recruitment of proteasomal subunits or regulators to PML-NBs in FUS mutant cells. We 
found that the 11S proteasome regulator in all cell lines was recruited into PML-NBs 
within 1 hour of ATO exposure. The 11S proteasome regulator resumed a diffuse nuclear 
distribution in control cells within 24 hour ATO exposure. In contrast, FUS mutant cells 
continued accumulation of the 11S proteasome regulator into enlarged PML-NBs with 
ATO treatment. Persistent accumulation of the proteasome regulator may be caused by 
dysfunction of proteasome activities. We next analyzed the activities of the 26S 
proteasomes in HEK293 cells and found that FUS mutant expression decreased their 
activities. Upon the inhibition of proteasome activities with MG132, FUS mutant cells 
expanded PML-NBs. These results support the notion that decreased proteasome 
activities in FUS mutant cells may contribute to the inhibition of PML-NB turnover. We 
also observed that primary fibroblasts from an ALS patient harboring the FUS mutant 
R521G exhibited enlarged PML-NBs under baseline conditions and a striking impairment 
of PML-NB turnover following ATO exposure. 
These results indicate that impaired cytoplasmic stress response, a novel gain of 
nuclear toxicity, or both may contribute to ALS pathogenesis. A future direction will be to 
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test whether enlarged PML-NBs can be identified in additional ALS patient tissues, as 
this pathology could potentially serve as a biomarker for the diagnosis of ALS. 
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IV.1 Stress granules, a common pathological mechanism in ALS  
In chapter II, we observed that stress conditions induce mutant FUS incorporation 
into stress granules in both cell culture and zebrafish models of ALS (Bosco, Lemay et al. 
2010). Later, many researchers found that FUS mutants are incorporated into stress 
granules upon insults with a variety of stressors (Dormann, Rodde et al. 2010, Kino, 
Washizu et al. 2011, Bentmann, Neumann et al. 2012). Moreover, other ALS-linked 
proteins and RNA-binding proteins such as TDP-43, profilin-1, hnRNPA1, hnRNPA2 and 
SMN1 are also reported to accumulate in stress granules under stress conditions 
(McDonald, Aulas et al. 2011, Figley, Bieri et al. 2014, Takanashi and Yamaguchi 2014), 
implicating a possible role for stress granule alternation or sequestration of essential RNA 
proteins related to RNA metabolism in ALS. 
It is not clear, however, whether FUS mutants alter either the assembly or dynamics 
of stress granules. Recently, Baron et al. found that FUS mutant cells delay the assembly 
of stress granules under the oxidative condition with sodium arsenite in both HEK293 
and neuronal NSC-34 cells (Baron, Kaushansky et al. 2013). Once stress granules are 
formed in FUS mutant cells, they become more dynamic, larger, and more abundant 
compared to those in control cells; this suggests the localization of mutant FUS to stress 
granules may impair stress response. In addition, similar observations have been reported 
recently in cells expressing ALS-linked mutations either in TDP-43 or profilin-1 (Figley, 
Bieri et al. 2014, Liu-Yesucevitz, Lin et al. 2014). These results suggest that altered stress 
response and impaired stress granule dynamics are common pathological events in ALS.  
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While most FUS mutants containing disrupted nuclear localization signal sequences are 
associated with stress granules under stress conditions, FUS-WT remains inside the 
nucleus (Bosco, Lemay et al. 2010, Dormann, Rodde et al. 2010, Gal, Zhang et al. 2011, 
Sun, Diaz et al. 2011). Sama et al. found that hyperosmolar stress with sorbitol enhanced 
translocation of FUS-WT to cytoplasm and its association into stress granules, indicating 
FUS-WT may also participate in stress response under certain conditions (Sama, Ward et 
al. 2013).  
Stress granules are dynamic structures. According to the results of our monitoring 
stress granule assembly and disassembly in FUS mutants, stress granules are formed 
within 10 minutes, and dissociation occurs within minutes after stressors are removed (in 
chapter II). How does the reversible form of stress granules become irreversible 
aggregates? According to the Two Hit Hypothesis proposed by the Haass group, the first 
hit, caused by accumulations of FUS mutants in cytoplasm, might be the initial step for 
the disease process, and the second hit, caused by cellular stress, induces incorporation of 
mutant FUS into stress granules (Dormann and Haass 2011). Later subsequent chronic 
stress eventually leads to irreversible protein aggregates (Dormann and Haass 2011, 
Wolozin 2012). Supporting this notion, neuronal cytoplasmic inclusions in patient tissues 
were labeled with stress granule markers such as PABP-1, TIA-1, TIAR, and eukaryotic 
translation initiation factor 3 subunit (elF3), suggesting that the deposition of stress 
granules may initiate pathological inclusion formation in ALS (Dormann, Rodde et al. 
2010, Liu-Yesucevitz, Bilgutay et al. 2010, Bentmann, Haass et al. 2013). Moreover, 
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while cytoplasmic localization of FUS mutants is accumulated into stress granules upon 
oxidative stress, FUS wild-type can interact with FUS mutants through prion-like 
domains, which causes sequestration into stress granules (Vance, Scotter et al. 2013). The 
result suggests that stress granules may serve as seeds to form inclusions (Dormann and 
Haass 2011, Wolozin 2012). These aggregates may have deleterious effects on neuronal 
cells by sequestering essential components, including mRNA and RNA-binding proteins 
(Wolozin 2012).  
What mechanism is involved in the dissociation of stress granules after acute stress is 
removed? One paper suggests that autophagy may contribute to this process. The authors 
found that FUS(R521C)-positive stress granules are colocalized with LC3-positive 
autophagosomes in oxidative stress conditions (Ryu, Jun et al. 2014). Moreover, 
autophagic activation with rampamycin enhances the clearance of mutant FUS positive 
stress granules in an autophagy-dependent manner. These results also point to a potential 
therapeutic approach in ALS-FUS pathology (Ryu, Jun et al. 2014). 
Is FUS critical to form stress granules? The depletion of TDP-43 exhibits altered 
stress granule dynamics including delayed formation and reduced size, suggesting that 
TDP-43 is essential for the formation of stress granules (McDonald, Aulas et al. 2011, 
Aulas, Stabile et al. 2012). Moreover, TDP-43 regulates the levels of G3BP mRNA, 
which is the essential component to form stress granules (McDonald, Aulas et al. 2011). 
In contrast to TDP-43, FUS knockdown does not affect the expression of two stress 
granule proteins, G3BP and TIA-1 (Aulas, Stabile et al. 2012). Moreover, the size and 
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number of stress granules are not altered in either HeLa and SK-N-SH cells with FUS 
knockdown, indicating that FUS itself is not required for stress granule assembly (Aulas, 
Stabile et al. 2012). Therefore, the exact role of FUS and stress granule formation in the 
context of the ALS condition should be investigated further. 
IV.2 Abnormal sumolyation and ALS 
Several stresses, including heat shock, oxidative stress, and proteasome inhibition 
have been known to induce protein sumolyation (Gallagher, Oeser et al. 2014), a 
reversible post-translational modification that can alter cellular distribution, cellular 
activity, and the stability of several proteins through covalent conjugation of small 
ubiquitin-like modifier (SUMO) proteins to target proteins (Geiss-Friedlander and 
Melchior 2007). Therefore, the stress-induced sumolyation of target proteins can alter 
their function to regulate cellular stress response. Recent analysis by chromatin 
immunoprecipitation assay coupled to high-throughput DNA sequencing and mRNA 
sequencing revealed that heat shock induced SUMO2 localization to active DNA 
regulatory elements which encode regulators of gene expression and the post-
transcriptional modification of RNA (Seifert, Schofield et al. 2015). SUMO2 did not 
directly activate or inhibit transcription during the heat shock, but may help to maintain 
the integrity of transcription regulatory protein complexes in response to heat shock 
(Seifert, Schofield et al. 2015). Therefore, abnormal SUMO modification may contribute 
to impaired cellular stress responses. 
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Sumolyation also regulates chromosome segregation, nuclear architecture, and 
embryonic viability (Nacerddine, Lehembre et al. 2005). An enzyme cascade involving a 
dimeric SUMO-activating enzyme (E1), a single SUMO conjugating enzyme (E2) and a 
limited amount of SUMO ligase (E3) mediates sumolyation. Ubiquitin-like conjugating 
enzyme 9 (UBC9) is the only SUMO-conjugating enzyme in mammalian cells. A UBC9-
deficient mouse model exhibited early lethality caused by chromatin-condensation and 
chromosome-segregation defects, indicating that sumolyation may play an essential role 
in genome stability (Nacerddine, Lehembre et al. 2005). In addition, these mice showed 
defects in nuclear organization, including disruption of nucleoli and PML-NBs. 
Interestingly, FUS is proposed to act like SUMO E3 ligase for Ebp1 sumoylation and to 
interact directly with a SUMO E2 ligase, UBC9 (Oh, Liu et al. 2010). Further study is 
needed to confirm whether mutant FUS causes abnormal sumolyation or altered nuclear 
organization by perturbing UBC9 localization or expression. Moreover, it is worth to 
investigate whether altered UBC9 localization or expression participates in the abnormal 
SUMO2/3 accumulation in FUS mutant cells observed in chapter III . 
Abnormal SUMO- or PML-positive inclusions have been observed in several 
neurodegenerative diseases including ALS, FTD, spinocerebellar ataxia, and neuronal 
intranuclear inclusion disease (NIID) (Dorval and Fraser 2007, Woulfe 2007, Woulfe 
2008). In chapter III, my results showed that abnormal Daxx sequestration into PML-NBs 
upon oxidative insult with ATO was increased in FUS mutant cells. PML mutants with 
sumolyation defects (K65/160/490R) are unable to recruit partner proteins such as Sp100 
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and Daxx, suggesting SUMO modification is a prerequisite for PML to form PML-NBs 
and recruit partner proteins (Zhong, Muller et al. 2000). Therefore, it is plausible that 
FUS mutant cells abnormally increased the accumulation of SUMO-modified proteins. In 
chapter III, we observed that FUS mutant cells increased accumulation of SUMO2/3-
modified proteins in Triton X-100 insoluble fractions under normal growth conditions, 
suggesting that increased SUMO modifications may contribute to ALS-FUS 
pathogenesis. The evidence for abnormal SUMO modification is emerging in ALS 
pathogenesis (Dangoumau, Veyrat-Durebex et al. 2013). For instance, mutant SOD1 
(G93C) or a splicing isoform of TDP-43 lacking the C-terminus (TDP-S6) is found in 
SUMO-positive inclusions in a cell culture model of ALS (Seyfried, Gozal et al. 2010, 
Dangoumau, Veyrat-Durebex et al. 2013). TDP-S6 forms highly insoluble nuclear 
inclusions conjugated with SUMO2/3 and mutant SOD1 (G93R) is conjugated with 
SUMO3 for increased stability, suggesting that SUMO modification can participate in 
aggregation of TDP-43 and SOD1 (Seyfried, Gozal et al. 2010, Niikura, Kita et al. 2014). 
Moreover, the impairment of excitatory amino acid transporter 2 (EAAT2) in astroglial 
cells is caused by the formation of a C-terminal fragment, which is conjugated with 
SUMO1 (CFT-SUMO). 
It is still controversial whether protein sumolyation associated with 
neurodegenerative diseases serves to enhance protein solubility or to promote aggregate 
formation (Gallagher, Oeser et al. 2014). For instance, sumolyation of α-synuclein is 
reported to prevent α-synuclein from forming fibrils, whereas decreased sumolyation of 
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α-synuclein leads to increased toxicity (Krumova, Meulmeester et al. 2011). Consistent 
with this finding, increased sumolyation of polyQ-expanded ataxin-1 (Atxn1 82Q) 
enhances its solubility and promotes ubiquitin-proteasome-mediated degradation (Guo, 
Giasson et al. 2014). In contrast, under oxidative stress conditions, increased SUMO 
modification on polyQ-expanded ataxin-1 promotes its insolubility and inclusion 
formation (Ryu, Cho et al. 2010). Therefore, the solubility of SUMO-modified proteins 
depends on the nature of target proteins. 
Does SUMO need to be detached before undergoing proteasome-mediated 
degradation in the case of SUMO modified PML-NBs? Bailey et al. found that increased 
free SUMO1 accumulation with ATO stimuli is detected by western blot analysis, 
implicating that SUMO detachment from PML-NBs is a necessary step for PML 
degradation (Bailey and O'Hare 2005). It is still unknown, however, which SUMO 
proteases participate specifically in PML-NB degradation. Six SUMO proteases are 
identified in mammalian cells, and each protease has a specific substrate and cellular 
localization (Hickey, Wilson et al. 2012). Interestingly, the depletion of SUMO protease 
SENP6 can enlarge the size of PML-NBs in HeLa cells along with increasing the number 
of PML-NBs (Hattersley, Shen et al. 2011). It would be interesting to analyze whether the 
expressions of FUS mutants affect SUMO protease localization or expression to cause 
enlargement of PML-NBs or abnormal SUMO2/3 accumulations in the Triton X-100 
insoluble fractions we observed in chapter III.  
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In addition to the role of sumolyation in protein aggregates, SUMO modification 
controls several cellular events including apoptosis and transcriptional regulation (Shih, 
Chang et al. 2007). Although the event of Daxx accumulation into PML-NBs is not 
compromised on cell viability in HEK293 cells under oxidative stress conditions, Daxx 
accumulation is reported to regulate apoptosis (Yang, Khosravi-Far et al. 1997, Torii, 
Egan et al. 1999). In a SOD1-G93A transgenic mouse, Daxx accumulation in the spinal 
cord was increased before disease onset, suggesting that Daxx accumulation contributes 
to motor neuron loss (Raoul, Buhler et al. 2006). Moreover, the SUMO E3 ligase PIAS1 
mediates ultraviolet (UV)-induced apoptosis by recruiting Daxx to sumolyated PIAS1 
foci in HeLa cells (Sudharsan and Azuma 2012). Sumolyation of the transcriptional co-
activator p300 promotes the recruitment of histone deacetylase 6 (HDAC6), leading to 
transcriptional repression (Girdwood, Bumpass et al. 2003). Protein de-sumolyation also 
regulates cellular mechanisms. Oxidative stress induces de-sumolyation of both c-fos and 
c-Jun, which results in a transcription activation for antioxidant proteins (Feligioni and 
Nistico 2013). Therefore, the balance between sumolyation and de-sumolyation is crucial 
to maintaining cellular homeostasis. 
IV.3 PML and RNF4 for nuclear homeostasis 
PML is a well-known target protein for SUMO in response to oxidative stress (Sahin, 
de The et al. 2014, Sahin, Ferhi et al. 2014). Moreover, PML-NBs are able to induce 
sumolyation of partner proteins that accumulate inside the shell of PML-NBs under the 
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condition of oxidative stress (Sahin, Ferhi et al. 2014). Therefore, oxidative stress-
induced PML-NB formation and associated protein degradation are critical to nuclear 
homeostasis.  
PML-NBs are the site for protein degradation in the nucleus. For example, a 
nucleolar protein, N4BP1, is also located in PML-NBs and undergoes SUMO-regulated 
polyubiquitylation and proteasomal turnover (Sharma, Murillas et al. 2010). PML-NBs 
work with RNF4 for sumolyated protein degradation in the nucleus. RNF4 is a poly-
SUMO-specific E3 ubiquitin ligase and promotes ubiquitination of SUMO-conjugated 
proteins for their degradation (Lallemand-Breitenbach, Jeanne et al. 2008, Tatham, 
Geoffroy et al. 2008). Nuclear factor erythroid 2-related factor 2 (Nrf2), which regulates 
oxidative stress response, is also sumolyated and located in PML-NBs upon ATO 
treatment (Malloy, McIntosh et al. 2013). In addition, ATO treatment induces RNF4-
mediated polyubiquitination of Nrf2 and its degradation through nuclear proteasomes. 
Therefore, PML-NBs are essential for regulating proteasomal turnover of target proteins. 
In cultured cells without oxidative stress, PML-SUMO-RNF4 has been proposed as a 
nuclear protein quality control system (Guo, Giasson et al. 2014). For instance, in a cell 
culture model of spinocerebellar ataxias (SCAs), the pathogenic ataxin-1 protein with 82 
contiguous gluatamines is targeted at PML-NBs. Interestingly, overexpression of PML is 
able to enhance degradation of Atxn1-82Q. The process for Atxn1-82Q protein 
degradation includes PML-mediated Atxn1-82Q sumolyation and RNF4-mediated 
ubiquitination of SUMO2-Atxn1-82Q. Consistent with this result, misfolded TDP-43 and 
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Huntingtin-97QP in cell nucleus exhibit sumolyation, ubiquitination, and degradations 
(Guo, Giasson et al. 2014). In addition, increased expression of PML by interferon beta 
stimulus enhances clearance of mutant ataxin-7 in a mouse model of SCA7 (Chort, Alves 
et al. 2013). Collectively, these results suggest that PML-SUMO-RNF4 is critical to 
cleaning up misfolded proteins and maintaining cellular homeostasis in cell nucleus. 
In addition to its role in protein degradation, RNF4 plays a role in DNA damage 
response in cell culture lines and in vivo (Galanty, Belotserkovskaya et al. 2012, Guzzo, 
Berndsen et al. 2012, Yin, Seifert et al. 2012, Hay 2013, Vyas, Kumar et al. 2013). 
Decreased expression of RNF4 in cultured cells increased sensitivity to ionizing radiation 
(Yin, Seifert et al. 2012, Vyas, Kumar et al. 2013). Interestingly, laser micro-irradiation 
induced endogenous RNF4 accumulation at the site of DNA damage where 
phospholyated H2AX (ɣH2AX) is localized (Galanty, Belotserkovskaya et al. 2012, Yin, 
Seifert et al. 2012). The SUMO-interacting motif (SIM) and the RING domain of RNF4 
are required for recruitment at the site of DNA damage (Yin, Seifert et al. 2012, Vyas, 
Kumar et al. 2013). The depletion of RNF4 expressions does not alter the recruitment of 
proteins required for DNA damage response, including Nijmegen breakage syndrome 1 
(NBS1), mediator of DNA-damage checkpoint 1 (MDC1), RNF8, p53-binding protein 1 
(53BP1), and breast cancer early-onset 1 (BRCA1) (Yin, Seifert et al. 2012). RNF4 
depletion did cause a delay in their removal from the DNA damage site, however (Yin, 
Seifert et al. 2012). Indeed, the recruitment of Rad51 and RPA70 to ssDNA is dependent 
on RNF4 expression, indicating that RNF4-depleted cells may impair the 5′-to-3′ 
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exonuclease-mediated resection from a DNA double strand break (Yin, Seifert et al. 
2012). Moreover, ionizing radiation enhances sumolyation of MDC1, which serves as a 
platform for recruiting RNF4 at the site of DNA damage (Yin, Seifert et al. 2012). RNF4-
deficient mice, whose phenotypes are similar to those of FUS knockout mice (Hicks, 
Singh et al. 2000, Kuroda, Sok et al. 2000), showed DNA damage and an age-dependent 
defect in spermatogenesis by ionizing radiation (Vyas, Kumar et al. 2013). FUS is also 
recruited at the site of DNA damage (Mastrocola, Kim et al. 2013, Wang, Pan et al. 2013, 
Rulten, Rotheray et al. 2014). We could not examine the localization or expression of 
RNF4 in HEK293 cells due to technical problems. Future studies should examine 
whether FUS mutant cells impair RNF4 expression or localization in the absence and 
presence of stress conditions with ionizing radiation. 
PML-NBs are also believed to participate in DNA damage response. Previously, 
PML in SiHa cells was reported to colocalize with the DNA damage response protein 
TopBP1 upon exposure to ionizing radiation (Xu, Timanova-Atanasova et al. 2003). In 
addition, upon DNA damage, PML-NBs are able to recruit ATM and phosphorylated 
histone H2AX, which are not associated with PML-NBs in normal conditions (Dellaire 
and Bazett-Jones 2004). Therefore, PML-NBs might regulate DNA-damage response by 
acting as storage bins that release or accumulate many proteins linked to DNA-repair and 
checkpoint (Bernardi and Pandolfi 2007). Further study is needed to investigate whether 
FUS mutant expression alters the role of PML-NBs in DNA damage response.  
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IV.4 Proteasome dysfunction links to ALS 
Ubiquitin-proteasome pathways account for 80-90% of protein degradation in 
cultured mammalian cells (Lee and Goldberg 1998), and proteasomes are present in both 
the cytoplasm and the nucleus. Although the 20S proteasome, the 19S proteasome 
regulatory complex, ubiquitin, the PA28 regulatory factor, the ubiquitin-specific protease 
HAUSP, and E1-E3 enzymes are present in the nucleus (von Mikecz 2006), it is still 
controversial whether nuclear proteins are degraded within the nucleus or transported  to 
the cytoplasm for hydrolysis. The microinjection of fluorogenic precursor substrate Suc-
LLVY-AMC into the nuclei of live HEp-2 cells showed a linear increase of nuclear 
fluorescence intensity over time without any change in cytoplasmic fluorescence, 
indicating that the nucleus has its own proteasomal activity (Rockel, Stuhlmann et al. 
2005). 
Protein aggregates in several neurodegenerative disease may result from an impaired 
protein degradation pathway (Goldberg 2003, Goldberg 2007). Proper degradation of 
toxic protein is critical to prevent aggregates, especially in neuronal cells because of their 
postmitotic and long-lived properties. Dysfunctions of this system includes impairments 
in ubiquitination, substrate delivery to the proteasome, or proteasome activity (McKinnon 
and Tabrizi 2014). Insufficient ubiquitination can be caused by depletion or reduced 
activity of E1, E2, or E3 enzymes. In addition, dysfunction of proteasome activity can be 
caused directly by disease-associated misfolded proteins or age-related decline in 
catalytic activity. Moreover, mitochondrial dysfunction can cause impairment of 
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proteasome activity through the depletion of ATP production and/or elevation of reactive 
oxygen species (ROS) (McKinnon and Tabrizi 2014). An age-related decline in 
proteasome activity may contribute to the pathogenesis of late-onset neurodegenerative 
disease. The age-related accumulation of ROS products causes the induction of oxidized, 
misfolded protein aggregation, which exacerbates the decline of proteasome activity. 
Interestingly, FUS-positive aggregates are hardly observed in cultured cells under basal 
conditions. For example, healthy cultured rat cortical neurons overexpressing FUS-
R521C mutants do not form FUS-positive aggregates (Ryu, Jun et al. 2014), which are 
often observed in the end-stage tissues; this suggests that FUS-positive aggregate 
formation might be induced by environmental factors. 
FUS mutant cells showed decreased activity of 26S proteasome, and this may 
contribute to increased nuclear p62/SQSTM1 accumulations and inhibition of PML-NB 
turnover (in chapter III). In addition, the pilot experiment for measuring the activities of 
26S proteasomes purified from brain lysates in our hFUS-R495X transgenic mice 
revealed that 26S proteasome activities were decreased significantly in hFUS-R495X 
transgenic mice compared to hFUS-WT transgenic and nontransgenic control mice. We 
could not conclude what mechanism causes the reduction of 26S proteasome activity. 
There is cumulative evidence that FUS may have a role in the ubiquitin-proteasome 
system. For instance, wild-type FUS target the gene, ZNF294, or LISTERIN, which 
encodes an E3 ubiquitin ligase (Tan, Riley et al. 2012). Moreover, PAR-CLIP analysis in 
HEK293 cells expressing FUS mutants (R521G or R521H) revealed that ALS-linked 
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FUS mutants target the transcripts for endoplasmic reticulum and ubiquitin-proteasome-
related genes (Hoell, Larsson et al. 2011). Using a stringent tandem-affinity purification 
method, FUS interacting proteins are identified in HEK293 cells expressing either FUS-
WT or FUS-P525L (Wang, Jiang et al. 2015). Interestingly, both FUS-WT and P525L 
interact with components for protein degradation pathways, such as ubiquitin-like 
modifier-activating enzyme 1 (UBA1) and 26S proteasome non-ATPase regulatory 
subunit 12 (PSND12/Rpn5). While overexpression of FUS-WT or P525L in HEK293 
cells and SH-SY5Y cells decreased ATP production significantly, there was no difference 
in ATP production levels in cells expressing WT or mutant FUS. Further study needs to 
be performed to investigate how FUS mutants cause the reduction of proteasome activity.  
In ALS cases, the down-regulation of proteasome activity has been observed in the 
spinal cord tissues from sporadic ALS patients and an SOD1-G93A transgenic mouse 
model, concomitant with a decrease in the level of 20S β5 catalytic subunits (Kabashi, 
Agar et al. 2008, Kabashi, Agar et al. 2012). Moreover, altered UPS function was found 
in human fibroblasts from individuals harboring either UBQLN2-T487I or TDP-43-
M337V mutants linked to ALS (Yang, Zhang et al. 2015). Motor neuron-specific 
knockouts of the proteasome subunit Rpt3 cause motor neuron degeneration and 
inclusion formation including TDP-43, FUS, OPTN, and ubiquilin-2, whereas knockouts 
of the autophagy-related protein Atg7 do not induce any motor phenotypes. This suggests 
that the motor neuron is sensitive in proteasome dysfunction (Tashiro, Urushitani et al. 
2012). Nevertheless, others argued that autophagy is also involved in ALS pathology. For 
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example, inhibition of either proteasome activity using MG132 or autophagic function 
with 3-MA increased the expression of TDP-43 and its pathological form, TDP-25, 
whereas trehalose treatment to enhance autophagic function decreased the expression 
levels, suggesting that both autophagy and the ubiquitin-proteasome system contribute to 
the degradation of TDP-43 (Wang, Fan et al. 2010). Moreover, stress granules containing 
FUS mutants are associated with LC-II, and autophagy mediates the disassembly of stress 
granules (Ryu, Jun et al. 2014). 
Several ALS-linked genes also participate in the ubiquitin-proteasome system. 
Ubiquilin-2 is a member of the ubiquilin family and plays a role in the ubiquitinated 
substrate delivery to the proteasome (Zhang, Yang et al. 2014). Mutations in UBQLN2 
are associated with dominantly inherited X-linked ALS (Deng, Chen et al. 2011). The 
expression of mutant ubiquilin2 (P497H or P506T) in SH-SY5Y cells exhibits 
impairment of proteasomal degradation by UbG76V-GFP reporter assay, whereas over 
expression of wild-type ubiquilin-2 promotes the clearance of C-terminal TDP-43 
fragment (261-414 aa) in human H4 cells (Cassel and Reitz 2013). Moreover, the 
mutations in genes encoding valosin-containing protein (VCP) or sequestosome1/p62, 
which regulates protein degradation through proteasome, are associated with ALS, 
supporting the notion that an impaired proteasome degradation system contributes to ALS 
pathogenies (Johnson, Mandrioli et al. 2010, Fecto, Yan et al. 2011).  
In chapter III, we found that the expression levels of proteasome subunits including 
PA200, Rnp2, Rpt5, Rpn13 and MCP were not changed, whereas the three peptidase 
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activities of 26S proteasome were decreased in FUS mutant cells. The 26S proteasome is 
a large macromolecular machine that consists of the proteolytic core particle, the 20S 
proteasome is composed of 14 different subunits, and the 19S regulatory particle is 
composed of 19 different particles. In proliferating cells, proteasome assembly 
continuously occurs from inactive precursor complex (Saeki and Tanaka 2012, Gu and 
Enenkel 2014). Further research is needed to examine whether FUS mutant expressions 
alter proper proteasome assembly. Moreover, where proteasome dysfunction in FUS 
mutant cells occurs-in the cytoplasm, the nucleus, or both-should be analyzed. 
IV.5 Intranuclear inclusions in ALS 
Aggregate formation is the hallmark of several neurodegenerative disease including 
ALS, Alzheimer’s disease, and Huntington’s disease (Mukai, Isagawa et al. 2005, 
Blokhuis, Groen et al. 2013, Jucker and Walker 2013). Some of these conditions exhibit 
nuclear aggregates that contain proteasomes, p62/SQSTM1, ubiquitin, SUMO1, PML, 
and chaperones (Woulfe 2008). In chapter III, FUS mutant cells increased sequestration 
of Daxx and 11S/PA28 proteasome regulators into large PML-NBs upon oxidative insult 
with ATO. In addition, FUS mutant cells increased abnormal nuclear p62 accumulation 
(in chapter III). Therefore, it is easy to assume that enlargement of PML-NBs may serve 
as an initial step for intranuclear inclusion formation. Previously, ubiquitin, p62/
SQSTM1, or SUMO1-positive intranuclear inclusions were identified in patient tissues 
affected by FTD-ALS (Bigio, Johnson et al. 2004, Mackenzie, Baker et al. 2006, 
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Pikkarainen, Hartikainen et al. 2008). Recently, abnormal, dot-like p62 positive, TDP-43- 
negative neuronal intranuclear inclusions were found in the hippocampus and cerebellum 
tissues harboring C9orf72 expansion linked to FTD-ALS (Al-Sarraj, King et al. 2011).  
Observation of the neuronal intranuclear inclusions is rare in ALS cases, however. In 
1997, eosinophillic intranuclear inclusions is the first observation in ALS (Kakita, 
Oyanagi et al. 1997). Seven years later, eosinophilic neuronal intranuclear inclusions 
labeled with PML, proteasomes, non-expanded ataxin-3, and ubiquitin were observed in 
ALS patients with rapid progression (Seilhean, Takahashi et al. 2004), suggesting that 
abnormal nuclear inclusions may participate in the pathogenesis of ALS.  
FUS itself is sequestered in nuclear aggregates (Nomura, Watanabe et al. 2014). 
ALS patient tissues harboring FUS mutations show intranuclear inclusions containing 
FUS in neurons having the hypoglossal nucleus and this observation is only found in 
early-onset cases (Mackenzie, Ansorge et al. 2011). FUS mutant, G156E, which contains 
intact nuclear localization signal, is sequestrated in nuclear aggregates in rat hippocampal 
neurons that occur cytotoxicity (Nomura, Watanabe et al. 2014). A subset of FUS mutant 
(G156E) at the SYQG region linked to fALS has the ability to form amyloid-like fibrillar 
aggregates, which can serve as seeds triggering the accumulation of wild-type FUS into 
aggregated structures forming intranuclear inclusions, concomitant with decreased cell 
viability. Nuclear aggregation containing FUS also presents along with abnormal RNAPII 
sequestration in patient fibroblast cells harboring mutant FUS (H517Q or NLS) 
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(Schwartz, Podell et al. 2014), suggesting that FUS nuclear aggregates may participate in 
ALS pathogenesis. 
Proteasome dysfunction may contribute to intranuclear inclusion formation. 
SUMO1-positive intranuclear inclusions are enhanced in PC12 cells by treatment of  the 
proteasome inhibitor, lactacystin (Pountney, Huang et al. 2003). Proteasome inhibition 
with MG132 also increased SUMO1 accumulation in the nucleus (Bailey and O'Hare 
2005). Interestingly, these SUMO1 are colocalized with ubiquitin (Bailey and O'Hare 
2005). Consistent with this finding, we observed that MG132 (1 µM) treatment for 24 
hours increased the size of PML-NBs in FUS mutant cells. Further study is needed to 
examine nuclear aggregates containing PML-NBs in motor neurons from our FUS-
transgenic mouse model expressing FUS-R495X.  
Do intranuclear aggregates induce cellular toxicity? Some experimental results 
support the notion that aggregation causes cellular toxicity. PC12 cells expressing mutant 
atrophin-1 with expanded polyglutamine stretches enhanced the formation of SUMO1-
positive intranuclear aggregates, which results in cell death. Moreover, cells expressing 
mutant ataxin-1, which is linked to spincerebellar ataxia 1 (SCA1) disease, increased 
nuclear aggregate formation, concomitant with cell death in oxidative stress conditions 
(Kim, Kim et al. 2003).  
Nuclear inclusions sequester essential nuclear proteins, including transcription 
factors, components for the ubiquitin-proteasome system, and RNA-binding proteins; 
this sequestration may cause dysregulation in transcription, splicing, and protein 
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degradation in the nucleus. Therefore, nuclear dysfunction may serve as a crucial 
mechanism in neurodegenerative disease. 
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Conclusion 
ALS is a progressive neurodegenerative disease characterized by loss of motor 
neurons in the brain and spinal cord. While mutations in FUS account for a subset of 
familial ALS, the mechanism by which FUS mutants cause motor neuron degeneration is 
still not known. The work in this dissertation demonstrates that FUS mutant expression 
impairs cellular stress response by (i) accumulation of mutant FUS into stress granules 
and (ii) inhibition of PML-NB dynamics. Abnormally enlarged PML-NBs under stress 
conditions may perturb nuclear homeostasis, implicating that a novel nuclear pathology 
specific to mutant FUS expression may contribute to ALS pathogenesis. Furthermore, 
FUS mutant expression leads to inhibit proteasome activity. Further analysis to reveal 
how FUS mutant expression alters proteasome activity will provide more evidence to 
understand the pathological mechanism in ALS and will contribute to the development of 
therapeutic approaches for this severe disease.  
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Appendix I: 
An approach to generate an FUS-knockout zebrafish model  
using zinc finger nucleases 
167
ALS is an adult-onset neurodegenerative disease. In zebrafish, both overexpression 
of genes via mRNA injection and down-regulation of genes using morpholino 
oligonucleotides are good tools for studying the transient effects of target proteins in 
zebrafish embryos. However, these tools are not suitable for examining progressive 
degeneration in the adult stage. Therefore, we aimed to generate a transgenic zebrafish 
model.  
To create an FUS knock-out zebrafish model, we adapted engineered zinc-finger 
nucleases (ZFNs). ZFNs has been used for genetic modifications in cell lines, 
invertebrates, and zebrafish (Meng, Noyes et al. 2008). ZFNs are a chimeric fusion 
between a Cys2His2 zinc-finger protein (ZFP) and the cleavage domain of FokI 
endonuclease (Carroll 2011). Each ZFP can recognize distinct three-base-pairs (bp) of 
DNA sequences. A zinc-finger cassette forms with 3 to 6 ZFPs and recognizes 9 to 18 bp 
of the DNA sequences. If a pair of ZFNs is assembled properly with opposite strands of 
the DNA sequences with a spacer of 5- or 6-bp distance between the binding sites, FokI 
forms dimerization to initiate nuclease activity. This cleavage activity leads to DNA 
double-stranded breaks at the target site. This gene disruption may be induced when the 
cells undergo DNA repair through non-homologous end joining (NHEJ). Alternatively, 
gene insertion or correction can be introduced by applying a desired DNA template; this 
event requires a DNA homology-direct repair system (Urnov, Rebar et al. 2010).  
Our collaborator, Dr. Wolfe, helped us find possible targets of ZFNs on the genomic 
DNA of the zebrafish FUS. In particular, we found candidates on exon 4, 6, and 13. We 
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targeted regions on exon 6 of the zebrafish FUS after validating the activity of the ZFNs 
on each target with the yeast-based MEL1 reporter assay (Figure A1-1) (Doyon, 
McCammon et al. 2008). The ZFN-6-1 contained 3 ZFPs with a 6-bp spacer between the 
ZFP recognition regions (Figure A1-1A). The ZFN-6-2 included an additional ZFP at the 
right ZFN recognition site to target a total 12 bp (Figure A1-1B). Through modular 
assembly-based approaches, individual ZFPs were ligated into the pCS2 vector 
containing modified FokI endonuclease. The ZFP modules and pCS6 vectors were 
provided by the Lawson lab (Meng, Noyes et al. 2008). RNA encoding ZFNs was 
generated in vitro using an SP6 Transcription kit (Ambion, AM1340), and different 
concentrations (100, 200 and 500 pg) of RNA were microinjected into one-cell-stage 
zebrafish embryos. The embryos were separated based on their morphology (normal or 
abnormal) at 30 hours post-fertilization (hpf), and DNA was extracted to validate the 
activities of ZFNs. 
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Figure A1-1. Possible targets of ZFNs were located on exon 6 of the zebrafish FUS. 
(A) The ZFN-6-1 contained 3 ZFPs to target a total 9 bp. (B) The ZFN-6-2 included an additional ZFP at 
the right ZFN recognition site to target a total 12 bp. Both ZFNs contained a spacer of 6 bp distance 
between binding sites.
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Analyzing the ZFN-mediated mutagenesis on exon 6 of the FUS gene required 
amplification of an ~100-bp fragment containing target regions on exon 6, followed by 
analysis of the PCR product via Cel-I SURVEYOR nucleases (Cel-I, SURVEYOR 
Mutation Detection Kit, Transgenomic) to validate the activity of the ZFNs. The Cel-I 
enzyme can detect any DNA mismatch generated by ZFN-mediated gene insertion or 
deletion. As validated by the Wolfe lab, the CelI digestion using the PCR product from 
the injection of active ZFNs (P-C) produced the small fragments caused by DNA 
mismatches (Figure A1-2). However, both candidate ZFNs on exon 6 did not exhibit any 
activity (Figure A1-2).  
One concern raised by applying ZFNs for gene manipulation includes cytotoxicity 
caused by the off-target effect. Furthermore, the efficiency of target-gene mutagenesis by 
ZNFs is quite low (Moore, Reyon et al. 2012). In future study, other genetic  modification 
tools such as transcription activator-like effector nucleases (TALEN) and clustered 
regularly interspaced short palindromic repeats (CRISPRs)/CRISPR-associated (Cas) 
systems, may be considered to manipulate FUS expression on zebrafish.  
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Figure A1-2. The activities of ZFNs (ZFN-6-1) were validated by Cel-I assay. 
Top panel: An ~100 bp fragment containing target regions was amplified by PCR. 
Bottom panel: The PCR products were analyzed by Cel-I assay to check the 
mutagenesis caused by the activity of ZFNs. Control, non-injected embryos; N, normal 
morphology; A, abnormal morphology; P-C, active ZFNs from the Wolfe lab. 
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Appendix II: 
A possible approach to identifying FUS interacting proteins 
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FUS may regulate several cellular functions, including RNA splicing, transcription, 
DNA damage repair, and microRNA biogenesis (Deng, Gao et al. 2014). FUS targets 
more than 5,500 mRNA in human brains (Lagier-Tourenne, Polymenidou et al. 2012). 
However, it is not clear what protein interacts directly with FUS or FUS mutants to cause 
motor neuron degeneration. Analysis of the interactions between FUS and partner 
proteins provides insights into FUS function in the context of ALS. We aimed to identify 
FUS-interacting proteins and validate whether FUS mutants generate new interactions or 
lose normal associations. 
For the pilot experiment, we performed immunoprecipitation of GFP-tagged FUS 
using anti-GFP beads (µMACS GFP Isolation Kits, Miltenyi Biotec) in HEK293 cells 
expressing FUS variants (WT or R495X). Next the products were analyzed via 2D gel 
electrophoresis to check if FUS mutants altered normal FUS interactions with partner 
proteins. This initial trial revealed that many proteins were immunoprecipitated with 
GFP-FUS together, which might have been caused by the nonspecific interactions. 
Therefore, we changed the method to increase specificity and minimize false interactions.  
To accomplish this, we decided to perform photo-cross-linking with an engineered 
aryl azide ligase, a special enzyme derived from the natural E. coli enzyme known as 
lipoic acid ligase (LplA) (Baruah, Puthenveetil et al. 2008). This engineered ligase 
catalyzes the covalent binding of a fluorinated aryl azide to an LplA acceptor peptide 
(LAP). The LAP is a 17-amino-acid unnatural peptide that may be fused with the protein 
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of interest. UV irradiation produces a reactive oxygen species that cross-links to any 
surrounding proteins, which may increase specificity. 
We generated four constructs containing LAP and myc sequences that were 
conjugated with either FUS-WT or FUS-P525L (Figure A2-A). The LM1 and LM2 
synthetic constructs had 12- and 7-amino-acid linkers between the myc and full length of 
FUS (1-526), respectively. The LM3 synthetic construct contained N-terminal truncation 
of FUS (225-526) with 5-amino-acid linkers. For negative control (or LAC), a lysine on 
the Lap peptide was substituted with alanine to inhibit the interaction with LplA, and 
eventually the photo-cross-linking product using the LAC construct represented non-
specific interactions. 
Each construct was cloned into a pcDNA5/FRT/TO/TOPO vector and transfected 
into FlipIn TRex HEK293 cells to generate doxycycline-inducible cell lines. After 48 
hour of doxycycline induction, cells were lysed in an RIPA buffer, and the expression 
level of each construct was evaluated by western blotting. The expression levels of all 
synthetic constructs were quite low in inducible HEK293 cells. Later, we transfected 
these constructs transiently in HEK293 cells and found the expression levels were 
detectably high (Figure A2-1B). Therefore, we decided to analyze these constructs via 
transient transfection. We checked FUS localization and found LAP-myc tag did not 
perturb its normal property (Figure A2-C). LM1-FUS-WT expressed in the nucleus, and 
LM1-FUS-P525L showed cytoplasmic mislocalization. Interestingly, the truncation form 
of FUS (LM3-FUS-WT) expressed throughout the nucleus, and it even localized inside 
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Figure A2. Constructs containing LAP-myc-FUS variants were designed and 
tested to identify FUS interacting proteins. 
(A) Constructs containing LAP-myc-FUS variants were designed. (B) A western blot of cellular lysates 
using anti-myc antibody showed the expression of Lap-myc-FUS constructs. (C) Fluorescence images 
showed the localization of Lap-myc-FUS constructs. (D) A blot with silver staining showed the 
immunoprecipitated proteins with LM1 and LAC constructs in HEK293 cells. (E) Fluorescence images 
showed the expression of LM1 and LAC constructs. Blue signals represented the ligation activities of 
LM1 constructs with coumarin. The negative control (LAC) also showed the ligation activities.
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the nucleolus where FUS expression is normally excluded (Figure A2-C). 
Next, we tried to test photo-cross-linking after transient transfection of LM1 and 
LAC constructs into HEK293 cells. At 48 h after transfection, the HEK293 cells were 
trypsinized and collected. The cells were then incubated in the ligation buffer containing 
LplA, aryl azide, ATP, and magnesium acetate for 30 minutes at 37℃ (Baruah, 
Puthenveetil et al. 2008). Photo-cross-linking was performed with 0.15 J/cm2 of 365 nm 
UV light using a Stratalinker (Stratagene) and the cells were immunoprecipitatied with 
anti-myc microbeads (Miltenyi Biotec). The immunoprecipitated product was further 
analyzed through silver staining after electrophoresis. Unfortunately, this trial did not 
result in any specific FUS interactions, producing instead lots of non-specific products. 
The lysis buffer had Dithiothreitol (DTT) and Tris that might have reduced and quenched 
reactions during aryl azide photo-activation. Therefore, several steps should be 
optimized, including the cell-lysis buffer, UV irradiation condition, and ligation-buffer 
composition. 
To validate ligation affinity between LplA and LAP in our cell system, we changed 
the substrate from aryl azide to coumarin fluorophore, which has a fluorescence signal 
easily detectable by live-cell imaging (Uttamapinant, White et al. 2010). Coumarin (20 
µM) was incubated for 5 minutes in HEK293 cells, overexpressing LAP-myc-FUS 
constructs, and was then washed out with culture media for 10 minutes to remove 
residual coumarin that was not ligated to LAP. We detected coumarin fluorescence 
signals in our cells (Figure A2-C), but the coumarin signal was also present in the cells, 
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expressing LAC constructs which should not conjugate with coumarin. Moreover, the 
cells expressing LM1-WT exhibited large amount of cytosolic coumarin expression, 
which FUS-WT should have expressed predominantly in the nucleus. For our next step, 
we should monitor a timeframe for coumarin expression and optimize the washing time 
to remove residual coumarin. To succeed in photo-cross-linking, we should consider 
several factors, including the concentration of LplA and aryl azide along with the 
duration and power of UV irradiation.   
Recently, the groups of FUS-interacting proteins have been found in HEK293 cells 
using dual-tag affinity purification and mass spectrometry (Wang, Jiang et al. 2015). 
Wang et al. found that FUS interacted with proteins such as VCP/p97, PSF, UBA-1, and 
26S proteasome non-ATPase regulatory subunit 12 suggesting the FUS mutant may 
perturb the mechanism related to energy metabolism and protein degradation pathway. 
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Appendix III: 
The expression of p62/SQSTM1 and PML-NBs in a transgenic mouse model of ALS 
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Our lab developed a transgenic mouse model expressing human FUS-R495X under 
the control of a mouse prion promoter. FUS-R495X showed cytoplasmic translocation in 
the cortex and spinal cord consistent with our observations in HEK293 cells (in Chapters 
II and III) (Figure A3-1A). Although we observed quite a large amount of FUS-R495X 
expressed in cytoplasm, transgenic mice have not developed obvious motor phenotypes. 
However, our collaboration with the Durham lab showed that overexpression of FUS-
R495X induced cytoplasmic sequestration of protein arginine methyltransferase 1 
(PRMT1) in the spinal motor neurons, while the localization of PRMT1 was not altered 
in the neuronal cells in transgenic mice expressing FUS-WT and non-transgenic controls 
(Tibshirani, Tradewell et al. 2015).  
In Chapter III, we observed that mutant FUS expression was associated with 
increased nuclear p62 foci accumulation and expanded PML-NBs in HEK293 cells. To 
check the relevance of these events in neuronal cells, we first examined the p62 
expressions in the brain and spinal cord of a FUS-R495X transgenic mouse. The tissue 
lysates were generated from 5-month-old FUS-R495X transgenic mice (n=7) and non-
transgenic controls (n=7). Overall, the level of p62 expression was higher in the lysates 
from the cortex than the spinal cord. However, we found that the level of p62 in the FUS-
R495X cortex had not changed when compared to the p62 levels in the non-transgenic 
controls (Figure A3-1B), consistent with our results in HEK293 cells (in Chapter III). 
Next, we examined the localization of p62 in tissue sections from the FUS-R495X 
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transgenic mice. However, due to technical issues, we could not detect p62 expressions in 
the cortex or spinal cord sections by the immunofluorescence method. 
In contrast, the levels of p62 expressions were elevated in the spinal cord lysates 
from a transgenic mouse model expressing SOD1-G93A (Gal, Strom et al. 2007). 
Moreover, p62 was co-localized with mutant SOD1 and ubiquitin in the spinal motor 
neurons of the SOD1-G93A transgenic mice, and overexpression of p62 induced 
aggregate formation of SOD1-G93A in NSC34 cells (Gal, Strom et al. 2007). 
Collectively, these results suggest that p62 plays a critical role in aggregation formation 
in ALS-SOD1. The role of p62 includes facilitation of misfolded protein degradation 
(Pankiv, Lamark et al. 2010, Lippai and Low 2014). Decreased activity of proteasome 
has been found in ALS patients’ tissues and a transgenic mouse model expressing mutant 
SOD1 (Kabashi, Agar et al. 2008, Kabashi, Agar et al. 2012). Therefore, down regulation 
of proteasome activity may contribute to mutant SOD1 aggregates with p62 in a SOD1-
G93A mouse model. 
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Figure A3-1. Expression of FUS-R495X showed no obvious change of p62 levels. 
(A) FUS expressions were observed in the cortex and spinal cord sections. The tissue sections were 
stained with anti-FUS antibody (1:500, Bethyl laboratory, A300-293A) (B) Western blots showed the 
expression of FUS (1:1000, Bethyl laboratory, A300-293A) and p62 (1:1000, BD Bioscience, 610832) in 
tissue lysates from the cortex and spinal cord. Tubulin and GAPDH were used as a loading control. 
182
Studies for examining PML-NBs in mouse tissues are limited. Recently, PML 
expression was analyzed throughout the adult brains of mice. Immunostaining analysis 
detected high PML expressions in the cortex and all hippocampal layers at the adult stage 
of mouse (2 to 3 months old) (Hall, Magalska et al. 2015). In addition, neuronal cells in 
the cerebral cortex expressed PML strongly, but other cell types, such as microglia, 
oligodendrocytes, and astrocytes, did not express PML (Hall, Magalska et al. 2015). 
We were challenged to detect PML-NBs in our transgenic mouse tissue sections. By 
applying different methods for tissue preparation, we finally detected PML signals 
through a “squash” method (Figure A3-2). This method was developed to detect several 
nuclear bodies such as Cajal bodies, Gems, and PML-NBs in mouse tissues (Tapia, 
Bengoechea et al. 2012). Briefly, perfused mouse brains and spinal cords were cut into 
small pieces and placed on a siliconized slide, which was covered with a glass coverslip. 
The tissue was squashed by gently tapping on the top of the tissue pieces to dissociate 
cell nuclei. We stained slides with anti-PML (Millipore, 05-718, 1:200) and anti-Daxx 
(Santa Cruz Biotechnology, ac-7152, 1:500) antibodies. PML and Daxx expressed 
diffusely throughout the nucleus in the cortex and spinal cord of both the transgenic and 
control mice (Figure A3-2). A population of cells expressed a focal accumulation of PML 
and Daxx. Daxx foci frequently localized inside the nucleolus and were observed in all 
samples. We could not conclude whether Daxx foci were increased in an FUS transgenic 
mouse. Previously, increased Daxx accumulation was associated with motor neuron death 
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in a SOD1-G93A mouse model (Raoul, Buhler et al. 2006). Further study is required to 
check whether neuronal cells enhance Daxx accumulations in an FUS transgenic mouse.  
Daxx was not co-localized with PML-NBs in our mouse model system (Figure 
A3-2). Cultured mouse fibroblasts showed localization of Daxx in PML-NBs (Tapia, 
Bengoechea et al. 2012). Interestingly, these PML-NBs were larger when compared with 
neuronal cells, suggesting that PML-NBs in neuronal cells may differ from those in 
fibroblast (Tapia, Bengoechea et al. 2012). Our findings suggest that PML-NBs are 
expressed in cortex and spinal cord of a 3-month-old FUS transgenic mouse. Our next 
step should be to focus on analyzing whether expression of PML-NBs is altered in FUS 
transgenic mice. 
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Figure A3-2. A population of cells expressed a focal accumulation of PML and 
Daxx. in cortex and spinal cord of a 3-month-old FUS transgenic mouse.  
Confocal z-stack maximum intensity of projections showed Daxx and PML expressions in cortex and 
spinal cord tissues. 
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